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Identification of proteins whose expression and/or activities are upregulated in clinical 
neoplasias provides insight into the mechanisms underlying carcinogenic transformation and 
malignancy. Validation of such proteins as biomarkers through correlation to patient 
outcomes can provide novel targets for the development of selective anticancer therapies. 
Therapeutics that target phenotypic alterations common to a variety of cancers could have a 
broad impact on the treatment of cancer as a whole. Increased invasive capability 
accompanying upregulated proteolytic activity is widely recognized as a critical determinant of 
metastatic potential and is commonly observed in progressive disease. The urokinase 
plasminogen activator (uPA) is a key contributor to cell invasiveness through the activation of 
plasminogen and downstream proteases. These proteolytic actions endow cancerous cells 
with the ability to degrade extracellular matrix and basement membrane components, 
facilitating their invasive spread. uPA and its cognate cell-surface receptor (uPAR) are of 
prognostic relevance in a variety of aggressive cancers where their overexpression predicts 
adverse patient outcomes and metastatic potential. 
 
A second phenotype observed in virtually all cancers is the reversal of transmembrane pH 
gradients relative to healthy tissues. Alkalinization of the intracellular pH (pHi) and the 
concomitant acidification of the extracellular space create a permissive environment that 
promotes further dysregulated growth, insensitivity to apoptotic checkpoints and increased 
motility and invasiveness that propel transformed cells towards malignancy and metastasis. 
The Na+/H+ exchanger isoform 1 (NHE1) is upregulated in a wide variety of tumours and is a 
primary contributor to the cancer-specific reversal of transmembrane pH gradients. 
Hyperactivation of NHE1 is an early event in oncogene-driven carcinogenesis and has been 
shown to be essential for maintenance of transformed phenotypes and growth of tumour 
x 
xenografts in mice. Amiloride, a commonly prescribed oral potassium-sparing diuretic, 
presents a unique opportunity for medicinal chemistry optimization into dual-targeting 
uPA/NHE1 inhibitors as anticancer therapeutics as it is a moderate inhibitor of both targets 
and shows robust anticancer side activities in vivo. 
 
5-substituted amiloride analogues are known to show greatly improved NHE1 potency relative 
to amiloride (e.g. 5-(N,N-hexamethylene)amiloride 27 (HMA) >520-fold) whilst exhibiting 
reduced activity against epithelial sodium channels (ENaCs), the target responsible for the 
diuretic and antkalliuretic properties of the parent drug. This PhD project explored structure-
activity relationships (SAR) of 6-HMA analogues as inhibitors of uPA and NHE1, with the 
overall aim of identifying 6-HMA analogues with high (nM) potency against both targets. 
 
Significant increases in uPA inhibitory activity were achieved through addition of various 
heteroaryl substituents at the 6-position of HMA (Chapter 2). Two structurally distinct lead 
scaffolds with divergent physicochemical properties were discovered that showed excellent 
inhibitory potency against uPA (43 IC50 = 143 nM, 50 IC50 = 69 nM). X-ray crystallographic 
analysis (Chapter 3) revealed that the potency gains were due to increased binding 
interactions in the uPA S1 subsite. Biochemical assays demonstrated a high degree of 
selectivity for uPA over closely related trypsin-like serine proteases (Chapter 4). In vitro assays 
revealed a diverse spread for cytotoxic activities of the lead inhibitors across a variety of cell 
lines.  
 
A novel fluorescence plate reader assay was developed for measuring NHE1 inhibition and 
was used to characterize SAR around the HMA scaffold (Chapter 5). In general, introduction of 
(hetero)aryl substituents at the 6-position did not decrease potency of HMA analogues against 
xi 
NHE1, and in some cases yielded potent uPA/NHE1 dual-targeting compounds (48 uPA IC50 = 
175 nM; NHE1 IC50 =  397 nM), along with uPA-selective inhibitors (49 uPA IC50 = 86 nM; NHE1 
IC50 =  21 M).  
 
Research perfomed under contract by Charles River Laboratories using a selection of 6-HMA 
analogues and HMA revealed the absence of activity against ENaCs, the diuretic and anti-
keliuretic target of amiloride.  
 
In summary, this work reports the discovery of potent, selective and non-toxic uPA/NHE1 dual 
targeting 6-HMA analogues suitable for entry into in vivo anticancer models. Further work 
should involve determining the absence of diuretic/anti-kaliuretic effects in mice to ensure 
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Cancer is the leading cause of death in the developed world and the second largest cause of 
death in developing countries.1 Cancer occurs when cells progressively accumulate growth 
promoting attributes that confer a survival advantage over neighbouring cells, resulting in 
dysregulated and disordered proliferation. The reigning paradigm in cancer biology over the 
past 25 years describes cancer as a genetic disease arising from mutations in genomic 
sequences that cause activation of growth-promoting genes (oncogenes) or inactivation of 
growth regulators (tumour-suppressor genes).2 Increased understanding of non-genetic 
factors, including epigenetic alterations, heterotypic interactions between cancerous and 
stromal cells and dynamic interactions between cancer cells and the tumor metabolic 
environment, has challenged the framing of cancer as a purely genetic disorder.2,3 With this in 
mind, targeting phenotypes and processes common to the majority of cancers is an attractive 
approach towards developing new anticancer agents with broad utility. Drugs able to 
simultaneously inhibit multiple cancer-associated processes could dramatically improve 
cancer treatment. 
 
The urokinase plasminogen activator (uPA) is a trypsin-like serine protease that is 
overexpressed in a wide variety of cancers and plays a key role in cell invasiveness and 
metastasis.4,5 uPA functions to activate plasminogen to plasmin and the subsequent activation 
of downstream proteases (e.g. pro-MMPs and pro-cathepsins) facilitates degradation and 
broad-scale remodeling of the extracellular matrix (ECM) and basement membrane (BM), 
serving to promote cancer cell invasiveness and ultimately metastatic spread.6,7 
7 
One phenotype observed in virtually all cancers is reversal of the pH gradient that exists 
across the cell membrane. Healthy cells typically feature a cytosolic pH (pHi) lower than that 
of their extracellular environment (pHe).
8 In cancer cells, the gradient is reversed, with the 
interior of cells becoming more alkaline than the immediate surroundings. Alkalinization of 
the cytosol and concomitant acidification of the tumour microenvironment has been shown to 
be an early event in carcinogenesis and essential for development and maintenance of the 
cancerous state.6 A key contributor to transmembrane pH gradient reversal in cancer cells is 
the Na+/H+ exchanger isoform 1 (NHE1).9,10 NHE1 facilitates the isoelectronic exchange of 
intracellular H+ for extracellular Na+ in a 1:1 ratio. NHE1 becomes constitutively activated in 
neoplastic cells, resulting in acidification of the tumor microenvironment and alkalinization of 
the cytosol, which both contribute to carcinogenesis and metastasis.11 The lowered pHe of the 
tumour microenvironment decreases avidity of cell-extracellular matrix (ECM) interactions, 
activates acid-dependent proteases, including members of the urokinase plasminogen 
activation system (uPAS), matrix metalloproteinases (MMPs) and cysteine/aspartyl 
cathepsins.12  
 
This chapter reviews the role of uPA and NHE1 in carcinogenesis and metastasis and highlights 
the potential for dual-inhibition of both targets as a novel anticancer strategy.  
 
1.2 Overview of cancer metastasis 
 
Modern cancer chemotherapy suffers from an inability to successfully treat disseminated 
versus localized tumours. In general, patients with localized tumours have good long-term 
prognoses following surgical excision and adjuvant radio- or chemotherapy. However, the 
outlook for patients with metastatic disease is much less optimistic.13,14 Formation of 
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secondary tumours via metastatic spread is responsible for ~ 90% of cancer-associated 
deaths.6,15  
 
Metastasis is a multistep process where cancer cells disseminate via the circulatory and 
lymphatic vasculature from their site of origin (primary tumour) to distant sites in the body, 
where they establish secondary tumours in vital organs (Leber & Efferth 2009, Figure 1.1).  
 
 
Figure 1.1: Overview of cancer metastasis. Altered expression of cell adhesion molecules and 
cytoskeletal proteins initiates a shift to a motile mesenchymal phenotype (EMT = epithelial to 
mesenchymal transition). Cells that have undergone EMT are able to invade through the local 
stroma and intravasate into blood vessels, allowing transport away from the primary site. 
Extravasation out of the bloodstream and into secondary tissues can trigger reversion to an 
epithelial phenotype. This process results in the establishment of metastases in distant 
organs. Figure adapted from reference 15. 
 
An early event in the metastatic cascade is growth of new vasculature in the tumour mass; a 
process known as angiogenesis. In healthy tissues, vascularization is tightly regulated by 
balanced expression of pro- and anti-angiogenic factors (e.g. pro: vascular endothelial growth 
factor (VEGF), anti: angiostatin). This equilibrium is known as the ‘angiogenic switch’ and is 
influenced by a wide range of metabolic (e.g. pO2, pH) and mechanical (e.g. compression) 
stressors and genetic alterations (e.g. oncogene-driven expression of pro-angiogenic signals, 
Figure 1.2). 16,17,18  
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Figure 1.2: The angiogenic switch. Angiogenesis is regulated by a dynamic balance between 
pro-angiogenic ‘activators’ and anti-angiogenic ‘inhibitors’. Environmental stimuli like pH and 
O2 concentration influence the balance through up/downregulation of inhibitors and 
activators. VEGF = Vascular Endothelial Growth Factor, FGF = Fibroblast Growth Factor, PDGF-
 = Platelet-derived Growth Factor subunit , EGF = Epidermal Growth Factor, LPA = 
Lysophosphatidic acid. Figure adapted from reference 17. 
 
Many of these alterations are observed to occur simultaneously in solid tumours (e.g. 
accumulation of acidic metabolites due to increased glycolytic metabolism, compressive stress 
due to hyperproliferative and disordered cell growth and overexpression of VEGF).19,20 This 
confluence of factors serves to switch the balance toward formation of new vasculature in the 
tumour mass. The circulatory system and lymphatic network satiates the increasing metabolic 
needs of the growing tumour mass and provides invasive cells with a pathway for 
disseminating to distant sites and seeding secondary metastases.21 
 
The growth of new blood vessels into tumours often occurs in a disordered and dysregulated 
manner, creating a structurally and functionally aberrant microvasculature that is unable to 
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adequately supply O2 and nutrients to the tissue or remove metabolic waste products. This 
deficiency produces regions of hypoxia and acidified tumour microenvironments, which drive 
carcinogenic progression.18,22 
 
Genetic mutations and metabolic alterations coinciding with angiogenesis create an invasive 
phenotype in cancer cells, where they are able to mobilize and spread throughout the body. 
Invasive cells can remodel their extracellular environment through overexpression of 
proteolytic enzymes (e.g. uPA, matrix metalloproteinases (MMP) 3, 9, 10, cathepsins B & D), 
facilitating degradation of ECM/BM components.23,24,25,26 Accompanying this is a shift from a 
sedentary epithelial phenotype to a motile fibroblastic phenotype (EMT).27  
 
In normal epithelia the continued production of pro-survival signals is heavily dependent upon 
maintenance of close contacts between neighbouring cells and the basal lamina. Through 
altered expression of cell adhesion molecules (e.g. integrins, cadherins, selectins), cells 
undergoing EMT are able to avoid the programmed cell death that accompanies loss of cell-
cell and cell-BM adhesion (anoikis).22,28-31 This shift allows transformed cells to take on a 
fibroblastic phenotype that is conducive to motile spread of cells away from the primary 
tumour (refer to Figure 1.1). Together with the enhanced proteolytic activity associated with 
tumours, these characteristics allow invasive cells to make a path through the primary stroma 
and intravasate into the circulatory and lymphatic vasculature. Once in the circulation, 
disseminated tumour cells can extravasate and establish life-threatening secondary tumours; 





1.2.1 The urokinase plasminogen activation system (uPAS) and its role in 
cancer 
 
A central contributor to the process of invasion and metastasis is the trypsin-like serine 
protease uPA, a component of the uPAS.34,35 The fundamental components of the uPAS are 
uPA, its cognate cell-surface receptor uPAR and the endogenous serine protease inhibitors 
(serpins) plasminogen activator inhibitor (PAI)-1, -2 and -3  (Figure 1.3).7,34,36  
 
 
Figure 1.3: Schematic of the urokinase plasminogen activation system (uPAS). Solid arrows 
represent activation. ECM = Extracellular matrix, MMP = Matrix metalloproteinase. 
 
The uPAS is an endogenous enzyme cascade that plays a fundamental role in fibrinolysis, 
tissue remodeling and cell migration.5,34 Pro-uPA, the inactive zymogen of uPA, is a single-
chain 53 kDa multidomain protein consisting of 411 amino acid residues (Figure 1.4).37-40 Upon 
excretion from cells, cleavage of pro-uPA at residues Lys158-Ile159, primariliy by the 
autocatalytic activity of uPA but also by extracellular proteases (e.g. cathepsin B, kallikrein, 
trypsin) yields catalytically active, high molecular weight (HMW)-uPA, also referred to as ‘two-
chain’ uPA.5,41 Cleavage at this position forms the N-terminal (α) and C-terminal (β) chains of 
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HMW-uPA, which are joined by a single disulfide bridge between Cys148 and Cys279.42,43  The 
α-chain consists of a kringle domain and an epidermal growth factor-like domain, the amino 
terminal fragment (ATF) of which mediates interactions with its cell-surface receptor uPAR. 
The β-chain contains the serine-protease domain, which is formed by the antiparallel 
arrangement of two subdomains, each composed of six β-strands, with the interface forming 
the active site of the protease.29,44  
 
Figure 1.4: Domain structures of: A) Pro-uPA and B) active-uPA. The single chain zymogen pro-
uPA is activated by a variety of extracellular proteases (e.g. cathepsin B, kallikrein, trypsin) 
through cleavage at Lys158-Ile159 to yield active ‘two-chain’uPA.  
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uPAR is an atypical multidomain member of the Ly-6 family.45 The protein lacks a 
transmembrane domain, but is able to adhere to the cell surface via a C-terminal glycosyl 
phosphatidylinositol (GPI) anchor that is attached during endoplasmic reticulum (ER) 
maturation.46 Mature uPAR is 283 amino acids in length and has a molecular weight varying 
between 55-60 kDa, depending on its glycosylation state. uPAR features three homologous 
domains (D1-D3) that mediate interactions with uPA and ECM components (e.g. vitronectin).47 
A highly conserved pattern of intradomain disulphide bonds creates the 3D structure 
necessary for high affinity binding of the ATF to uPAR.5 
 
uPA displays a relatively narrow substrate scope, selectively cleaving plasminogen at the 
Arg561-Val562 peptide bond to reveal the active, broad spectrum serine protease plasmin.42,48 
Plasmin is also a feedback activator of Pro-uPA. Plasminogen binds to cell surfaces 
predominantly via interactions between exposed C-terminal Lys residues and binding sites 
found within kringle domains 1,4 and 5.37,49 A variety of multifunctional cell-surface proteins 
(e.g. α-enolase, dipeptidyl peptidase-4, tissue factor apoprotein, Plg-RKT) bind to plasminogen 
with high affinity.41,50-52 The endogenous inhibitor α2-antiplasmin regulates free plasmin 
activity through interactions with the kringle domain Lys binding sites of plasmin(ogen).7,53 
These inhibitory sites are obscured upon binding to cell surfaces, preventing inactivation of 
surface-bound plasmin.54 Cell surface binding of plasminogen via Lys residues also initiates 
conformational changes that increase activation by uPA.55 
 
Binding of Pro-uPA to uPAR co-localizes the complex at the cell surface, initiating a reciprocal 
activation loop that generates more plasmin and uPA.56 Once activated, plasmin degrades a 
variety of matrix proteins (e.g. fibrin, fibronectin, laminins, aggrecan and assorted 
proteoglycans) and activates numerous matrix metalloproteinases (e.g. MMPs 1, 2, 3, 9, 10, 
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13 and 14) and cathepsins that show broad specificity for many ECM and BM 
components.25,26,57,58 uPA-dependent plasmin-mediated activation of this cascade effectively 
triggers a proteolytic storm in the pericellular environment, leading to degradation of 
surrounding ECM.39  
 
In the context of cancer, overexpression of uPAS allows cancer cells to initiate proteolysis of 
the local ECM/BM barriers that confine them within the primary tumour mass, while at the 
same time liberating latent ECM-associated growth (e.g. TGF- and Hepatocyte Growth Factor 
(HGF) and pro-angiogenic factors (e.g. VEGF and FGF-2).59,60 Once activated, these factors act 
in a paracrine manner on neighbouring cells, promoting proliferation, angiogenesis and 
further uPA/uPAR overexpression to amplify invasive potential.61,62 
 
uPAS components also regulate cell adhesion and motility via mechanisms distinct from 
proteolytic activation of plasminogen.63 uPA binding to uPAR modulates integrin associations 
with vitronectin proteins present in the ECM. This occurs through uPAR interactions with the 
 subunit of 31, 51, v3 and v5 integrins.
38,46 uPAR-mediated modulation of integrin 
binding alters cell-ECM adhesion and promotes migration via the integrin-mediated activation 
of mitogen-activated protein kinases (MAPK) Erk 1 and 2.64-66 In addition, activation of the 
Erk/MAPK signaling pathway via uPAR-integrin binding causes deactivation of the growth 
inhibitory p38/MAPK pathway, promoting cell proliferation.67,68 uPAR also modulates cell 
adhesion via direct association of its D1 and D2 domains with the somatomedin-B domain of 
vitronectin.47,69,70  
 
uPA is efficiently inhibited by three serpins, PAIs 1, 2 and 3. Serpins are highly conserved, 
irreversible inhibitors of serine and cysteine proteases that circulate in an unstable high-
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energy conformation. Reaction of the protease active site with the serpin reactive center loop 
initiates a rapid conformational change in the complex that distorts the shape of the His57, 
Asp102, Ser195 catalytic triad, shutting down proteolysis.71 Covalent inactivation of  uPAR-
bound uPA by serpins PAI-1 and PAI-2 leads to internalization of the entire complex via the 
Low Density Lipoprotein related (LDLR) protein-1 and other endocytosis receptors of the LDLR 
family.72,73 Following lysosomal degradation of the complex, uPAR is recycled back to the cell 
surface.40 In spite of it’s physiological role as an inhibitor of the uPAS, the paradoxical 
protumourgenic effect of PAI-1 has been attributed to various interactions with ECM 
components and endocytosis/signaling co-receptors that promote tumour growth and 
metastasis.40 
 
1.2.2 uPA as an anticancer target  
 
The prognostic relevance of overexpressed uPAS components in relation to tumour 
aggressiveness has been established over the past three decades. In 1988, Duffy et al. 
reported a correlation between uPA activity in primary breast carcinomas and tumour size 
and the number of auxiliary node metastases.74,75 Correlations between uPA, uPAR and PAI-1 
overexpression and poor patient prognosis (i.e. shortened disease-free interval and shortened 
overall survival) have been since observed in breast, ovarian, endometrial, cervical, colorectal, 
prostate, gastric, head and neck and renal cancers.76-84  
 
The prognostic relevance of uPAS biomarkers is strongest in breast cancer, where high levels 
of uPA and PAI-1 are better predictors of disease progression than commonly used clinical 
metrics, including patient age, hormone receptor status, tumour grade and size and HER-
2/neu expression.85,86 Two retrospective analyses of data pooled from 2780 and 8377 
patients, respectively, and a randomized multicenter clinical trial have generated Level 1 
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evidence (i.e. highest possible) supporting the use of uPA and PAI-1 as prognostic biomarkers 
in breast cancer.76,87-89 Clinically, uPA and PAI-1 can be used to stratify node-negative breast 
cancer patients who would benefit from adjuvant chemotherapy (intermediate-high 
expression in primary tissue) from those for whom chemotherapy may be unnecessary (low 
expression in primary tissue).90,91 Recognition of the prognostic utility of uPA/PAI-1 
quantitation is reflected in the breast cancer specific guidelines issued by the American 
Society of Clinical Oncology, the European Society of Clinical Oncology and the German 
Gynaecological Society.86,92 (AGO Website, http://www.ago-online.de/en/guidelines-
mamma/march-2016/, accessed 29th Jan 2017). 
 
Despite the longstanding standing acceptance of uPA and PAI-1 as valid prognostic biomarkers 
for various breast cancers, widespread adoption in the clinic has not yet been realized.93 This 
failure has been partly attributed to the need for large amounts of freshly biopsied tissue for 
analysis using available diagnostic uPA/PAI-1 ELISAs.93 Improvements in assay sensitivity that 
enable use of formalin fixed and paraffin embedded tissue samples would facilitate routine 
diagnostic use.  
 
uPA and uPAR Knockout (KO) mice show non-lethal developmental phenotypes and no 
impairment of fertility or altered fibrinolytic activity.16,94,95 In comparison, plasminogen KO 
mice show severely impaired development and other phenotypes, including aberrant fibrin 
deposition, impaired wound healing and formation of spontaneous thromboses.96,97 
Redundancy in plasminogen activation in uPA/uPAR KO mice is thought to occur through 
compensatory activation by tPA.98 As such, it is predicted that on-target inhibition of uPA 
would not cause significant adverse side effects in vivo. Importantly, uPA and uPAR-deficient 
mice show significantly reduced tumour growth and metastasis in xenograft models.99-101  
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Specific inhibition of uPA proteolytic activity produces antitumour and antimetastatic effects 
in a variety of murine models (Table 1.1 and Figure 1.5). Xing et al. found that inhibition of 
uPA in Fisher rats bearing MAT-BIII syngeneic breast xenografts with benzothiophene-based 
inhibitor 1 decreased primary tumour volume by ~ 40 % and lung, liver and auxiliary lymph 
node metastases by up to 66% over a 14 day continuous i.p. infusion. 102. An earlier study 
demonstrated a 60% reduction in lung metastases for C57b mice bearing B16 murine 




Figure 1.5: Structures of uPA inhibitors 1-4. 
 
 
Following on from this work, Ossowski et al. reported a significant decrease in local primary 
site invasion in BALB/c mice bearing anti-uPA treated HEp3 human squamous cell carcinoma 
xenografts.104 More recently (2010), Hennekke et al. observed  >40% decrease in lung 
metastases and more than 60% reduction in primary tumour volume with the peptidomimetic 
inhibitor CJ-463 2 in C57b/N mice bearing murine Lewis Lung carcinoma xenografts.105 
 
Similar results have been reported for compounds that show trypsin-like serine protease 
(TLSP) inhibitory activity beyond just uPA inhibitory effects. The combination of tranexamic 
acid 3 with cisplatin completely inhibited ascites formation and prolonged overall survival by 
18 
70% in BALB/c mice bearing HRA human cystadenocarcinoma xenografts.106 Treatment of 
BALB/c mice receiving SW1990 human pancreatic adenocarcinoma xenografts with the 
guanidine-containing broad spectrum TLSP inhibitory small molecule gabexate 4 resulted in a 
50% decrease in liver metastases.107 Taken together, these findings support uPA as an 
attractive target for the development of novel anticancer drugs. 
 
Table 1.1: Representative in vivo data demonstrating the anticancer effects of uPA inhibitors. 
TLSP = trypsin-like serine protease. 
Mode of inhibition Model Result Reference 
Small molecule active 
site inhibitor – B428 
Allograft with Mat B-
III Rat breast 
carcinoma cells or 
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1.3 Regulation of cellular pH in cancer and the role of NHE1 
 
Regulation of transmembrane pH gradients is a tightly controlled aspect of cell physiology that 
involves the concerted action of multiple transmembrane ion transporters and enzymes. In 
the vast majority of cell types, intracellular pH (pHi) is slightly more acidic (pH 7.0-7.1) than the 
alkaline extracellular environment (pHe 7.3-7.4).
108,109 In contrast, a key hallmark of 
transformed cells is a reversed transmembrane pH gradient, where pHi can exceed pHe by as 
much as one log unit (tumour pHi 7.1-7.7, tumour pHe 6.2-6.9).
110,111 Acidification of the 
tumour microenvironment and the concomitant increase in pHi create a vicious cycle that 
promotes dysregulation of cell growth and progression towards malignancy. In cancerous 
cells, an assembly of proteins coordinate their actions to maintain the reversed pH gradient. 
These include H+-ATPases, monocarboxylate transporters (MCTs), HCO3
--transporters, 
carbonic anhydrases and the Na+/H+-exchanger isoform 1 (NHE1).12,108 NHE1 is considered an 
early and primary contributor to the dysregulated pH dynamics that fuel neoplastic 
progression.10,112 
 
NHE1 is a ubiquitously expressed transmembrane ion transporter that functions primarily to 
protect cells from intracellular acid. It is a 12-helical protein comprised of 815 amino acids. 
Residues 1-500 make up the N-terminal transmembrane domain responsible for transporter 
function. Residues 501-815 constitute the C-terminal cytoplasmic regulatory tail that features 
numerous serine/threonine phosphoregulatory sites (Figure 1.6).112,113 NHE1 is one of 10 
characterized isoforms of the SLC9A subfamily of Na+/H+-exchanger proteins. Isoforms 2-5 and 
10 show limited tissue and organellar distribution, whereas NHE1 is expressed in the plasma 




Figure 1.6: Schematic of NHE1. Oncogenic modulation of the affinity of the C-terminal tail for 
intracellular protons leads to constitutive hyperactivation of NHE1 activity. Binding sites on 
the C-terminal tail for ezrin/radixin/moesin (ERM) family members enable interactions with 
cytoskeletal proteins, allowing NHE to mediate pseudopodial protrusion and directed cell 
motility. Figure adapted from reference 6. 
 
NHE1 functions in a number of physiological processes, including  regulation of cell volume, 
Na+ flux and glycolysis, alteration of functional states and promotion of cell growth, cellular 
proliferation and differentiation. The transporters primary role, however, relates to 
maintenance of pHi homeostasis.
116-120 
 
NHE1 mediates an isoelectronic 1:1 exchange of extracellular Na+ for intracellular H+ ions, 
exploiting the inward Na+ electrochemical gradient to drive extrusion of protons against their 
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concentration gradient (Figure 1.6). In addition to their role as substrates in the exchange 
process, intracellular protons act as allosteric modulators of NHE1 activity.121  
 
Under normal conditions NHE1 exists in a quiescent state, becoming activated only when pHi 
drops below a threshold value, referred to as the activation ‘set point’.11 In transformed cells, 
alterations in the cytoplasmic H+-allosteric binding site, believed to occur via 
phosphoinositide-3-kinase-dependent mechanisms, increase affinity for intracellular protons 
to lower the set point for exchange activation.121,122 These events lead to constitutive 
hyperactivation of NHE1, driving acidification of the extracellular environment and 
alkalinization of the cytosol (Figure 1.7). 
 
Expression of functionally active NHE1 has been shown to be necessary for development of 
transformed phenotypes (e.g. anchorage-independent growth, growth in serum-deprived 
media, preference for glycolytic metabolism) in E7 oncoprotein-induced NIH3T3 fibroblasts 
and HPKIA keratinocytes.123  
 
Reversal of transmembrane pH gradients driven by NHE1 hyperactivation promotes 
progression of transformed cells towards an invasive and malignant phenotype. A well-
established hallmark of transformed cells is their preference for glycolytic metabolism over 
oxidative phosphorylation (OxPhos), even in the presence of sufficient O2 (aerobic glycolysis), 
a phenomena known as the “Warburg effect”.2,124 Originally thought to be a primary cause of 
neoplastic transformation, Warburg metabolism is increasingly being recognized as a 





Figure 1.7: Summary of NHE1 activity in normal and transformed cells. In normal cells NHE1 is 
quiescent until pHi decreases below the activation set point, after which NHE1 rapidly 
exchanges extracellular Na+ for excess intracellular H+. Oncogene-driven alterations increase 
the affinity of the NHE1 cytoplasmic tail for H+, lowering the set point and triggering 
constitutive activation of the exchanger. Hyperactive NHE1 drives acidification of the 
extracellular space (ECS) while simultaneously alkalinizing pHi, resulting in the characteristic 
reversal of transmembrane pH gradients relative to normal cells. Increased pHi promotes 
aerobic glycolysis, creating acidic metabolites like lactate (Lac-) that activate monocarboxylate 
transporters (MCT) and maintain the reversed transmembrane pH gradient. Figure adapted 
from reference 6. 
 
Oncogene-driven activation of NHE1 and subsequent alkalinization of the cytosol cause 
upregulation of key glycolytic enzymes, including lactate dehydrogenase and the glucose 
transporter GLUT-4, supporting aerobic glycolytic metabolism.117 The preference for glycolysis 
is reinforced by reliance of glycolytic enzymes (e.g. phosphofrucokinase-1) on alkaline pHi for 
optimal activity, compared to the acid-activated OxPhos pathway.10 The production of acidic 
metabolites (e.g. lactate) from increased glycolytic metabolism provides an intracellular H+ 
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pool that further drives NHE activity, creating a positive feedback loop that delivers steady 
alkalinization of pHi, decreased pHe and increased glycolytic metabolism.
125  
 
Increased pHi protects transformed cells from acid-dependent apoptosis through a variety of 
mechanisms. For instance, acidic pHi upregulates DNAse II activity to promote apoptosis-
associated DNA fragmentation and stabilization of the pro-apoptotic BAX protein, triggering 
the formation of pores in the mitochondrial membrane and release of cytochrome-c (cyt-
c).112,126,127 Apoptotic effector caspases activated by cytosolic cyt-c show maximal activity at 
acidic pH (pH ~ 6.8).128,129 High pHi has also been shown to destabilize acid sensitive mutants 
of the canonical tumour suppressor gene p53.130,131 In this way, NHE1 upregulation is 
considered an adaptive strategy that protects cancer cells from apoptosis and promotes 
progression towards malignancy.11,132  
 
NHE1 driven alkalinization of the cytosol drives cell proliferation by facilitating cell-cycle 
progression past the G2 checkpoint into mitosis.
133 It was shown that ras p21 or v-mos-driven 
oncogenic activation of NHE1 in quiescent NIH 3T3 fibroblasts results in entry into S phase and 
increased DNA synthesis.134,135 Intracellular alkalinization also creates optimal conditions 
thymidine kinase and thymidylate synthase activities, the rate-limiting enzymes in DNA 
synthesis.136,137  
 
Dysregulated cell proliferation causes disordered growth of an expanding tumour mass, 
creating regions of hypoxia as the increasing O2 demands fail to be met by passive diffusion 
from the surrounding (aberrant) vasculature. This effect supports the shift to glycolytic 
metabolism and encourages angiogenesis as the tumour attempts to satiate it’s increasing 
need for nutrients and O2.
138
 The functionally poor and chaotic blood vessels fail to adequately 
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remove acidic metabolic byproducts (e.g. carbonic acid, lactate) from the intratumoural space, 
further acidifying the extracellular environment.17 The pro-proliferative, pro-angiogenic and 
anti-apoptotic effects of NHE1 hyperactivation synergize with the increased proteolytic 
capabilities that accompany acidification of the tumour microenvironment, creating a self-
perpetuating cycle that promotes carcinogenic progression and ultimately metastatic spread.  
 
Cancer cell invasiveness requires polarization of cells, a key feature of EMT (Figure 1.1). 
Rearrangement of the cytoskeleton and altered interactions with ECM components leads to 
formation of a migratory ‘leading edge’ at the front of moving cells.139 NHE1 is intrinsically 
involved in the formation and function of pseudopodia and invadopodia, two pro-invasive 
structures at the leading edge.140 Pseudopodia are specialized finger-like structures that 
project in the direction of the circulatory vasculature, creating a path for cell migration. 
Invadopodia are discrete acidic, protease-rich microdomains that facilitate focal remodeling of 
ECM and BM attachments.141 
 
NHE1 localizes to invadopodial structures, where its activation leads to acidification of pHe 
and increased in pHi.
142 Acidification of pHe promotes secretion and activation of co-localized 
proteases (e.g. MMPs-2, 9, MT1-MMP, cathepsins D & B, uPA etc.), allowing remodeling of 
cell-matrix attachments and degradation of confining ECM components.60,140,143 Local 
acidification of pHe is partially driven by upregulated glycolytic enzymes in the invadopodia.
10 
Alkalinization of pHi facilitates the dynamic reorganization of cytoskeletal components (e.g. 
cofilin association with cortactin) within invadopdial structures.143 These concerted processes 
allow successive protrusion of pseudopodia and degradation of ECM at the leading edge of 
cells, enabling directed invasion of tumour cells through the stromal environment.144 NHE1 
25 
hyperactivation is thus considered as a key contributor to cell invasiveness in addition to its 
central role in the initiation and maintenance of underlying carcinogenic transformation. 
 
Direct interplay between the uPAS and NHE1 at the invasive edge of cells has been studied in 
non-small cell lung carcinoma (NSCLC). Upon binding of uPA, the uPA/uPAR complex localizes 
to invadopodial structures, where it facilitates directed uPA-mediated proteolysis. The process 
is supported by the activity of co-localized NHE1.145,146  In addition to its proteolytic activity, 
uPA binding to uPAR promotes pro-invasive stress-fibre formation, increased cell proliferation 
and MMP 9 release via activation of the ras/ERK pathway.147 Stimulation of downstream ERK 
signaling following uPAR occupation by uPA was shown to be due to NHE1-mediated increases 
in pHi in HL460 NSCLC cells, with NHE1 knockdown cells showing significantly decreased stress 
fibre formation and MMP-9 activity.148 
 
NHE1 is overexpressed in cervical cancer and hepatocellular carcinoma and its activity is 
upregulated in breast tumor and glioma cells.149-151 In 1989, Rotin et al. demonstrated the 
importance of NHE activity in tumourigenesis by showing that bladder carcinoma cells lacking 
functional NHE fail to grow or show greatly reduced tumour growth in murine xenografts.152 
Tumours able to grow in this model consisted of cells that had reverted through gain-of-
function mutations to normal NHE1 activity. Taken together, these findings support NHE1 as a 








1.4 Small molecule inhibitors of uPA 
 
Active site inhibition of uPA proteolytic activity presents unique challenges and opportunities 
compared to other members of the trypsin-like serine protease (TLSP) family. TSLPs show high 
homology in the structure of their protein folds and they all feature the canonical His57-
Asp102-Ser195 catalytic triad and a deep S1 binding pocket with a highly conserved Asp189 at 
its base.153 Asp189 forms an essential salt-bridge interaction with the positively charged side 
chains of P1 amino acid residues (e.g. Arg, Lys) in their various protein substrates.154 Substrate 
specificity in TLSPs is largely dependent on the strength of the P1-S1 interaction.153 
 
The TLSP family is divided into subgroups based on the identity of residue 190. In uPA, 
plasmin, trypsin and factor VIIa this residue is serine, while in tPA, thrombin and factor Xa it is 
alanine and in kallikrein it is threonine.155,156 These differences contribute to the selectivity of 
small molecule inhibitors as the OH sidechain of Ser190 can form hydrogen bonds to ligands. 
This H-bond partially compensates for interactions lost through displacement of a water 
molecule from the S1 site upon inhibitor binding.155,157  
 
The unique insertion of Thr98A and Leu98B in uPA (termed the “99-loop”), greatly reduces the 
size of its S3 and S4 sites relative to other TLSPs. The S2 site is also reduced in size by the 
imidazole side-chain of His99 in uPA (Figure 1.8).158 Reduced access to these regions, which 
are commonly targeted in TSLP inhibitor design, provides excellent scope for generation of 
uPA-selective small molecule inhibitors.159 
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Figure 1.8: Schematic representations of the active sites of trypsin, factor Xa, tPA, uPA. The 
S2, S3 and S4 sites in uPA are reduced in size relative to the other TLSP due to the Thr98A, 
Leu98B and His99 insertions which collectively form the ’99-loop’. Figure adapted from 
reference 158.  
 
Rational design of uPA inhibitors was advanced after publication of the uPA catalytic binding 
site by Spraggon in 1995 and later through the availability of higher resolution X-ray crystal 
structures of a re-engineered recombinant uPA (‘micro-urokinase’).160,161 The structures 
revealed a novel subsite in uPA termed S1β.161 S1β is flanked by the Cys191-Cys220 disulfide 
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bond, residues Gly216, Gly219, Ser145 and the side chain of Lys143. The site is unique to uPA 
making it a prime region to target for achieving uPA-selective small molecule inhibitors.  
 
Development of uPA inhibitors began in the 1980’s with early inhibitors based on ε-caproic 
acid 5, as well as (benz)amidine and phenylguanidine that showed sub-micromolar potencies 
(Figure 1.9).162-165 In 1987 Vassalli and Belin reported that amiloride 6 is a moderately potent 
(Ki = 7 μM) and selective inhibitor of soluble uPA.
166 Potent and selective 4-substituted-
benzo[b]thiophene-2-carboxamidine inhibitors were reported with IC50 values as low at 70 nM 
(e.g. 7).284 4-Iodo-benzo[b]thiophene-2-carboxamidine (B428, 1) inhibited tumour cell growth 
and invasion in syngeneic mouse breast and rat breast and prostate cancer models.102,167,168 
The S1β subsite was identified as a major contributor to the high uPA affinity of 4-substituted-
benzo[b]thiophene-2-carboxamidines, where interactions between the substituent at the 4-







Figure 1.9: Small molecule inhibitors of uPA, including amiloride 6 (red box). 
 
Inhibitors based on a 2-naphthamidine scaffold were designed to specifically target S1β with 
substituents at the 8-position.4 Additional substitution at the 6-position created potent 
inhibitors with improved uPA selectivity.169 Optimization of the 8-substituted-2-
napthamidines yielded very potent inhibitors (e.g. 8, Ki = 4.7 nM) that showed further 
improvements in selectivity for uPA and high oral bioavailability (Foral = 55% in rats).
170 
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The high selectivity of 6,8-disubstituted 2-napthamidine inhibitors was attributed to 
interactions that complemented those made in the S1 and the S1β subsites, namely H-
bonding between the 6-substituents and Asp60A.156 Asp60A is a component of the 60-loop 
region, an area of the uPA binding site that shows large sequence diversity across different 
TLSPs. Targeting interactions at this site in addition to making the key interactions at the 
larger sites (i.e. S1, S1β) is thus an attractive strategy for achieving potency and selectivity in 
uPA inhibitors. 
 
Despite the high potency and selectivity of several reported small molecule inhibitors of uPA, 
only a single example (to our knowledge) has progressed to clinical evaluation in the cancer 
setting. WX-UK1 9, a peptidomimetic derivative of 3-amidinophenylalanine, (uPA Ki = 410 nM), 
showed demonstrable antitumor efficacy in phase II trials (Wilex website, 
http://www.wilex.de/portfolio-english/mesupron/phase-i-ii-with-mesu/, Published 2015, 
accessed 29th Jan 2017). Phase II evaluation of an orally bioavailable prodrug form 
(MESUPRON) in combination with gemcitabine led to a 17% increase in 1-year survival in 
pancreatic cancer patients compared to patients treated with gemcitabine alone.171 Similar 
results were found when the prodrug was trialed in combination with capecitabine in the 
treatment of HER2-negative breast cancer.172  
 
3-Amidinophenylalanine-based inhibitors (including MESUPRON) show low selectivity, 
inhibiting both plasmin and trypsin with similar or higher potency than uPA.173 Lack of 
specificity of the compounds confounds interpretation of the clinical data as antitumour and 
antimetastatic effects may arise from inhibition of multiple cancer-relevant proteases. Since 
completion of Phase II studies the rights to MESUPRON were acquired by Red Hill Biopharma, 
who are currently raising funds for further clinical development. (RedHill Website, 
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http://www.redhillbio.com/Mesupron, accessed 29th Jan 2017). No clinical data with truly 
selective uPA inhibitors have been reported to date.  
 
Early small molecule inhibitors of uPA were mostly arginine mimetics containing a mono or 
biaryl core with an appended amidine or guanidine group. These basic functional groups are 
positively charged at physiological pH (pKa ~ 11-13) and serve to anchor the inhibitor in the S1 
binding site via the salt-bridge with Asp189. Basic groups were considered essential for potent 
uPA inhibition until recently.156,157  High basicity of these groups can restrict efficient intestinal 
uptake and oral bioavailability and promote rapid clearance. Less basic groups that are able to 
maintain the Asp189 salt-bridge interaction have long been sought after.157,174 The uPA 
inhibitor amiloride uses the much less basic acylguanidine moiety (pKa = 8.71) to make the 
key interaction, suggesting it could serve as an attractive scaffold for development of novel 
inhibitors.295 Amiloride’s long history as an oral K+-sparing diuretic provides clear evidence of 
its excellent drug properties further supporting its potential utility.175 
 
Recent efforts have attempted to address the poor pharmacokinetic properties of positively 
charged arginine mimetic inhibitors by replacing the amidine/guanidine groups with 
uncharged moieties. Heynekamp et al. developed potent uPA inhibitors based on an 
isocoumarin scaffold bearing an uncharged bromopropyloxy group after docking simulations 
predicted that the terminal bromine would interact with Asp189.175 3-Bromoalkoxy-4-chloro-
7-benzamidoisocoumarin 10 was synthesized and found to inhibit uPA with a Ki of 34 nM. 
Selectivity of 10 for uPA over other TLSPs was not reported.176  
 
Primary amines have also been investigated as replacements for amidine/guanidine groups. 
Fragment-based screening by X-ray crystallography identified the (R)-enantiomer of the 
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antiarrhythmic drug mexiletine as a possible uPA inhibitor.177 Although mexiletine displayed 
low affinity for uPA (IC50 >1mM), the favourable orientation of the interactions it made with 
the protein coupled with its high bioavailability justified further investigations. Medicinal 
chemistry efforts led to the development of 11 a potent  and moderately selective uPA 
inhibitor (Ki = 72 nM).
177 The favourable pharmacokinetic profile of this compound (Foral (rat) = 
60%, t1/2 = 7.5 hours, high volume of distribution) indicates this was an effective strategy for 
reducing basicity of the S1-occupying moiety. In 2009 West et al. reported a potent and 
selective uPA inhibitor 12 (IC50 = 39 nM) based on a linear poly-aryl scaffold that used a 
primary amine group to make the interaction with Asp189.178 Unfortunately this series 
showed poor bioavailability and high clearance rates  in vivo (12, Foral (rat) = 18%, t1/2 = 0.26 
hours).178 
 
Linear, cyclic and bicyclic peptide inhibitors of uPA have been described, with some showing 
single digit nM potencies.179-181 However, unmodified peptidic inhibitors often suffer from 
poor bioavailability and short half-lives.156 Inclusion of non-natural, chemically modified amino 
acids (e.g. phenethylsulfonamidino-D-serine) were used to address these issues in some 
recent peptidomimetics (e.g. 13, Ki 20 nM).
182 Compound 13 displayed high antimetastatic 
activity in mice with HT-1080 fibrosarcoma xenografts, decreasing the number of pulmonary 
metastatic foci by over 95% and significantly increasing animal lifespan (>3-fold).182 Low-
nanomolar irreversible peptidic inhibitors of uPA bearing electrophilic diarylphosphonates 
that react with the active site Ser195 hydroxyl have been reported.183 Second generation 
diarylphosphonates (e.g. 14, IC50 = 3.1 nM) showed in vivo efficacy in rat cancer models, 
decreasing primary breast tumour weight by up to 27% and lung metastases by up to 70%.184 
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1.5 Small molecule inhibitors of NHE1 
 
Due to the difficulties in crystalizing membrane proteins, a complete X-ray crystal structure of 
NHE1 has not yet been described, which has complicated efforts to define the exact target 
site(s) for small molecule inhibition. Mutagenesis studies and comparisons with prokaryotic 
homologues identified residues in transmembrane helix IV (TM-IV), TM-IX and TM-X as being 
involved in inhibitor and/or Na+binding.185,186,187-191 Crucially, Phe161 of TM-IV was identified 
as a key determinant of susceptibility to small molecule inhibition as non-neutral missense 
mutations cause dramatic increases in inhibitor Ki (see Table 1, Slepkov et al., 2007 for 
details).192 Amiloride and related inhibitors likely bind at or near the Na+ binding site via 
interactions with Glu346 (TM-IX).193,194 
 
The design of small molecule inhibitors of NHE1 effectively began with amiloride in 1982, 
when it was reported by Benos et al. as an inhibitor of Na+ entry into cells that acted through 
inhibition of the NHE and ENaC families of Na+ transporters (Figure 1.10).175 Modification of 
amiloride by double substitution at the 5-NH2 group yielded NHE inhibitors that have become 
standard tools for investigating Na+ transport. These include  HMA 27 (5-N,N-
hexamethyleneamiloride), DMA 28 (5-N,N-dimethylamiloride), EIPA 29 (5-(N-ethyl-N-
isopropylamiloride) and MIBA 30 5-(N-methyl-N-isobutylamiloride) (Figures 1.10 and 1.11).195 
These inhibitors show greatly improved potency towards NHEs and reduced activity against 
ENaCs and other Na+ transporters (e.g. NCX). Amilorides tend to show only moderate 
selectivity for NHE1 over other NHE isoforms.196,197  
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Figure 1.10: Reported small molecule inhibitors of NHE1, including amiloride 6 (red box). 
 
Direct replacement of the pyrazine core of amiloride with an isosteric pyridine produced the 
more potent 15 (IC50  = 1.2 µM). Use of a phenyl acylguanidine led to highly selective NHE1 
inhibitors cariporide (16, IC50 = 120 nM) and eniporide (17, IC50 = 30 nM). These compounds 
underwent clinical trials, Phase III in the case of cariporide 16 and Phase II in the case of 
Eniporide 17, for the treatment of post-ischemic cardiac reperfusion injury.198-201 Second 
generation orally-active phenyl and heteroaryl acyl guanidines have since been reported, 
including 18 (EC50 31 = nM, Foral = 73%, t1/2 = 3.2 h) and the eniporide analogue rimeporide (19, 
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IC50 = 300 nM), which recently received orphan drug designation from the European Medical 
Administration (EspeRare.org) for the treatment of Duchenne Muscular Dystrophy.202,203 
 
Cyclopropyl acylguanidine BMS-284640, 20 (IC50 9 nM, Foral = 63%, t1/2 = 3 h) and 
carboximidamide T-162559 21 (IC50 = 0.96 nM) inhibitors have also been reported. 
Cyclohepta[b]pyridine-3-carbonylguanidine derivative TY-12533 (22, IC50 = 32 nM)  showed 
strong inhibition of NHE1 in vivo along with decreased neural toxicity; a significant issue with 
earlier NHE1 inhibitors.204,205 Uncharged inhibitors include the substituted benzamide 
SL59.1227 (23, IC50 = 3.3 nM) and aminopyrimidine compound 9t (24, IC50 = 6.5 nM).
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Clinical studies with NHE1 inhibitors have focused exclusively on treating myocardial 
infarction-related reperfusion injuries.207-209 Reperfusion injury results from NHE1 
hyperactivation that occurs during ischaemia and reperfusion following myocardial 
infarction.210 Excess accumulation of intracellular Na+ drives the rapid influx of Ca2+ by Na+-
gradient-linked transporters (e.g. NCX), leading to apoptosis of cardiac cells.211 NHE1 
inhibitors are thought to prevent cardiac tissue damage following ischaemia by preventing the 
toxic accumulation of Ca2+, provided they are administered within a suitable timeframe 
following a heart attack.199,212 The potential of these molecules in cancer treatment has only 
recently attracted interest, with several authors now calling for investigation of NHE1 




1.6 Amiloride analogues 
 
Amilorides as a class show broad utility in the clinic and the research laboratory. More than 
1000 amiloride derivatives have been synthesized to date and their pharmacology examined 
across a wealth of biological platforms. Some analogues have become valuable chemical 
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biology tools for probing cation transport mechanisms and related processes.175,214,215 Potent 
and selective amiloride based inhibitors have been discovered for epithelial sodium channels 
(ENaC), sodium hydrogen exchangers (NHEs) and sodium calcium exchangers (NCX). A 
summary of the structural determinants underpining activity of amiloride analogues against 
these exchangers is provided in Figure 1.11.  
 
The parent drug amiloride 6 is a potent inhibitor of ENaC but shows only low/moderate 
activity against NCX. N-substitution of the guanidine in amiloride with alkyl and aryl groups, as 
in DCB 25, significantly increased potency against both ENaC and NCX.175 Alkyl or aryl 
substitution of the 5-NH2, as in HMA 27, selectively removed ENaC activity while greatly 
enhancing NHE1 inhibition. Aryl/alkyl substitution on both the guanidine nitrogen and 5-NH2 
group yielded potent and selective NCX inhibitors that lack activity against ENaC (e.g. CBDMB 
26).183 Despite the plethora of amiloride analogues bearing substitutions on the amines in the 
3 and 5 positions, or on the acyl guanidine nitrogens, very few 6-substituted amilioride 
analogues have been described (<20). A single patent describing the synthesis of 6-phenyl 
HMA, the sole example of a 6-HMA analogue, has been reported.216 
 
In addition to tunable activities against cation transporters, amiloride analogues show a host 
of side activities against a variety of extracellular and intracellular targets. These include 
protein kinase-C, serine-threonine kinases, adenylate cyclase, monoamine oxidase, several 
adrenergic and purinergic receptors and other GPCRs.217-223 At a functional level, amiloride 







Figure 1.11: Structural determinants for differential activity of amiloride analogues against 
various cation transporters. ENaC = epithelial Na+ channel, NCX = Na+/Ca2+ exchanger, NHE = 
Na+/H+ exchanger. Data summarized from reference 195. 
 
Inhibition of diverse biological targets by amiloride is due, at least in part, to the cation 
mimetic properties of its pendant acyl guanidine. Protonation of the guanidine moiety at 
physiological pH confers analogues with a net positive charge that is functionally similar to a 
monovalent cation (e.g. Na+). This cation mimetic property permits interactions with the 
monovalent cation binding sites prevalent in many proteins, as evidenced by the competition 




Amiloride.HCl was first approved for clinical use in 1967.228 The drug acts as an inhibitor of 
ENaCs in the distal nephron of the kidney. As a relatively weak diuretic, amiloride is more 
commonly used as an antikalliuretic in combination with thiazide or loop diuretics (e.g. 
frusemide), particularly in patients suffering from hepatic cirrhosis or congestive heart 
failure.229,230 Amiloride is also used in combination with other diuretics to control K+-levels.231 
The antikaliuretic qualities of amiloride arise as a downstream consequence of ENaC 
inhibition, which diminishes the Na+ gradient needed to drive Na+-K+ ATPase-mediated K+ 
excretion.232,233 
  
Use of amiloride at normal doses (<20 mg/day) produces few side effects and it is generally 
well tolerated. The drug is contraindicated in patients displaying hyperkalemia, acidosis or 
impaired renal function. Hyperkalemia and associated cardiac arrhythmias are potentially life 
threatening side-effects of amiloride overdose due to the increased blood potassium levels, 
however, when used in combination with thiazide diuretics incidences of these events are 
rare (<2%).234 
 
Since the early 1980s numerous studies have demonstrated the antitumour properties of 
amiloride in a variety of animal models. Sparks et al.235 first reported on its antitumor effects 
in 1983 after demonstrating that amiloride produces dose-dependent decreases in tumor 
growth and tumor cell proliferation in A/J mice bearing H6 hepatocellular carcinoma (HCC) or 
DMA/J mammary adenocarcinoma xenografts. Later reports showed that amiloride 
suppresses metastasis and primary tumour growth in allo/xenograft and mutagen-induced 
murine cancer models. Very high oral doses (200 mg/kg/day) reportedly produced complete 
remission in a prostate carcinoma xenograft model.236 For a comprehensive review on the 
antitumor effects of amiloide in animals see Matthews et al., 2011.13 
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In addition to the many observations in animal models, sporadic reports also exist of 
spontaneous remission of cancers in patients who have received chronic amiloride 
treatment.85 Amiloride (5-10 mg three times daily) administered as the sole chemotherapeutic 
treatment following failure of cyclophosphamide and cisplatin therapy achieved complete 
remission in a patient with metastatic ovarian carcinoma (i.e. disease free interval >11 
years).237  
 
1.7 Hypothesis: Anticancer effects of amiloride arise through dual inhibition of 
uPA and NHE1 
 
There is considerable evidence to support the hypothesis that the in vitro and in vivo 
anticancer effects of amiloride arise through dual inhibition of both uPA and NHE1. 
 
1.7.1 Amiloride and analogues as uPA inhibitors 
 
As described earlier, amiloride is a moderately potent, reversible and competitive active site 
inhibitor of uPA. Inhibition of uPA by amiloride has been shown to produce antimetastatic 
effects in several models.166,238 Highly invasive PC-3 prostate adenocarcinoma cells exhibiting 
amplified expression of PLAU (gene encoding uPA) showed reduced invasiveness in the 
presence of amiloride compared to cells lacking PLAU amplification (DU145 and LNCaP).239 
Similar results were observed with the small molecule uPA inhibitor B428 1.240 
 
Amiloride 6 significantly inhibited in vitro plasmin formation and invasion by highly invasive 
(UCT-2) and non-invasive (UCT01) transitional cell carcinomas. UCT-2 cells showed 
significantly higher uPA mRNA expression, uPA protein levels and uPA activity relative to 
UCT01 cells.241 Amiloride also inhibited IGF-1 and HGF-stimulated migration and invasion of 
L3.6pi pancreatic carcinoma cells.242 Inhibition of invasiveness was equivalent to treatment 
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with uPA-specific monoclonal antibodies. Amiloride and B428 1 caused dose-dependent 
decreases in cell migration and invasion in MDA-MB-231 and MDA-MB-436 breast 
adenocarcinoma cell lines, with the effects attributed to uPA inhibition.243 
 
A recent report found that amiloride causes dose-dependent decreases in uPA mRNA and 
protein levels and activity in MKN45 gastric carcinoma cells.244 Oral administration of 
amiloride reduced tumour growth and prolonged survival in BALB/c mice with MKN45 
xenografts. Similarly, amiloride suppressed human fibrosarcoma cell invasion in vitro (HT-
hi/diss, highly intravasating variant of HT-1080 cell line) through inhibition of uPA. In vivo 
experiments using a chick embryo chorioallantoic membrane HT-hi/diss xenograft model 
showed amiloride treatment decreased tumour weight, intravasation and metastasis.245 
Amiloride also prevented formation of secondary lymph node metastases and decreased 
tumour volume in rats bearing with highly metastatic, uPA-overexpressing R3327-AT3 
prostatic tumour xenografts.246 Finally, oral amiloride administration significantly decreased 
the number of pulmonary metastatic foci in MATB 13762 rat breast adenocarcinoma 
xenograft models.247-249 
 
1.7.2 Amiloride analogues as NHE1 inhibitors 
 
Amiloride 6 is a moderately potent inhibitor of NHE1 (IC50 range = 7-84 µM), although specific 
values for inhibitory constants vary between experimental techniques and species.215 It is 
known from NHE1 SAR data that amiloride analogues bearing alkyl substitutions at the 5-NH2 




Figure 1.12: Summary of 5-N,N-disubstituted amiloride analogues as NHE1 inhibitors. DMA = 
5-(N,N-dimethyl)amiloride, EIPA 5-(N,N-ethylisopropyl)amiloride, MIBA 5-(N,N-
methylisobutyl)amiloride, HMA 5-(N,N-hexamethylene)amiloride. Apparent Ki values were 
derived from 22Na+-efflux experiments conducted using N-formyl-methionyl-leucyl-
phenylalanine stimulated human primary neutrophils.197 
 
As described in section 1.3, NHE1 overexpression and hyperactivation provides cancer cells 
with an adaptive advantage over neighbouring healthy cells because the high Na+/H+ exchange 





252 Experimentally, hyperactivation 
of NHE1 was found to selectively sensitize murine KHT sarcoma and EMT-6 breast 
adenocarcinoma cells to intracellular acidification following NHE1 inhibition with EIPA 29.253 
To explore this concept further, amiloride analogues have been tested in combination with 
nigericin, a H+-ionophore that equilibrates pHe with pHi. Inhibition of NHE prevents pHi 
recovery (i.e. pHi) following nigericin treatment in acidified media. Nigericin in combination 
with amiloride or its analogues DMA 28, EIPA and MIBA 30 caused cell death in MGH-U1 
Human or EMT-6 breast adenocarcinoma cells at pH < 7, whereas no cytotoxic effect was 
observed for each amiloride in isolation. The effect was confirmed as being NHE-1 dependent 
using NHE-deficient PS120 cells.254 Nigericin in combination with amiloride or EIPA was shown 
to significantly reduce tumour cell viability following radiotherapy in vivo. 255 
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NHE1 inhibition by amiloride analogues potentiates thermosensitivity in cancer cells.256,257 For 
example, SCK murine mammary caricinoma cell killing is enhanced by treatment with 
amiloride, HMA 27 or EIPA in pH 6.6 media at 43 C, relative to cells in pH 7.5 media.258 HMA 
can delay tumour growth in vivo and it significantly increases SCK cell killing post heating of 
xenografted mice, as determined by clonogenic assay of excised tumours.259 
 
NHE1 overexpression in HCC correlates with increased tumour size, invasion, tumour stage 
and shortened survival.260,261 Amiloride analogues have been shown to inhibit HCC motility 
and invasion through inhibition of NHE1.150 Oral EIPA produced dose-dependent decreases in 
HCC primary tumour weight in nude mice receiving HepG2 xenografts.261 Alkalinization of pHi 
in response to tumour promoting xenobiotics (e.g. phorbol esters) or growth factor 
treatments promoted hepatocyte proliferation through upregulation of DNA synthesis and 
transcription via an NHE1-driven process.262 Amiloride, HMA and EIPA suppressed hepatocyte 
proliferation in a dose-dependent manner via inhibition of NHE1. Similarly, NHE1-driven 
hepatocyte proliferation triggered in residual liver tissue following hepatectomy is blocked by 
HMA.263 These results highlight the central role NHE1 in hepatocyte proliferation and suggest 
the potential of amiloride analogues as possible treatments for HCC. 
 
NHE1-mediated acidification of pHe causes selective activation of acid sensing ion channels 
(ASICs) in adenoid cystic carcinoma cells.264 ASICs form part of the ENaC/degenerin 
superfamily of ion channels and are primarily found on neurons.265 The physiological roles of 
ASICs continue to be elucidated but specific isoforms are thought to be involved in 
nociception and mechanosensation.266 In the context of cancer, it has been proposed that 
ASIC upregulation may help tumour cells cope with increasingly acidic extracellular 
environments driven by NHE hyperactivation. Constitutive activation of ASICs regulates cell 
43 
volume in glioma cells, allowing alterations in cell size and shape that contribute to high 
invasive capacity.267 Inhibition of ASICs by amiloride disrupts volume regulation in glioma cells, 
reducing migration in vitro.267-269 ASIC1 regulation of cell-cycle progression and migration via 
the ERK1/2 pathway is disrupted by benzamil, leading to potent inhibition of D54-MG 
glioblastoma cell migration in vitro.269  
 
A recent publication demonstrating the role of ASIC1 in cell invasiveness with a panel of 
breast cancer cell lines showed that amiloride significantly suppresses LM-4142 tumour 
growth in an orthotopic murine xenograft model.270 Aside from the downstream effects of 
NHE inhibition on ASIC activation, various amiloride analogues inhibit ASICs in their own 
right.266 In 2009 scientists from Merck (the original developers of amiloride) published 
structure-activity relationship (SAR) study exploring 5-substituted amiloride analogues as 
ASIC3 inhibitors for the treatment of chronic pain.271 
 
Tumour selective effects of amiloride analogues on NHE inhibition have been noted in 
leukemic cell lines relative to healthy hematopoietic cells. Constitutive activation of NHE1 in 
leukemic cells and leukemic patient primary blood samples results in a higher resting pHi 
relative to normal hematopoietic tissues, which sensitizes these cells to the effects of NHE1 
inhibition.272 HMA treatment was found to trigger apoptosis in >90% of KG-1a leukaemic cells 
and primary acute lymphoblastic leukaemia cells, while equivalent doses caused no cell death 
in healthy hematopoietic cells.272 Sequence comparison of cDNA from peripheral blood 
mononuclear cells (PBMCs) of leukaemic patients and leukaemia cell lines relative to healthy 
primary PBMCs revealed greater rates of nucleotide polymorphisms, which could contribute 
to pathogenesis. However leukaemia specific NHE1 sequence mutations were not detected.273 
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In an earlier study, amiloride was found to block cell cycle progression in murine L 1210 
lymphocytic leukaemia cells without effects on cell viability.274 
 
The NHE1 inhibitor cariporide 16 was found to reduce the colony forming ability of primary 
PBMCs taken from BCR-abl-positive leukaemia patients following relapse after imatinib 
treatment.3 Cariporide treatment was also able to resensitize K562 BCR-abl-positive cells to 
imatinib-mediated apoptosis via inhibition of NHE1.3 Another report found that amiloride 
causes alternate splicing of apoptosis regulators Bcl-x and HIPK3 and oncogenic BCR-abl, 
leading to potentiation of imatinib-induced apoptosis in K562 and BaF3/Bcr-Ablt315l cells.275 
Alternative splicing was not seen with EIPA, leading the authors to suggest that modulation of 
apoptosis by amiloride occurs via NHE1-independent mechanisms, although this was not 
tested experimentally.  
 
Tescalin-mediated NHE1 upregulation was recently shown to play a key role in sorafenib 
resistance observed in FLT3-ITD acute myeloid leukaemia patients.276 HMA treatment showed 
increased cell killing of sorafenib-resistant primary AML cells relative to sorafenib-naïve 
samples, whilst showing no effects on healthy hematopoietic cells. Selectivity for resistant 
cells was attributed to inhibition of NHE1 by HMA and the associated acidification of pHi. In 
combination with sorafenib, HMA potentiated sorafenib-mediated apoptosis in MOLM-13 
sorafenib-resistant cells. HMA alone suppressed engraftment of sorafenib-resistant primary 
acute myeloid leukaemia cells in nude mice and engraftment was completely abolished when 
HMA was combined with sorafenib.276 
 
Amiloride, HMA and EIPA decrease pHi-dependent DNA synthesis in rat hepatocytes treated 
with tumour-promoting 12-O-tetradecanoylphorbol-13-acetate, while EIPA decreased 
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metastasis and invasion of hepatocellular carcinoma cells.10,150,262 HMA-induced acidification 
of pHi by NHE blockade promotes maturation of leukocyte elastase inhibitor into its pro-
apoptotic form L-DNAse II, leading to the apoptotic fragmentation of DNA in corneal 
endothelial cells.277 
 
1.8 Dual uPA/NHE1 inhibitors derived from amiloride  
 
Several lines of evidence support investigation of amiloride 6 or one of its analogues as an 
anticancer therapeutic in the clinical setting.13 The repeated demonstration of antitumour and 
antimetastatic effects of amiloride and analogues across a plethora of in vitro and in vivo 
cancer models would typically provide a strong motivation for clinical studies. Impressive pre-
clinical efficacy coupled with oral bioavailability and a long history of safe usage in humans 
should make amiloride an attractive clinical candidate. Furthermore, anecdotal reports of 
amiloride treatments causing remission of neoplastic disease in human patients should bolster 
interest in clinical anticancer investigations with the drug.237 Despite this, only a single report 
exists of amiloride undergoing clinical evaluation for cancer. In this study, no significant 
difference in cancer risk was observed in 6614 elderly hypertensive patients receiving a fixed-
ratio of 2.5 mg amiloride/25 mg hydrochlorothiazide per day compared to age-matched non-
recipients over a 5-year period.278 
 
Assuming that the bulk of amiloride’s anticancer effects arise through dual inhibition of uPA 
and NHE1, the relatively modest in vitro potency of amiloride against these targets presents 
significant challenges to its successful use clinically as an anticancer drug. Amiloride has a 
relatively low maximum allowable daily dosage (20 mg/day) due to the risk of hyperkalemia 
and potentially life-threatening cardiac arrhythmias at higher doses. As a result, cancer 
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patients receiving amiloride would require costly and inconvenient monitoring of blood K+-
levels over a prolonged period, making out-patient administration impractical. Indeed, co-
administration with a kalliuretic agent (e.g. a thiazide diuretic) might be necessary to mitigate 
the risk of adverse events. Moreover, administration at the maximum allowable dosage (e.g. 
20 mg/day) would be unlikely to afford sufficiently high plasma concentrations to strongly 
inhibit these two targets and evoke a robust antitumour effect in humans.  
 
A possible solution would be to create an analogue that shows decreased affinity for ENaCs, 
the target responsible for the drug’s diuretic and antikalliuretic effects. This would allow 
administration of higher doses without the risk of hyperkalemia. Equally desirable would be to 
increase the potency of amiloride towards both uPA and NHE1 so that lower plasma 
concentrations could achieve the desired anticancer effects. Medicinal chemistry campaigns 
of this type, known as Selective Optimization of Side Activity (SOSA), are a popular modern 
approach in drug development.279,280 
 
Fortunately, structure activity relationships of amiloride analogues as ENaC inhibitors are well 
characterized.195,281 As mentioned in section 1.7.2, substitution of the NH2 group at the 5-
position reduced activity against ENaCs, which would be expected to diminish the diuretic and 
antikalliuretic effects of these analogues in vivo.281 The dramatically reduced inhibition of 




Figure 1.13: Inhibition of ENaC-mediated Na+ currents across an electrically tight monolayer of 
FRTL-5 Rat Fischer Thyroid Epithelial cells by amiloride and HMA. Amiloride inhibition is more 
than 3 orders of magnitude higher than HMA. Data (unpublished) courtesy of A. Dinudom 
(University of Sydney, Australia). 
 
Another significant issue facing development of an amiloride analogue into an anticancer drug 
is the lack of chemical novelty around the scaffold. As the cost of bringing a new drug to 
market can exceed $1.5 billion dollars (USD), investors are afforded the opportunity to recoup 
this expenditure and generate profits by securing exclusive rights for 20 years to the 
manufacture and sale of new drugs through patenting.282 In order to secure patent rights, an 
inventor must create a new chemical entity (NCE), a novel chemical structure that is 
considered non-obvious and for which there exists no prior reference in the scientific or 
patent literature (prior art). As patent protection for amiloride has long since expired, the 
incentive to invest in development of amiloride as an anticancer drug is significantly reduced. 
If, however, novel amiloride-based structures could be discovered that show increased 
antitumour effects, for example, by improving activity against uPA/NHE1, such compounds 
would be more attractive in terms of patentability and commercialization. 
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Previous work from the Kelso and Ranson Labs at UOW saw completion of a comprehensive 
SAR study of amiloride analogues as inhibitors of uPA. Diverse compounds were synthesized 
to investigate the effects of various substitution patterns on uPA affinity, including isosteric 
replacement of the acylguanidine group and pyrazine core, removal of 3 and 5-position 
exocyclic amines and substitution at the 5 and 6-positions.6 Key SAR findings from this work 
are summarized in Figure 1.14. 
 
The authors concluded that amiloride analogues featuring short aryl/alkyl amino substituents 
at the 5-position and/or bulky substituents at the 6-position show slightly increased affinity 
for uPA. Specifically, the 5-substituted amiloride analogues HMA and EIPA and the 6-
substituted 6-iodoamiloride and 6-phenylacetyleneamiloride showed improved potency 
against uPA (HMA IC50 = 6 µM, EIPA IC50 = 6 µM, 6-iodoamiloride IC50 = 6 µM and 6-




Figure 1.14: Summary of amiloride SAR study completed by Matthews et al. from the Kelso 
Group.6 Regions of amiloride altered in each approach are highlighted in red. 
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This study suggested that further activity gains might be possible by combining favourable 
substitutions at the 5- and 6-positions (i.e. additive SAR). HMA represents an excellent starting 
point for exploration of 5,6-disubstituted amilorides due its very high potency against NHE1 (Ki 
= 162 nM) and greatly reduced activity against ENaCs relative to amiloride.197,281 Additionally, 
HMA has been shown to exhibit a variety of anticancer properties in its own right (see section 
1.7). Importantly, the 6-Cl substituent on amiloride is oriented towards the S1β subsite of 
uPA, forming predominantly hydrophobic interactions with residues Gln192, Gly219 and the 
Cys220-Cys191 disulfide bond (Figure 1.15).238 
 
 
Figure 1.15: X-ray co-crystal structure of amiloride bound to the active site of uPA. S1β subsite 
is labelled. The 6-Cl atom (Green stick) forms favourable hydrophobic interactions with the 
S1β residues. Substituents bulkier than Cl may be better able to fill the subsite, improving 
affinity for uPA. (Image generated from PDB #:1F5L, originally reported in reference 226). 
 
Amiloride analogues bearing substituents larger than Cl at the 6-position will likely show more 
complete occupancy of S1β leading to increased uPA affinity. Provided HMA occupies a similar 
pose to amiloride upon binding to uPA, it is likely that similar or greater increases in potency 
might be achieved upon substitution of HMA at the 6-position.  
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1.9 Thesis Aims  
 
Despite significant advances in targeted anticancer therapeutics over the past 20 years, 
relatively small gains have been made in chemotherapeutics that could provide general 
treatments for diverse neoplastic conditions, especially in advanced disease. For this reason, 
therapeutics able to target phenotypes observed in many different tumour types would 
provide significant benefits in the clinic. Drugs able to simultaneously inhibit different aspects 
of carcinogenesis and metastasis processes are particularly well suited to this aim.  
uPA is a key regulator of metastatic potential and is overexpressed in many aggressive 
cancers.5 Small molecule inhibitors of uPA show potent antimetastasis activities in vivo, with 
one compound showing efficacy in Phase II clinical trials.182 NHE1 activation is an essential 
contributor to the ‘pro-malignant’ reversal of transmembrane pH gradients observed in 
virtually all cancers and is upregulated in many cancer cell types.10  
 
The amiloride analogue HMA is an ideal starting point for development of novel, dual-
targeting uPA/NHE1 inhibitors as anticancer drugs due to its low- µM inhibition of uPA, potent 
inhibition of NHE1 and demonstrated ability to selectively inhibit multiple cancer-related 
processes, both in vitro and in vivo. Identification of novel 6-substituted HMA analogues that 
show increased potency against uPA whilst maintaining high potency against NHE1 and low 
activity against ENaCs would be attractive candidates for development towards a new class of 
anticancer drugs with a novel ‘dual’ mechanism of action. 
 
6-Substituted HMA analogues were synthesized in this work with the aim of increasing 
potency through enhanced binding interactions in the S1β subsite. Targeting S1β to increase 
ligand affinity was a successful strategy in previous uPA inhibitor programs.161 Since S1β is 
unique to uPA, increasing interactions at this site will likely improve selectivity of the 
51 
compounds for uPA over other TLSPs. Synthesis of 6-HMA analogues was approached using 
Pd-catalyzed cross-coupling chemistries (e.g. Suzuki-Miyaura and Sonogashira reactions) due 
to their wide functional group tolerability, mild reaction conditions and generally high yields. 
This type of chemistry has not been reported previously in the synthesis of 6-amiloride 
analogues (6-phenyl HMA). It should be noted that to date only a single example of a 6-HMA 
analogue has been reported.216 As such, generation of a library 6-HMA analogues using this 
approach represented a significant novel contribution to amiloride/HMA chemistry. 
 
The overall aim of the work was to use the tools of medicinal chemistry to discover novel 6-
HMA analogues that show high potency against both uPA and NHE1 and low activity against 
ENaCs, along with other interesting anticancer properties in vitro. Discovery of such 
compounds could pave the way for further studies of anticancer efficacy in animal models and 






















1.9.1 Specific aims 
 
The specific aims of the thesis were to: 
 
 Synthesize a library of 6-HMA analogues through a novel application of Pd-
catalyzed cross-coupling chemistry (Chapter 2). 
 Evaluate the inhibitory potency of synthesized analogues against uPA using 
solution-phase enzyme inhibition assays (Chapter 2). 
 Obtain X-ray co-crystal structures of lead inhibitors bound to uPA (Chapter 3). 
 Measure TLSP selectivity and cytotoxicity of leading compounds (Chapters 2 
and 4). 
 Characterize the effects of leading compounds on cell growth and behavior 
(Chapter 4). 
 Develop a new medium-throughput assay for quantitating the NHE1 inhibitory 



















CHAPTER 2: Synthesis and in vitro evaluation of 6-HMA analogues 
 
Previous efforts in the Kelso/Ranson laboratories focused on the synthesis and evaluation of 
amiloride analogues bearing substitutions at the 2, 3, 5 and 6 positions of the pyrazine core, 
with an emphasis on novel 5-amino substituted compounds.6 Key insights from the SAR 
included the requirement for exocyclic amines at the 3 and 5-positions and retention of the 
pyrazine core. Slight increases in uPA potency were achieved when short, uncharged alkyl or 
aryl amines occupied the 5-position and groups larger than Cl occupied the 6-position (Figure 
1.12). With this in mind, it was hypothesized that analogues bearing substituted amines at the 
5-position were suitable scaffolds for structural elaboration at the 6-position, with the goal to 
increase uPA affinity by establishing new contacts within the S1 subsite. 
 
Of the 5-substituted amiloride analogues examined, HMA 27 was selected as a starting 
scaffold due to its improved potency against both uPA (~ 2-fold) and NHE1  
(~ 520-fold) relative to amiloride.13 Superposition of the HMA-uPA X-ray co-crystal structure 
(Jiang et al., unpublished) onto the published AML:uPA structure indicated that the two 
compounds adopt almost identical binding poses within the uPA active site (Figure 2.1), with 
the 6-Cl groups of both compounds projecting directly into towards S1.160 This provided 
compelling evidence that 6-HMA analogues would similarly project other 6-substituents into 
S1, potentially leading to increased uPA/affinity. In this chapter the synthesis and in vitro 




Figure 2.1: X-ray co-crystal structures of AML and HMA bound to the serine protease domain 
of human uPA. A) AML-uPA complex (PDB:1F5L)226, B) HMA-uPA co-crystal structure (Jiang et 
al., FJIRSM, Fuzhou, China, unpublished), C): Backbone superposition of the AML:uPA and 
HMA:uPA structures highlighting the similarity between the binding poses of AML and HMA in 
the uPA active site. Orientation of the pyrazine core and 2-acylguanidine regions are virtually 
identical and the 6-Cl substituents project towards S1 in both structures. 
 
2.1 Synthesis of 6-HMA Analogues 
 
The route to 6-HMA analogues commenced with a nucleophilic aromatic substitution at the 5-
position of dichloropyrazine methyl ester 31 with hexamethyleneimine to yield the HMA 
precursor 32 (Scheme 2.1). Pd-catalyzed Suzuki-Miyaura was used to install aryl and 
heteroaryl substituents at the 6-position to provide 6-HMA methyl esters 33a-55a. The methyl 
esters were reacted with guanidine.HCl and the products purified by preparatory reverse 
phase HPLC (rp-HPLC). Anion exchange yielded the 6-substituted acyl guanidines as HCl salts. 
 
The late-stage common intermediate 32 was accessed on multigram scale from the 
commercially available 3-amino-5,6-dichloropyrazine methyl ester 31 via nucleophilic 
aromatic substitution with hexamethyleneimine in DMF at 80 C (Scheme 2.1). 
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Scheme 2.1: Strategy for the synthesis 6-HMA analogues. Reaction of pyrazine methyl ester 31 
with hexamethyleneimine afforded the late-stage common intermediate 32. Reaction of 32 
with aryl boronic acids or boronic acid pinacol esters via Suzuki-Miyaura-cross coupling 
afforded the 6-substituted methyl esters 33a-56a. Reaction of 33a-56a with guanidine 
afforded the 6-substituted acyl guanidines 33-56. Preparative rp-HPLC followed by anion 
exchange yielded the final products as HCl salts. 
 
A total of 10.42 g of 32 was obtained from 7 reactions in a combined yield of 56% (yield range 
for individual reactions 46%-74%). The reaction conditions had been previously developed in 
the Kelso group by Dr. Ghazala Yacoub, who adapted the original method of Cragoe et al. 
where hexamethyleneimine is reacted with 1 in isopropanol (iPrOH) at reflux.281 
 
Selective reaction of hexamethyleneimine at the 5-position (as opposed to the 6-position) 
occurs due to increased resonance stabilization of the nascent anion in the transition state 
afforded by the electron withdrawing carbonyl group located at the para position (Figure 2.2). 




Figure 2.2: Additional resonance stabilization from the electron withdrawing carbonyl group 
para to C5 favours substitution at the 5-position in 31 rather than the 6-position.283 
 
Intermediate 32 was subjected to Suzuki-Miyaura cross-coupling reactions using a variety of 
commercial aryl/heteroaryl boronic acids or pinacol boronate esters (Scheme 2.1). The 
mechanism of the Pd-catalyzed reactions is outlined in Figure 2.3. 
 
 
Figure 2.3: Proposed mechanism for Suzuki-Miyaura cross-coupling reactions with 32. 
  
The initial step involves formation of an organopalladium intermediate via oxidative addition 
of the Pd(0) catalyst into the carbon-chlorine bond of 32 (Figure 2.3).283 Attack of the newly 
formed Pd(II) centre by the base (CO3
2-) displaces the Cl- ion. Transmetalation between the 
activated organopalladium(II) intermediate and the boronate species in situ yields the aryl-aryl 
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Pd(II) complex. The cross-coupled product is formed in the final step via reductive elimination, 
which regenerates the Pd(0) catalyst. 
 
The first attempt at a Suzuki-Miyaura cross-coupling employed the conditions reported by 
Reyes et al., 2008 (Table 2.1) with phenylboronic acid as the coupling partner.284 One 
equivalent of 32 was reacted with 1.5 mole equivalents of phenylboronic acid in the presence 
of a 10-fold excess of K2CO3 and 5 mole % Pd(PPh3)4. The reaction was carried out in a 4:1 
toluene:EtOH mixture at reflux for 1 h. This initial attempt yielded the desired product along 
with the transesterified ethyl ester. Substituting EtOH with MeOH solved the problem and the 
modified conditions were employed in the synthesis of all methyl ester intermediates 33a-
55a. Yields for the reactions ranged between 36-98%. 
 
In the majority of cases, reactions were complete after 2 h, as evidenced by the consumption 
of starting material (SM) by thin layer chromatography (TLC) and electrospray ionization mass 
spectrometry (ESI-MS). Reaction mixtures were cooled and the catalyst removed by vacuum 
filtration through celite. After concentration in vacuo the crude products were purified by 
silica gel column chromatography using gradients of EtOAc in pet. spirit. 
 
Of the two reactions that used aryl pinacol boronates, 4-isoquinoline analogue 37a formed at 
a similar rate to reactions that used boronic acids (i.e. 2 h total reaction time). In comparison, 
N-ethylmorpholinopyrazole 39a formed more slowly, requiring 16 h at reflux for complete 
consumption of the SM.  
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Table 2.1: Suzuki-Miyaura cross-coupling reactions of 32 with aryl boronic acids to give methyl 
esters 33a-55a.*Compounds synthesized as described in reference 216. †Reaction conducted 
using aryl pinacol boronate. 
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The methyl esters were generally not soluble in CH2Cl2 or EtOAc:pet.spirit mixtures and 
required adsorption of the crude products onto silica gel for loading onto silica gel columns. 
All compounds were obtained in pure form and comprehensively characterized. Spectroscopic 
data for a representative compound 49a are provided in Figure 2.4.  
 
The 1H spectrum was referenced to a tetramethylsilane (TMS) internal standard at δ 0.00 
(Figure 2.4). The singlet at δ 8.66 integrated to two protons and was assigned to the 2’ and 6’ 
protons on the pyrimidine ring. A singlet at δ 4.05 with an integration of 3H was assigned to 
the methyl protons of the para methoxy group. This signal was shifted downfield by the 
deshielding effects of the pyrimidine ring nitrogens. Further upfield, a second 3H singlet at δ 
3.89 was assigned to the methyl ester CH3. Assignment of the methoxy versus methyl ester 
signals was provided by the observation that the methyl ester peak appeared at δ 3.89 for all 
methyl ester products. A triplet with an integration of 4H (J =5.75 Hz) at δ 3.36 was assigned 
to the 2” and 7” methylene protons positioned α to the tertiary amino group. Two singlets, 
each with an integration of 4H at δ 1.67 and δ 1.48, were assigned to the 3”/6” and 4”/5” 
methylene protons, respectively. Signals observed at δ 1.26 and δ 0.88 were assigned to 
‘grease’ impurities from solvents. The methyl ester and methylene signals were observed in 











Figure 2.4: 1H and 13C-APT spectra for 49a. 
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13C-APT spectra were referenced to CDCl3 at δ 77.2 and phased such that CH3 and CH carbon 
signals are positive and carbonyl groups, CH2 and carbons with no protons attached are 
negative (Figure 2.4). The carbonyl signal appeared in the expected region at δ 167.0. The 4” 
pyrimidine carbon was heavily deshielded by the two adjacent nitrogen and one oxygen 
atoms, appearing at δ 164.5. The single positive peak appearing in the aromatic region (δ 
158.1) was assigned to the symmetrical 2’ and 6’ carbons of the pyrimidine ring. These signals 
were deshielded by inductive electron withdrawal from the neighbouring ring nitrogens. The 5 
and 3-position pyrazine carbons were assigned based on their attachment to either a more 
deshielding cyclic tertiary amine in the case of 5 (δ 155.2), or a less deshielding primary amine 
in the case of 3 (δ 153.7). The negative signals found at δ 128.7 and δ 125.1 were assigned to 
the 6 and 1” aromatic carbons respectively. The signal at δ 113.8 was assigned to the carbon 
at position-2 of the pyrazine ring, this signal being significantly shielded by resonance 
contributions from the exocyclic amines at the ortho and para positions. The positive peaks 
observed at δ 55.1 and δ 52.1 were assigned to the methoxy group and methyl ester protons, 
respectively. The negative peak at δ 51.2 corresponded to the 2’ and 7’ hexamethylene ring 
methylene units, the signal being significantly deshielded by the neighbouring tertiary amine. 
The negative peaks at δ 28.0 and δ 27.2 were assigned to the 3’ and 6’ methylene carbons and 
4’ and 5’ methylenes carbons, respectively, as the deshielding effects decreased with 
increasing distance from the electron withdrawing group.  
 
Methyl esters 33a-56a were next subjected to guanidinylation reactions using free base 
guanidine formed in situ from guanidine.HCl in iPrOH in the presence of Na metal (Scheme 




Figure 2.5: Proposed mechanism for the guanidinylation of methyl esters 33a-56a to yield acyl 
guanidines 33-56. The mechanism is exemplified with the p-methoxypyrimidine analogue 49. 
 
Addition of sodium metal to iPrOH forms sodium propoxide and liberates H2 gas in the 
process. Next guanidine.HCl is added to obtain the nucleophilic free guanidine by the 
neutralization of HCl by iPrO-. The free guanidine attacks the carbonyl of the methyl ester via 
nucleophilic acyl substitution, expelling methoxide (MeO-) as the leaving group. Loss of a 
proton on the amide-like NH2
+ group affords the desired acyl guanidine (e.g. 49). 
 
Crude reaction products were purified by preparative rp-HPLC and the acylguanidines 
obtained as trifluoroacetate (TFA) salts after lyophilization. The TFA salts were stirred with the 
quaternary ammonium Cl- anion exchange resin in MeOH to yield the targets 33-56 as 
hydrochloride (HCl) salts. Acyl guanidines were fully characterized and their structures 
confirmed by spectroscopic analysis. Spectroscopic data for a representative acyl guanidine 49 
is provided in Figure 2.6. Yields from the guanidinylation reactions and overall yields from 32 
over 2-steps for all compounds are provided in Table 2.2. 
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Figure 2.6: 1H and 13C-APT spectra for 49. 
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The 1H spectrum for 49 was referenced to a TMS internal standard at δ 0.00 (Figure 2.6). 
Guanidinylation of the methyl ester 49a to give 49 was inferred by the loss of the methyl ester 
peak at δ 3.89 and the appearance of three heavily deshielded signals in the aromatic region 
(δ 8.00-11.00). The singlet at 10.76 with an integration of 1H was assigned to the amide NH of 
the acyl guanidine sidechain, this proton being deshielded by the electron withdrawing 
carbonyl and guandino NH2 groups. The broad singlets at δ 9.27 and δ 8.48, each with an 
integration of 2H, and were assigned to the two guanidino NH2 groups. The singlet at δ 8.51 
showed an integration of protons and was assigned to the 2’- and 6’- aromatic protons. The 
broad singlet at δ 6.75 with an integration of 2H and was assigned to the 3-position NH2 
group. In concordance with assignments for 49a, signals for the aromatic OCH3 group (δ 9.27, 
3H) and azepane ring methylene protons appeared in the same chemical shift regions, with 
each signal integrating to give the expected number of protons (δ 3.35, 4 H, 2’ and 7’; δ 1.66, 
4 H, 3’ and 6’; δ 1.47, 4 H, 4’ and 5’).  
 
Analysis of the 13C-APT spectrum of 49 supported observations from the 1H data (Figure 2.6). 
As expected, an additional peak at δ 161.9 was observed for to the guanidine carbon, and the 
OCH3 signal observed at δ 52.0 for 49a was absent.  All other signals varied from the 
assignments made for methyl ester 49a by less than 1.5 ppm. Accordingly, the negative signals 
at δ 166.6 and δ 164.0 were assigned to the carbonyl and 4” carbons, respectively. The 
positive peak at δ 157.8 corresponded to the 2’ and 6’- carbons of the pyrimidine ring. The 5-
and 3- pyrazine carbons were observed at δ 156.1 and δ 153.8, respectively. The aromatic 
peaks at δ 127.8, δ 124.7 and δ 112.5 corresponded to the pyrazine 6- carbon, pyrimidine 1”- 
carbon and pyrazine 2- carbons, respectively. The positive peak observed at δ 55.6 was 
assigned to the CH3 group and the negative peak at δ 51.6 corresponded to the 2’ and 7’ 
methylene carbons. Signals for the 3’ and 6’ and 4’ and 5’ methylene carbons were observed 
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at δ 27.8 and δ 27.1, respectively. A small impurity signal at δ 4.9 was also present in the 
spectrum. 
 
Low to moderate yields were obtained for guanidinylations due to competing formation of 
side products common in all reactions. 1H NMR and MS analysis of samples obtained from 
preparative rp-HPLC fractions revealed the presence of the isopropyl esters, presumably 
formed via transesterification with the reaction solvent under the basic reactions conditions. 
Lower reactivity of the isopropyl esters towards guanidinylation significantly decreased 
formation of desired products, with transesterification in effect creating a reservoir of 
unreactive material. 
 
Complete consumption of the methyl ester SM was not observed over the reaction times 
employed (1-3 h). Closer analysis of the guanidinylation reaction of 42a revealed that longer 
reaction times were required (up to 18 h) for complete consumption of the methyl ester but 
this was accompanied by increased formation of isopropyl ester and an unidentified polar side 
product. Attempts to substitute iPrOH for MeOH as the reaction solvent led formation of 














Table 2.2: Guanidinylation of methyl esters 33a-56a to provide target acyl guanidines 33-56. 
Yields over 2-steps from the starting methyl ester 31 are also shown.  
  
67 
Previous work from the Kelso and Ranson Labs had shown that 6-phenylacetylenyl amiloride 
(IC50 = 2 µM) is ~ 5-fold more potent against uPA than amiloride (IC50 = 10 µM).
6 Sonogashira 
cross-coupling was employed to obtain the equivalent 6-phenylacetenyl HMA methyl ester 
56a and the target acyl guanidine 56 to see whether similar increases in potency were 
observed with the azepane ring present at C5 (Scheme 2.2). 
 
 
Scheme 2.2: Sonogashira cross-coupling of phenylacetylene with 32 yielded 56a (58%), which 
was converted to acyl guanidine 56 in 14% isolated yield. 
  
Methyl ester 32 was reacted with phenylacetylene using a Pd(PPh3)Cl2:CuI catalytic system in 
DMF with trimethylamine (TEA) present as base. The reaction was stopped by filtering 
through celite after 24 h and the product isolated by silica gel chromatography. The methyl 
ester 56a was obtained as a bright yellow solid in 58% yield. Ester 56a was then subjected to 
the above guanidinylation procedure to give 56 in 14% yield.   
 
With the exception of 33a and 33, all methyl ester and acyl guanidine products were novel 
compounds that had not reported in either the patent or scientific literature (SciFinder search, 
1st December, 2016). For 33a and 33, specific methods had been described in a single patent 





2.2 Solution phase uPA inhibition assays 
The synthesized acyl guanidines 33-56 were subjected to a fluorometric solution phase uPA 
activity assay to measure inhibitory potencies. Assays were conducted in black 96-well plates 
using a commercially available fluorogenic substrate (Calbiochem 672159, Z-Gly-Gly-Arg-AMC, 
Merck Millipore, Massachusetts, USA), Urokinase from human kidney cells (Sigma-Aldrich, Cat 
# U4010) and a POLARStar fluorescence plate reader (BMG-Labtech, Ortenberg, Germany) 
(Figure 2.7). Compounds were dissolved in anhydrous DMSO to create 10-50 mM stock 
solutions. Stocks were serially diluted in assay buffer in the 96-well plate then added to a 
separate black assay plate containing fluorescent substrate (in assay buffer) via multichannel 
pipette. Assays were conducted such that each well contained a final concentration of 1% 
DMSO (v/v). Detailed experimental methods for the assays are provided in Chapter 7.3. Two 
compounds were assayed in each plate with each dilution was carried out in triplicate. Drug 
blanks were included to correct for intrinsic fluorescence in the compounds. An inhibitor-free 
vehicle control was included in each assay to determine maximal enzymatic activity, allowing 
for correction of day to day and enzyme batch variations. Assay plates were prepared and 
kept on ice until final addition of enzyme immediately prior to first reading. Assays were 
conducted at 37 °C with double orbital shaking before each read. Wells were excited at 355 
nm and the emitted fluorescence at 460 nm was measured. Data points from the linear 
portion of reaction progress curves were averaged and used to determine initial velocities, 
which were then blank corrected and plotted to calculated IC50 values for each compound. 
IC50 is defined as the concentration of compound needed to inhibit one half of enzyme activity 
under the conditions used. Representative concentration-response curves for compounds 42 
and 50 are provided in Figure 2.8. Modification of the assay allowed determination of Ki 
values for selected inhibitors (Table 2.3, as described in detail in Chapter 7.3), where Ki is the 
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concentration of compound at which the reaction rate is one half of the maximal reaction rate 
(Vmax) under saturating substrate conditions. 
  
 
Figure 2.7: Schematic of uPA activity assay. uPA cleaves the pro-fluorogenic tripeptide 
substrate to liberate the highly fluorescent 7-amino-4-methylcoumarin (AMC), providing a 
quantifiable measure of enzymatic activity. When 6-HMA analogues are added, reversible 
competition with the substrate for binding to the uPA active site inhibits proteolytic activity, 
reducing fluorescence. Decreased fluorescence in the presence of 6-HMA analogues was used 




Figure 2.8: Curves from solution-phase uPA inhibition assays with representative compounds 
42 and 50. Data points represent the mean ± SEM (n = 3) from a representative experiment.  
 
The aryl-boronic acid coupling partners for the Suzuki-Miyaura cross-coupling reactions were 
selected based on commercial availability and structural diversity. To probe the SAR of the 6-
position of HMA, boronic acids were initially chosen to cover a breadth of structural diversity 
that appeared to have the correct size for occupancy of the S1 subsite. Later compounds 
were chosen as the SAR trends emerged and as X-ray co-crystal structures came to hand 
















Table 2.3: Inhibitory potencies of 6-HMA analogues 33-56 against Human uPA. For 
compounds where  n >1, values represent the mean ± SEM from identical repeat assays 
conducted on different days. 
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2.2.1 Structure-activity analysis 
 
The 6-Phenyl derivative 33 (33 IC50 = 8,158 nM) showed a ~ 3.7-fold decrease in potency 
relative to HMA (IC50 = 2,206 nM). Addition of a methylthioether group at the para position 34 
resulted in a ~ 12.1-fold decrease in potency (IC50 = 26,717 nM). Substitution of the 
methylthioether of 34 with a trifluoromethyl group 35 produced a ~ 3.1-fold decrease in 
potency (IC50 = 6,914 nM). Methylenedioxy derivative 36 showed a ~ 1.5-fold increase in 
activity over HMA (IC50 = 1,518 nM). The 4-isoquinoline compound 37 showed ~ 2.6-fold lower 
activity than HMA (IC50 = 5,751 nM) while the N-methylpyrazole 38 showed increased activity,  
~ 2.7-fold higher than HMA (IC50 = 825 nM). Substitution of the N-methyl group of 38 with N-
ethylmorpholine 39 (IC50  = 1,070 nM) did not improve activity.  
 
The 2-Indole derivative 40 (IC50 = 9,214 nM) showed ~ 4.2-fold lower activity than HMA. 
Similarly, substitution of the indole N with S to yield benzothiophene 41 did not afford potent 
inhibition, with 41 showing ~ 2.4-fold decreased activity relative to HMA (IC50 = 5,375 nM). 
However, substitution of the ring heteroatom with O to yield benzofuran 42 provided a ~ 7.4-
fold boost in potency (IC50 = 297 nM). Potency was further increased by fluorination of 42 at 
the benzofuran 4-position to give compound 43, which showed ~ 15.4-fold greater potency 
than HMA (IC50 = 143 nM).  
 
The 2-thiophene derivative 44 was slightly better than its benzothiophene analogue 41 (IC50 = 
3,927 nM). The 3-thiophenyl isomer 45 slightly more potent (IC50 = 1,669 nM). Removal of the 
phenyl ring of 42 to yield the 2-furanyl derivative 46 had little effect on activity, with both 
compounds showing similar potency (IC50 = 254 nM). Similarly, 3-furanyl isomer 47 (IC50 = 270 
nM) showed activity comparable to 42 and 46. 
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The 5-pyrimidine derivative 48 (IC50  = 175 nM) showed ~ 12.6-fold higher activity than HMA. 
Methoxy substitution at the para position of 48 to yield 49 increased potency into the <100 
nM range, affording a ~ 25.6-fold increase relative to HMA (IC50 = 175 nM). Dimethoxy 
substitution of the 5-pyrimidine to give 50 afforded the most potent inhibitor arising from this 
work, some 32-fold more potent than the parent HMA (IC50 = 69 nM). The importance of the 
5-pyrimidinyl scaffold for high potency was highlighted with the 2,3-dimethoxy-3-pyridinyl 
analogue 51. Here, removal of the second ring N resulting in a dramatic loss in potency (IC50 = 
1,437 nM). The 2-fluoro-3-pyridinyl derivative 52 was ~ 1.3-fold less potent than HMA. 
Removal of ring nitrogens altogether from 50 carbocyclic analogue 53 reduced activity ~ 1.6-
fold relative to HMA (53 IC50 = 3,571 nM). The 3,5-dimethoxyphenyl isomer 54 (IC50  = 2,143 
nM) was approximately equipotent with HMA. The 3,6-Dimethoxypyridazine derivative 55 
showed ~ 4.3-fold greater potency than HMA (IC50 = 512 nM). The phenylacetylene derivative 
56 proved to be the least potent inhibitor studied (IC50 = 29,816 nM). In comparison, the 
analogous 6-phenylacetylamiloride reported by Matthews et al., showed a 5-fold increase in 
uPA inhibitory activity relative to amiloride (6-phenylacetylamiloride IC50 = 2 µM; Amiloride 
IC50 = 10 µM, using a chromogenic assay).
6 It is possible that the steric bulk of the azepane ring 
at the 5-position of 56 prevents the 6-phenylacetylene substituent from orienting favourably 
in the S1 subsite. 
 
Inhibitory constants (Ki) were determined for HMA and 11 inhibitors using a modified 
fluorogenic assay (Table 2.3). Double reciprocal plots of initial reaction velocities (1/RFU.min-1) 
versus substrate concentration (1/S) for representative inhibitors 43 and 48 confirmed 
competitive inhibition of uPA, since Km increased with increasing [inhibitor] while Vmax 




Figure 2.9: Double reciprocal plots of uPA inhibition by 6-HMA analogues 43 and 48. Data 
points represent the mean from duplicate wells at each concentration and are representative 
of three repeat experiments. 
 
The rank order of potencies according to Ki agreed well with the IC50 values obtained earlier 
(Table 2.3). Compounds 43 and 48 were exceptions, however, occupying slightly different 
positions in their two rank orders. With the exception of HMA, all values indicated affinities 
that were higher than the IC50 concentrations determined for each compound, as expected for 
competitive inhibitors.286 
 
2.3 Selectivity for uPA over related trypsin-like serine proteases 
 
A shortcoming of previous small molecule inhibitors of uPA has been their lack of selectivity 
for uPA over related trypsin-like serine proteases, such as thrombin, plasmin and tPA.157 Off-
target inhibition of these proteases raises the risk of unwanted side effects being observed if 
the compounds were to be used as cancer drugs in humans.  
 
To examine the uPA selectivity of the 6-HMA analogues, three examples were screened against 
a panel of human TLSPs using chromogenic enzyme inhibition assays (detailed experimental 
methods in Chapter 7.3). Representative inhibition curves from these experiments are 
presented in Figure 2.10. In experiments using the chromogenic uPA substrate S-2288 
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(Chromogenix, Massachusettes, USA) benzofuran analogue 42 showed IC50 = 529 nM, or 
approximately 2-fold higher than the value observed in the fluorogenic assay (IC50 = 297 nM). 
This general trend was observed across all inhibitors, with the chromogenic assay IC50 values 
only 2 to 4-fold higher than those obtained from assays from fluorescence-based assays. The 
exception was compound 49, which showed IC50 = 39 nM (n = 1) in the chromogenic assay and 
IC50 = 86 nM in the fluorescence assay. Nevertheless, the rank order of inhibitor potencies 
against uPA was preserved across both assays (e.g. 49 < 43 < 48 << HMA). The variation 
between assays likely arises from difference in the affinity of the two substrates for the uPA 
active site. Differences in assay buffer composition may have also contributed to the 
variations. For all other TLSPs tested, half-maximal inhibitory concentrations were not reached 
at the highest concentrations tested (10 M). Compound 42 showed slight inhibition of trypsin, 
but this was only 24% inhibition at 10 µM.  
 
 
Similar results were observed for compounds 43 and 49 (Table 2.4), where half-maximal 
inhibition of tPA, plasmin or thrombin was not reached. Of the enzymes tested, plasmin 
activity was inhibited to the greatest extent by 43 (16%) and 49 (48%) at 20 M. These results 
clearly demonstrated that 6-HMA analogues with high uPA inhibitory potency are 10-100-fold 





Figure 2.10: Activity of 42 against uPA and related trypsin-like serine proteases determined 







Table 2.4: Inhibitory potencies of 6-HMA analogues 42, 43 and 49 against uPA and related 




A wider selection of 6-HMA analogues were also screened against a panel of TSLPs involved in 
the blood coagulation cascade, including human plasma kallikrein, Factor Xa, Factor XIa and 
Activated Protein C (Table 2.5). Experiments used the chromogenic substrates S-2288, S-2366 
or S-2444 (Chromogenix, Massachusetts, USA), depending on their suitability for each enzyme 
based on manufacturer Vmax values. Due to time constraints (experiments were performed 
during a three week international research visit to the laboratory of the Prof. Mingdong 
Huang, Fujian Institute for Research into the Structure of Matter (FJIRSM), Fuzhou (China), 
compounds were not tested simultaneously against wildtype human uPA, thus a 
determination of fold-change in activity relative to uPA was not possible. Nevertheless, a 
similar profile to that observed with 43, 48 and 49 against tPA, plasmin and thrombin was 
seen with most of the compounds, where half-maximal inhibition was not observed at the 
highest concentration tested (50 M). 
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Half-maximal inhibition of Factor Xa activity was not observed for any of the compounds in 
the range of concentration range tested (50 nM-50 M). For Factor XIa, half-maximal 
inhibition was achieved at concentrations lower than 50 M for 5 of the 12 compounds 
screened. The 3,6-dimethoxy-4-pyridazine 55 the showed greatest inhibition, returning an IC50 
of 8.7 M. The 4-fluoro-2-benzofuran analogue 43 (IC50 = 23.3 M) showed slightly higher 
inhibition of Factor XIa than the unadorned 2-benzofuran 42 (IC50 = 31.0 M). The 2,4-
dimethoxypyrimidine analogue 50 showed intermediate potency (IC50 = 25.8 M) and IC50 was 
not reached for any of the other compounds against Factor XIa. The 5-pyrimidine analogue 48 
was the only compound for which an IC50 could be calculated against Activated Protein C (IC50 
= 26.9 M).  
 
While slight activity was observed for some of the compounds against Factor XIa, Plasma 
kallikrein and Activated protein C, a >10-fold difference in potency was generally seen 
between uPA potency and potency against the off-targets.  
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2.4 Selectivity of inhibitors for human versus murine uPA 
 
Species specificity and potency differences of active site inhibitors against human and murine 
uPA have been noted in the literature.22,287,288 Smaller inhibitors that interact primarily with 
the S1 binding pocket tend to show similar potencies against the two enzymes, (selectivity 
ratios = 0.5-5), whereas Inhibitors that make contacts in other sites (e.g. S1, S2) show a 
pronounced preference (10-100 fold or more) for the human enzyme.22 These trends arise 
because the four active site amino acid substitutions between the species are located in sites 
outside S1. HuPA:MuPA D60Q is located near the catalytic triad, H99Y is on the edge of S2/S4, 
S146E is in S1 and Q192K is on the boundary of S1/ S1.22 
 
The preference of inhibitors for human over murine uPA presents challenges for conducting 
studies with compounds in mouse xenograft tumour and metastasis models. This is because 
enzymes derived from both the xenografted human tissue and the murine host may 
contribute to plasminogen activation, invasion and metastasis. The issue is further 
complicated by the variable propensity of uPA/uPAR-upregulating tumour cells from different 
tissues to recruit uPA from the surrounding stromal environment. For example, breast 
carcinomas recruit the majority of their uPA complement from surrounding stromal cells.289,290 
The differing affinities of human uPAR for human and murine uPA and the higher rate of 
activation of both human and murine plasminogen by the human enzyme add even more 
complexity.291 
 
If an inhibitor being studied in vivo showed a marked preference for HuPA there is a possibility 
that a xenograft model may underestimate its efficacy, making it difficult to demonstrate in 
vivo proof-of-concept. The activity of two of the more potent analogues 42 and 50 analogues 
against wild-type murine uPA was therefore assessed using a fluorogenic assay. Comparative 
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data for the two compounds, amiloride and HMA against the human and murine enzymes is 
presented in Table 2.6. 
 
As expected amiloride, which binds to uPA primarily through contacts within the S1 pocket, 
showed virtually no difference in activity against the two enzymes. HMA was found to lose the 
most potency against MuPA (IC50 = 13.3 M), experiencing a ~ 6-fold drop in activity. As 
amiloride and HMA differ only in the identity of the 5-amino substituent, the drop in potency 
can be attributed to unfavourable interactions between the 5-azepane ring of HMA and the 
active site of MuPA. Assuming that HMA adopts a similar binding pose when bound to both 
enzymes, the 5-substitutent would occupy space corresponding to the junction of S1 and S2 
and the oxyanion hole (Figure 2.11).  
 
Table 2.6: Inhibitory potencies of amiloride, HMA and 6-substituted analogues 42 and 50 
against human and murine uPA. 
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In murine uPA, the S2 residue His99HuPA is substituted by a bulkier Tyr (His van der Vaal’s 
volume =118 Å3; Tyr =141 Å3), with the three other active site substitutions lying outside of 
this area.292,293 Assuming that these distant substitutions do not cause major structural 
differences in the S1/S2 and oxyanion hole regions, it is possible that the drop in activity 
observed for HMA and 6-HMA analogues relative to amiloride is due to unfavourable 
interactions between the 5-hexamethyelene ring and the side chain of Tyr99 in murine uPA. 
 
 
Figure 2.11: X-ray co-crystal structure of HMA bound to WT human uPA highlighting the 
position of His99, presented in coral, and its close proximity to the azepane ring. In Murine 
uPA, residue 99 is substituted with a larger Tyr. Unfavourable interactions between the Tyr99 
sidechain and the azepane ring of HMA and analogue(s) may be responsible for reducing 
activity against MuPA. Gln192 and Ser146, two other active site residues that differ between the 
human and murine enzymes, are presented in purple and orange respectively. 
 
Benzofuran analogue 42 showed improved potency relative to HMA against both human (IC50 
= 297 nM, c.f. 2,206 nM ~ 7.4-fold increase) and murine uPA (IC50 = 2,579 nM, c.f. 13.3 M for 
HMA, ~ 5.2-fold increase). This compound showed ~ 8.7-fold selectivity for Human uPA. 
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Species differences were most pronounced for the dimethoxypyrimidine analogue 50, where 
33-fold greater potency was observed against (IC50 = 69 nM vs. MuPA IC50 = 2,305 nM). The 
compound showed 5.8-fold higher potency than HMA against MuPA. Taken together, these 
results indicate that substitution of HMA at the 6-position is beneficial for activity against 
MuPA. The presence of the 2-benzofuranyl and 2,4-dimethoxypyrimidinyl groups in 42 and 50 
restored some of the activity lost due to the presence of the of the 5-azepane ring. 
Restoration of potency is likely due to the new favourable interactions established between 
the 6-substitutents and the S1 subsites in both enzymes.  
 
The similarity in inhibitory potencies of 42 and 50 (42 IC50 = 2,579 nM, 50 IC50 = 2,305 nM) 
against MuPA suggests that the S1 subsite of this enzyme is less able to make favourable 
contacts with 6-substituents relative to HuPA, where increases in inhibitory potency 
approaching two orders of magnitude were observed upon varying the 6-substituent against 
the human enzyme (see Table 2.4). 
  
Decreased tolerability of these substituents in MuPA is likely due to the Ser146Glu and 
Gln192Lys substitutions in S1, as these residues define part of the pocket boundary in HuPA 
(Figure 2.11). These data corroborate previously described selectivity trends for S1-targeting 
small molecule inhibitors, where the subsite was generally more accepting of ligand 
substituents in the human enzyme.22 
 
To further explore the effect of H99Y substitution on inhibitory potency, selected, analogues 
were screened against a recombinant human uPA mutant carrying the H99Y mutation  
(HuPAH99Y, Table 2.7).294 In line with predictions, the “murinized” H99Y uPA substitution 
decreased the activity of all 6-HMA analogues relative to WT HuPA (e.g. HMA IC50
H99Y > 50 M, 
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HMA IC50
WT 2206 nM). While amiloride was not tested against HuPAH99Y, the results suggest 
that the ~ 4-fold lower potency of HMA relative to amiloride against MuPA is, at least in part, 
a result of unfavourable interactions with Tyr99. The losses in activity observed for HMA and 6-
HMA analogues against HuPAH99Y generally aligned with those observed between WT HuPA 
and MuPA. 
 
The observation that 6-substitution was generally beneficial to interactions in both WT HuPA 
and MuPA was recapitulated with compounds 38, 42, 43, 48, 50 and 55, which returned IC50 
values in the range 3.0-9.7 M. Supporting X-ray co-crystal structures of some 6-HMA 
analogues bound to H99Y are presented in Chapter 3.2. 
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Table 2.7: Inhibitory activities of 6-HMA compounds against a site-specific mutant of human 




2.5 Physicochemical properties of 6-HMA analogues 
 
In order to understand how the intrinsic properties of 6-HMA analogues affect uPA potency, 
relationships between inhibitory activity (pIC50) and a variety of physicochemical parameters 
were calculated for each using Biovia Insight for Excel (Dassault Systemes, Velizy-Villacoublay, 
France, Figure 2.12). 
 
A weak positive correlation (r2 = 0.2025) between polar surface area (PSA) and pIC50 (Figure 
2.12A) was observed for compounds 33-56.29 A stronger correlation (r2 = 0.3141) was found 
between the number of hydrogen bond acceptors, which ranged between 8 and 12, and 
inhibitory potency (Figure 2.12C). Sub-micromolar IC50 values (pIC50 > 6) were achieved only 
for compounds bearing more acceptors than HMA (i.e. > 8). All compounds contained the 
same number of hydrogen bond donors (i.e. 6) except indole analogue 40 (7 H-bond donors), 
making correlation analysis for this variable uninformative. No correlation was found between 
inhibitory potency and the number of rotatable bonds present in each structure (r2 = 0.001), 
with clustering of data around 4 and 6 rotatable bonds (4 rotatable bonds: 15 of 25 
compounds; 6 rotatable bonds: 5 of 25 compounds). Likewise, no relationship was observed 
between molecular weight and pIC50 (r
2 = 0.0005, Figure 2.12B). 
 
Due to the basic nature of the acyl guanidine moiety (amiloride pKa = 8.71) present in all 
analogues a significant proportion of each compound would exist in a charged state in 
solution at physiological pH.295 For this reason, LogD values were calculated at pH 7.4 to 
account for the contributions of both the charged and uncharged species to the partitioning 
coefficient. Comparison of CLogD to CLogP values (which considers partitioning of uncharged 
species only) for each compound revealed that both metrics were virtually equivalent, with 
cLogD values < 0.04 units higher for all analogues. The exception was 4-isoquinoline analogue 
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37, whose CLogD was affected by the basic isoquinoline ring nitrogen (pKa ~ 5.4-5.5). This 
comparison suggests that the identity of the distal 6-substituent does not strongly influence 
the pKa of the acyl guanidine. 6-substituents bearing ionizable functional groups featuring pKa 
values closer to 7.4 would experience greater shifts in LogD relative to LogP due to the 
functional group contribution to the total molecular pKa, as observed with 37 (ClogP 2.37 vs. 
ClogD 2.60).  
 
An inverse correlation was found between uPA inhibitory potency and ClogD (Figure 2.12D, r2 
= 0.2772). This correlation was strengthened by exclusion of the hydrophobic 2-benzofuranyl 
analogues 42 and 43 (r2 = 0.5158). The presence of 2-benzofuranyl 42 or 4-fluoro-2-
benzofuranyl 43 substituents at the 6-position caused large increases in ClogD relative to HMA 
(HMA ClogD 1.52; 42 3.19; 43 3.39). The finding that two structural classes of 6-HMA 
analogues that differ significantly in hydrophobicity (5-pyrimidinyl 48 ClogD 0.82, IC50 = 175 
nM; 4-fluoro-2-benzofuranyl 42 ClogD 3.39, IC50 = 143 nM) are nearly equipotent suggests 
that uPA inhibition with this class is not a function of ClogD and that affinity is instead driven 
by specific intermolecular interactions between the inhibitors and uPA.  
 
The physicochemical differences between 2-benzofuranyl 42 and 5-pyrimidinyl 48 were 
further highlighted by their lipophilic ligand efficiencies (LLE) (Figure 2.12D, diagonal lines). 
LLE is an estimation of the preference of a compound for a target over partitioning into 1-
octanol, and is used to evaluate the benefit of increasing hydrophobicity relative to effects on 
potency.32 For compounds showing properties typical of orally active drugs (ClogD ~ 2.5-3, 
target potency ~ 1-10 nM) LLE is typically > 5, which is considered an indicator of a well 
optimized drug candidates.34 A compound with LLE 6 will have a 106-fold greater affinity for 
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interaction with a given target than 1-octanol.34 The diagonal lines in Figure 2.12D indicate LLE 
units. 
 
Only the pyrimidine-based analogues displayed LLEs >5, with the unadorned 5-pyrimidinyl 48 
showing the highest LLE (LLE: 48 5.94, 49 5.74, 50 5.32). The 2-benzofuranyl analogues 42 and 
43 showed LLEs below 4 (42 3.33, 43 3.45), or lower than the parent HMA (LLE 4.13). Increases 
in potency associated with inclusion of the benzofuranyl moieties was thus not sufficient to 
offset the concomitant increases in hydrophobicity. Inclusion of the 2-benzofuranyl 
substituent would require a 46-fold increase in potency relative to HMA (required IC50 = 48 
nM, observed IC50 = 297 nM, observed fold-increase 7.4-fold) to maintain an LLE equivalent to 
the parent structure (HMA LLE 4.13). additionally, to match the ‘well optimized’ LLE of the 5-
pyrimidinyl 48 (LLE 5.94) the potency of 48 would have to increase 2,997-fold, giving an IC50 = 
741 pM.  
 
Despite the increases in potency afforded by 6-substitution, none of the 6-HMA analogues 
were able to match the high LLE of amiloride (LLE 6.16). This finding illustrates the effect of 
polarity relative to potency on LLE calculations. In the case of amiloride, high LLE arising from 










Figure 2.12: Relationship between uPA inhibitory activity (pIC50) and calculated 
physicochemical parameters for a library of 6-HMA analogues. A) pIC50 vs polar surface area. 
B) pIC50 vs molecular weight. C) pIC50 vs number of H-bond acceptors. D) LLE plot, solid lines 
represent linear regression fits for each data set and dotted curves describe 95% confidence 
intervals. Analogues lying above the blue line (LLE >5) are considered well optimized in terms 
of their activity against uPA relative to their intrinsic hydrophobicity. 
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The changes in CLogD and inhibitory potency relative to HMA further highlights the intrinsic 
differences between the 2-benzofuranyl and 5-pyrimidinyl-based lead classes (Figure 2.13, red 
and green boxes, respectively). During the optimization process it is desirable for leads to 
progress towards the top left corner of a pIC50/CLogD plot.
34 The 2-benzofuranyl class 
clearly deviates from this trajectory due to accompanying increases in CLogD, while the 5-
pyrimidinyl analogues clearly localize in the correct region. Relative to HMA, 5-pyrimidinyl 




Figure 2.13: Changes in ClogD and pIC50 for 6-HMA analogues relative to HMA. 
 
Based on calculated physicochemical properties (Table 2.8), the 6-HMA analogues were 
evaluated for ADMET liabilities using a set of predictive computational tools within the Biovia 
Insight for Excel software suite (Dassault Systemes, Velizy-Villacoublay, France). The majority 
of 6-HMA analogues (56%, 14/25 compounds) were predicted to cause dose-dependent 
hepatotoxic injuries (e.g. hepatitis, zonal necrosis, cholestasis etc.) or trigger elevated blood 






In contrast, the 5-pyrimidinyl analogues 48, 49 and 50 were predicted to be non-hepatotoxic.  
Compounds with CLogP values exceeding 3, including benzofuran 42 and 43, were predicted 
to have very low aqueous solubility (at the lower limit of 95% of orally active drugs). All other 
compounds, including the 5-pyrimidinyl leads 48, 49 and 50 and HMA, were predicted to have 
low solubility (towards the lower end of 95% of orally active drugs), with the exception of N- 
1-methyl-1H-4-pyrazole 38, which was predicted to have good solubility.41  
 
The 5-pyrimidinyl leads 48, 49 and 50 and structures featuring methoxy (51, 53, 54 and 55), 
morpholino (39) or methylenedioxy (36) substituents, were predicted to show very low 
passive intestinal absorption following oral administration (outside 99% confidence ellipse for 
orally active compounds). Good-moderate (within 95% confidence ellipse) absorption was 
predicted for the 2 and 3-thiophenyl analogues 44 and 45, HMA and phenyl analogue 33. All 
other compounds, including the 2-benzofuran leads 42 and 43, were predicted to exhibit low 
passive intestinal absorption (between 95% and 99% confidence ellipses).  
 
Predictions regarding favourable solubility and absorption characteristics for small molecules 
are often made using the well-known Lipinski’s “rule of five” (MW <500 g.mol-1, CLogP < 5, ≤ 
10 H-bond acceptors and ≤ 5 H-bond donors).42 HMA and the 6-HMA analogues all exceed the 
H-bond donor criteria as the guanidine and 3-NH2 groups provide 6 potential donors. 
Compounds 36, 38, 39, 51, 54 and 55 and the 5-pyrimidines 48, 49 and 50 violate both the H-
bond donor and acceptor criteria. 
 
Reliable predictions of blood-brain barrier permeability were not possible as the compounds 
were predicted to lie outside of the 99% confidence ellipse in the model used by Biovia Insight 
for Excel. All compounds were considered unlikely to be substrates for cytochrome P450 
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isozyme CYP2D6 and no compound was predicted to bind strongly to human plasma proteins. 
(strong binder = > 90% bound).  
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Table 2.8: Summary of uPA inhibitory potencies, predicted physiochemical properties and calculated ADMET metrics for 6-HMA 
analogues. All physicochemical parameters and ADMET predictions were calculated using Biovia Insight for Excel v2.6. tPSA = 
topographical polar surface area.27 HAC = Heavy atom count. LE = ligand efficiency  ((1.37/heavy atoms)*pIC50).
296 Rotatable bonds = 
number of bonds within structure that possess meaningful rotational freedom for molecular mechanics, excluding terminal hydrogens. 
Liver toxicity = Predicted dose-dependent hepatotoxicity.35 Predicted aqueous solubility (see reference 41). Predicted intestinal 
absorption (see reference 53). 
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2.6 Summary and Conclusions  
The new synthetic methods described herein provided divergent access to 6-substituted HMA 
analogues using common, commercially available reagents. Based on published X-ray co-crystal 
structures of amiloride bound to uPA, we correctly hypothesized that 6-substitution of HMA 27 
may afford increases in inhibitory potency by establishing new interactions within the S1 subsite 
of uPA. Screening the synthesized library of analogues against Human uPA revealed that, in 
general, the S1 subsite is able to tolerate a variety aryl and heteroaryl substituents. The greatest 
increase in potency was observed with the dimethoxypyrimidine analogue 50 (IC50 = 69 nM). The 
2-benzofuranyl and 5-pyrimidinyl classes emerged as two structurally and physicochemically 
distinct lead classes. 
 
Screening of selected inhibitors against a variety of potential TLSP off-targets revealed good uPA 
selectivity across all analogues. As half-maximal inhibition was not achieved for trypsin, plasmin 
and tPA, retesting against these enzymes at higher concentrations would be needed to determine 
selectivity factors. We conclude that off-target TLSP inhibition should not be a major issue with 
this class of compounds if used as drugs.  
 
Experiments with murine uPA revealed that the 6-HMA analogues show substantially lower 
potency against the murine enzyme relative to human uPA. Experiments with a ‘murinized’ variant 
of human uPA carrying a H99Y substitution suggested that the decreased potency was at least 
partially caused by unfavourable interactions between the larger, Tyr99 side chain in mouse uPA 
and the 5-azepane ring present in all HMA analogues. These findings have significant implications 
for in vivo xenotransplantation studies in mice as the decreased activity may lead to 
underestimation of the antimetastatic efficacy of the inhibitors since both human and endogenous 
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murine uPA will play roles in this process. Ongoing studies in the Kelso and Ranson Labs are 
seeking to identify compounds that potently inhibit both mouse and human uPA to address this 
Analysis of the calculated physicochemical properties of the 6-HMA analogues suggested that high 
potency is not reliant on intrinsic hydrophobicity, given that nM inhibitors were generated from 
structures varying widely in ClogD. Indeed, strong correlations were not found between potency 
and a range of physicochemical and structural parameters, suggesting that uPA affinity likely arises 
from a combination of specific and non-specific interactions, in addition to hydrophobicity. LLE 
analysis revealed that the large increases in hydrophobicity associated with inclusion of 2-
benzofuranyl moieties cancelled out the moderate increases in potency in terms of LLE. 
Conversely, all members of the 5-pyrimidine class were calculated to have LLE values in the ‘well 
























CHAPTER 3: X-ray co-crystal structures of HMA and 6-HMA analogues 
bound to uPA 
 
X-ray crystallographic analysis of ligand-protein complexes occupies a central position in modern 
drug discovery.297,298 Three dimensional visualization of drug-target interactions allows the 
rationalization of SAR trends arising from biological assays and can be used to guide the direction 
of chemical synthesis towards analogues with improved potency and selectivity. This process is 
known as structure-based drug design.299 Collaborative efforts between the Kelso/Ranson 
laboratories at UOW and scientists at the Fujian Institute for Research into the Structure of Matter 
(FJIRSM), Fuzhou (China), allowed for integration of X-ray structural data into the selection of 
synthetic targets. Novel co-crystal structures were obtained for HMA 27 (Figures 2.1 and 3.1) and 
the 6-HMA analogues 38, 42, 43 and 46-50 at resolutions ranging from 1.6-3.0 Å. Complexes were 
obtained by soaking each inhibitor into pre-formed Human uPA crystals over a period of 14 days 
prior to X-ray diffraction experiments. All co-crystals were obtained and their structures solved by 
Dr. Longguang Jiang at the FJIRSM. A summary of the data collection and refinement statistics is 
provided in Appendices 9.1 and 9.2. 
 
3.1 HMA:uPA co-crystal structure 
 
The expected salt bridge was observed between the positively charged acylguanidine of HMA and 
the Asp189 side chain at the base of the S1 binding pocket (Figure 3.1). H-bonds were present 
between the backbone carbonyl of Gly219 and the terminal NH2 and amide NH groups of the acyl 
guanidine. The other guanidino NH2 formed a H-bond to the Ser190 side chain OH and the 
exocyclic NH2 group at C3 was H-bonded to the side chain OH of Ser195. A bridged H-bonding 
network was formed between a surface-bound water molecule, the acyl guanidine carbonyl, the 




Figure 3.1: A) X-ray co-crystal structure of HMA bound to the serine protease domain of uPA (1.6 
Å). The electron density map (2mFo-DFC) is contoured at 1.5 σ. Electrostatic potential surfaces of 
uPA are shown with blue = negative and red = positive. A bridging water molecule is shown as a 
red ball. All non-bridging water molecules have been omitted for clarity. A sulfate from the 
cyrstalization buffer is bound to the oxyanion hole and is presented in stick representation. B) 
Equivalent structure to A) with surfaces coloured according to electrostatic potential (uPA) or cyan 
(HMA). C) Summary of the binding interactions between HMA and uPA. Residues comprising the 
S1 subsite are labeled in blue. Dashed lines represent H-bonds and ionic interactions. Curved 
dashed lines represent van der Waals contacts.  
 
The hydrophobic nature and compact size of the S1 subsite is highlighted by the electrostatic 
potential surface map in Figure 3.1A. The accessibility to S1 from the 6-position of the HMA 
scaffold was clear. The 6-Cl group of HMA interacted primarily at the mouth of S1, participating 
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in van der Waals interactions with the Cys191-Cys220 disulfide bond, Gly219 and Gln192C (Figure 
3.1C).  
 
3.2 Co-crystal structures of 6-HMA analogues 
 
Evaluation of the 6-HMA analogue:uPA X-ray co-crystal structures revealed that the hydrogen 
bonding and ionic interactions observed between the acyl guanidine of HMA and Asp189, Gly219, 
Ser190 and the H-bond from the exocyclic NH2 group at C3 and Ser195 in the HMA-uPA structure 
were preserved, showing only slight variations in bond distances (measured as the distance 
between the two heteroatoms in all cases). Participation of the terminal guanidino NH2 in the 
bridging network comprised of the surface H2O, Ser190 and the acyl guanidine carbonyl showed 
more variation as prospective H-bonds distances for these interactions exceeded accepted limits 
in some cases (i.e. >3.3 Å). The SAR trends observed for the 6-HMA analogues can largely be 
rationalized in terms of formation of new favourable (or unfavourable) interactions between the 
6-substitutent and the S1β subsite. 
 
3.2.1 Furanyl analogues 46 and 47 
 
2-Furanyl analogue 46 (IC50 = 254 nM) showed 8.7-fold higher potency than HMA (IC50  = 2,206 
nM). The increase in affinity appeared to arise, at least in part, by formation of new H-bonds 
between the furanyl O, a bridging water molecule and the amide NH of Gly219 (Figure 3.2C). 
Interactions were also observed between the furan ring and Gly219, Cys191-Cys220, Ser146 
backbone carbonyl and the side chain C and Cγ of Gln192. Figure 3.2B highlights the increased 







Figure 3.2: A) X-ray co-crystal structure of 46 bound to the serine protease domain of human uPA 
(1.7 Å). The electron density map (2mFo-DFC) is contoured at 1.5 σ. Electrostatic potential surfaces 
of uPA are shown with blue = negative and red = positive. Bridging water molecules are 
represented as red balls. All non-bridging water molecules have been omitted for clarity. A sulfate 
from the cyrstalization buffer is bound to the oxyanion hole and is presented in stick 
representation. B) Equivalent structure to A) with surfaces coloured according to electrostatic 
potential (uPA) or cyan (46). C) Summary of the binding interactions between 46 and uPA. 
Residues comprising the S1 subsite are labeled in blue. Dashed lines represent H-bonds and ionic 
interactions. Curved dashed lines represent van der Waals contacts.  
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Altering the position connecting the furan ring to produce the 3-furanyl analogue 47 had little 
effect on the activity (IC50 = 270 nM). Movement of the furanyl oxygen abolished the H-bond 
interaction with the bridging water molecule bound to Gly219, as seen in the 2-furanyl 46:uPA 
structure (Figure 3.3C). Flexibility of the Arg217 side chain was apparent in this structure as it had 
moved significantly to participate in the Gly219-bridging water H-bonding network (Figure 3.3A). 
Relative to 46, the plane of the furan ring in 47 had tilted 11˚, adopting a pose that appears to 
facilitate van der Waals interactions with Cys220. Interactions between S1 residues Cys191-
Cys220, Ser146 and the Gln192 side chain were preserved and there appeared to be a polar 
interaction between the side chain carbonyl of Gln192 and the δ+ CH at the 2-position of the 
furanyl ring. The new combination of interactions appeared to compensate for the lost H-bonding 
















Figure 3.3: A) X-ray co-crystal structure of 47 bound to the serine protease domain of uPA (1.7 Å). 
The electron density map (2mFo-DFC) is contoured at 1.5 σ. Electrostatic potential surfaces of uPA 
are shown with blue = negative and red = positive. Bridging water molecules are represented as 
red balls. All non-bridging water molecules have been omitted for clarity. B) Equivalent structure 
to A) with surfaces coloured according to electrostatic potential (uPA) or cyan (47). C) Summary of 
the binding interactions between 47 and uPA. Residues comprising the S1 subsite are labeled in 
blue. Dashed lines represent H-bonds and ionic interactions. Curved dashed lines represent van 







3.2.2 1-Methyl-pyrazolyl analogue 38 
 
In contrast to furanyl analogues 46 and 47, 1-methyl-pyrazolyl analogue 38 positioned its ring 
coplanar with the pyrazine core, reducing its penetration into S1 (Figure 3.4). This orientation 
limited potential interactions between the N-methyl group and the Lys143-Gln192-Ser146 
hydrophobic dimple, instead projecting it out towards solvent. Interactions appeared to exist 
between the pyrazole C3 and C5 CH groups and the Gly219 backbone and Gln192 side chain, 
respectively. The surface water bound to Gly219 in the furanyl structures was observed, however 
it did not interact with the 6-substituent of 38. The decreased occupation of S1 due to the 
coplanar orientation of the pyrazole with the pyrazine core probably contributed to its lower 














Figure 3.4: A) X-ray co-crystal structure of 38 bound to the serine protease domain of human uPA 
(1.9 Å). The electron density map (2mFo-DFC) is contoured at 1.5 σ. Electrostatic potential surfaces 
of uPA are shown with blue = negative and red = positive. Bridging water molecules are 
represented as red balls. All non-bridging water molecules are omitted for clarity. B) Equivalent 
structure to A) with interacting surfaces coloured according to electrostatic potential (uPA) or cyan 
(38). C) Summary of the binding interactions between 38 and uPA. Residues comprising the S1 
subsite are labeled in blue. Dashed lines represent H-bonds and ionic interactions. Curved dashed 





3.2.3 Benzofuran analogue 42 
 
Fusion of a phenyl ring to the 2-furanyl ring of 46 to create benzofuran 42 resulted in a slight 
decrease in potency (42 IC50 = 297 nM). Figure 3.5B shows that the benzofuran ring system 
extends well into S1, almost completly filling the subsite. The plane of the benzofuran ring was 
almost perpendicular to the pyrazine core, but the ring oxygen appeared to have moved to the 
opposite side of the pyrazine relative to the furanyl oxygen of 46. This orientation allowed the 
benzofuran 7-position CH to fill the Lys143-Gln192-Ser146 hydrophobic dimple. Additional 
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hydrophobic contacts were observed between the benzofuran 3- and 4-position CHs and Gly219. 
As seen with the HMA:uPA and 46:uPA structures, the Arg217 side chain adopted a conformation 
well away from S1. The surface water bound to the Gly219 carbonyl O, as present in other 













Figure 3.5: A) X-ray co-crystal structure of 42 bound to the serine protease domain of human uPA 
(1.6 Å). The electron density map (2mFo-DFC) is contoured at 1.5 σ. Electrostatic potential surfaces 
of uPA are shown with blue = negative and red = positive. Bridging water molecules are 
represented as red balls. All non-bridging water molecules have been omitted for clarity. B) 
Equivalent structure to A) with interacting surfaces coloured according to electrostatic potential 
(uPA) or cyan (42). C) Summary of the binding interactions between 42 and uPA. Residues 
comprising the S1 subsite are labeled in blue. Dashed lines represent H-bonds and ionic 







3.2.4 4-F Benzofuran analogue 43 
 
A 2-fold improvement in uPA-inhibitory potency was achieved by adding fluorine to the 4-position 
of the benzofuranyl ring of 42 to yield 43  (IC50 = 143 nM versus  IC50 = 297 nM for 42).  
The X-ray co-crystal structure with 43 revealed that the increased potency possibly arises from 
favourable interactions between the 4-fluoro group and the side chain guanidine of Arg217 and 
the backbone amide NH of Gly219 (Figure 3.6A). These interactions were not observed in the 
42:uPA structure as the sidechain of Arg217 adopted a position away from S1, as observed with 
38, 46 and HMA. The interaction between the 4-fluoro group and Arg217 caused a slight rotation 
about the benzofuran-pyrazine axis, where the dihedral angles were 78 for 42 and 68 for 43 
(Figure 3.7). Similar to the 42:uPA structure, the surface water interacting with the Gly219 














Figure 3.6: A) X-ray co-crystal structure of 43 bound the serine protease domain of human uPA 
(1.9 Å). The electron density map (2mFo-DFC) is contoured at 1.5 σ. Electrostatic potential surfaces 
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of uPA are shown with blue = negative and red = positive. A bridging water molecule is 
represented as a red ball. All non-bridging water molecules have been omitted for clarity. B) 
Equivalent structure to A) with interacting surfaces coloured according to electrostatic potential 
(uPA) or cyan (43). C) Summary of the binding interactions between 43 and uPA. Residues 
comprising the S1 subsite are labeled in blue. Dashed lines represent H-bonds and ionic 





Figure 3.7: Superposition of 42 (gold) and its 4-fluorinated analogue 43 (green). The plane of the 
benzofuran moiety relative to the pyrazine ring is rotated slightly in 43 (dihedral angle = 78) 
compared to 42 (dihedral angle = 68), allowing formation of a favourable interaction between the 
polarized fluorine and the positively charged sidechain of Arg217. 
 
3.2.5 Pyrimidine analogues 48, 49 and 50 
X-ray diffraction data sets of varying quality (1.7-3.0 Å) were obtained for the three 5-pyrimidine-
based compounds 48, 49 and 50. Analysis of the unadorned 5-pyrimidine 48:uPA structure at 2.0 Å 
showed that this substituent partially fills S1 (Figure 3.8). Interactions with the Cys191-Cys220 
disulfide, Ser146 and Gln192 residues were preserved with the addition of an apparent dipole 
interaction between the δ+ CH at the 4-position of the pyrimidinyl and the Gln192 side chain 
carbonyl (Figure 3.8A). A H-bond was observed between the backbone amide NH of Gly219 and 
the lone pair of electrons on the pyrimidine nitrogen. The pyrimidine ring was oriented favourably 
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to form a polar interaction between the δ+ CH at 6-position and the Gly219 backbone carbonyl. 
The sidechain of Arg217 was positioned close to the pyrimidine 6-substituent, potentially forming 
a favourable polar interaction with the ring. The bridging water molecule contributing to the H-
bonding network between the acylguanidine carbonyl, NH2 groups and the side chain hydroxyl of 
Ser190, which was consistently observed in other structures, was not present. This may have been 




Figure 3.8: A) X-ray co-crystal structure of 48 bound to the serine protease domain of human uPA 
(2.0 Å). The electron density map (2mFo-DFC) is contoured at 1.5 σ. Electrostatic potential surfaces 
of uPA are shown with blue = negative and red = positive. Water molecules have been omitted for 
clarity. B) Equivalent structure to A) with interacting surfaces coloured according to electrostatic 
potential (uPA) or cyan (48). C) Summary of the binding interactions between 48 and uPA. 
Residues comprising the S1 subsite are labeled in blue. Dashed lines represent H-bonds and ionic 
interactions. Curved dashed lines represent van der Waals contacts. The backbone NH of the 
Gly219 was observed to donate a H-bond to the pyrimidine nitrogen lone pair. 
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Methoxy derivatization at the pyrimidine 2-position of 48 to create 49 resulted in a 2-fold increase 
in potency (49 IC50 = 86 nm, 48 IC50 = 175 nM). Superposition of the 48:uPA and 49:uPA  co-crystal 
structures revealed that the inhibitors adopt very similar poses, with rotation about the plane of 
pyrimidinyl ring relative to the pyrazine core varying by only 22 (Figure 3.9).  
 
Figure 3.9: Superposition of the uPA:48 (green, uPA in orange) and uPA:49 (magenta, uPA in 
mauve) structures. In both structures the sidechain of Arg217 is positioned close to the pyrimidine 
substituents to form dipolar interactions. 
 
The methoxy CH3 group of 49 was oriented towards bulk solvent (Figure 3.10A). Compared to 48, 
the Gly219 NH-pyrimidine nitrogen H-bond was lengthened considerably, weakening the 
interaction (2.9 Å in 48 versus 3.4 Å in 49, Figure 3.10C). The sidechain of Arg217 had again flipped 
into close proximity with the substituent to make polar interactions with the pyrimidine nitrogen. 
The bridging water molecules observed in other structures were not present, most liekly due to 








Figure 3.10: A) X-ray co-crystal structure of 49 bound to the serine protease domain of human uPA 
(3.0 Å). Electron density map (2mFo-DFC) is contoured at 1.5 σ. Electrostatic potential surfaces of 
uPA are shown with blue = negative and red = positive. Water molecules have been omitted for 
clarity. B) Equivalent structure to A) with interacting surfaces coloured according to electrostatic 
potential (uPA) or cyan (49). C) Summary of the binding interactions between 49 and uPA. 
Residues comprising the S1 subsite are labeled in blue. Dashed lines represent H-bonds and ionic 




Introduction of a second methoxy substituent onto the 5-pyrimidinyl ring (48) resulted in a small 
increase in potency relative to the mono-methoxy 49 (50 IC50 = 69 nM, 49 IC50 = 86 nM), affording 
the most potent 6-HMA analogue identified in this study. Compared to pyrimidine analogues 48 
and 49, compound 50 displayed greater rotation about the pyrimidine-pyrazine axis, adopting a 
dihedral angle of 80(c.f. 66 for 49 and 44 for 48). This led to increased occupancy of S1 and 
allowed the o-methoxy CH3 to fill a small hydrophobic dimple formed by the side chains of Lys143, 
Gln192 and the Ser146 backbone (Figure 3.11). The p-methoxy substituent was projected towards 
bulk solvent, with its CH3 group (δ+) appearing to interact with the Gly219 backbone NH lone pair 
(3.0 Å). The pyrimidine ring appeared to make an additional hydrophobic contact with the Gly219 
C. In contrast to 48 and 49, the Arg217 side chain was positioned away from S1, apparently to 
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avoid a steric clash with the p-methoxy substituent. It would appear that loss of favourable 
interactions with the Arg217 sidechain, as observed in the uPA:48 and uPA:49 structures, was 
compensated for by the new interaction between the o-methoxy CH3 group and the hydrophobic 















Figure 3.11: A) X-ray co-crystal structure of 50 bound to the serine protease domain of Human 
uPA (1.7 Å). The electron density map (2mFo-DFC) is contoured at 1.5 σ. Electrostatic potential 
surfaces of uPA are shown with blue = negative and red = positive. A bridging water molecule is 
represented as a red ball. All non-bridging water molecules have been omitted for clarity. A sulfate 
from the cyrstalization buffer is bound to the oxyanion hole and is presented in stick 
representation. B) Equivalent structure to A) with interacting surfaces coloured according to 
electrostatic potential (uPA) or cyan (50). C) Summary of the binding interactions between 50 and 
uPA. Residues comprising the S1 subsite are labeled in blue. Straight dashed lines represent H-
bonds and ionic interactions. Dashed lines represent van der Waals contacts. Favourable 
interactions were observed between the o-methoxy CH3 and the small hydrophobic dimple of S1 
formed by the side chains of Lys143, Gln192 and the Ser146 backbone. The sidechain of Arg217 




3.3 X-ray co-crystal structures of HMA, 42 and 50 in complex with H99Y 
‘murinized’ uPA 
 
A key active site difference between murine and human uPA is the substitution at residue 99 
(occupying S2 and S4), where His in the human enzyme is replaced by the bulkier Tyr in the mouse 
equivalent. X-ray co-crystal structures of HMA, 42 and 50 in complex with HuPA H99Y were solved 
to aid explanation of the SAR trends for HuPAH99Y (and by extension MuPA) presented in Chapter 
2.4. 
 
The Tyr99 sidechain OH was found to be located close to the proximal methylene group of HMAs 7-
membered ring (3.2 Å). In the equivalent huPA structure, the closest distance from the same CH2 
group to His99 was 4.1 Å (Figure 3.12). Similar observations were made for 42 and 50, where the 





Figure 3.12: Superpositions of X-ray co-crystal structures of H99Y uPA with WT HuPA; A) HMA,B) 
42 and C) 50. H99Y X-ray co-crystal structures HuPA structures. The H99Y is presented in orange 
and the WT backbone in mauve. Residue 99 in each variant (His99 in WT, Tyr99 in H99Y mutant) is 
highlighted by a black box. Positioning of backbone residues in each uPA variant was preserved 
across all structures and inhibitor binding poses were very similar across matched complexes. In 
the H99Y structures, the Tyr sidechain is positioned closer to the proximal CH2 of the azepane ring 
than in the HuPA structures, potentially creating unfavourable interactions. Structures were 
obtained at the following resolutions: HMA 2.3 Å, 42 2.9 Å and 50 2.4 Å. 
 
This close orientation suggests that an unfavorable interactions between the polar Tyr99 sidechain 
and the hydrophobic azepane ring may be occurring, which could explain the greatly decreased 
potency of these analogues against H99Y relative to HuPA. The topology of the S1 subsite was 
preserved across both co-complexes for all three inhibitors. The binding poses of HMA and 50 
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were very similar across the WT and mutant structures and the two methoxy groups of 50 
occupied virtually identical positions. Interestingly, the pyrazine core and azepane ring of 42 were 
shifted towards the S2 pocket in the H99Y structure, apparently to present the 6-benzofuranyl 
substituent in identical configurations in both structures. The positioning of the sidechain of 
Arg217 was similar in both the HMA and 42 structures. However, the Arg217 sidechain in the 50 
H99Y structure was positioned close to the pyrimidine methoxy group of 50. In the HuPA structure 
it was positioned well away from S1. Despite the potential for H-bonds allowed by this 
positioning, potency was actually decreased against the murinzed enzyme (H99Y IC50 = 9.7 M). 
 
3.4 Summary and conclusions 
 
The X-ray co-crystal data presented herein allowed rationalization of some of the potency trends 
observed for the 6-HMA series. In general, appending substituents to the 6-position did not alter 
the binding pose or interactions formed between the parent structure and the HuPA active site. 
Favourable interactions between the 6-substituents and S1 were observed in all examples, 
confirming that this subsite is accessible from the 6-position of HMA and that increased S1 
occupancy can drive increases in potency.  
 
The observation that significant modifications (e.g. 46 vs 43 and 48 vs 50) resulted in modest 
changes in potency may reflect contributions from bulk effects, such as differences in desolvation 
energies for the respective substituents as the formation of specific and distance-dependent 
interactions appeared not to fully explain the observed trends. Experiments with the H99Y 
‘murinized’ human uPA suggested that unfavourable interactions between the Tyr99 sidechain 
and the 5-azepane ring of 6-HMA analogues may be contributing to the decreased activity relative 
to HuPA. By extension, analogous (unfavourable) interactions between the 6-HMA analogues and 
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CHAPTER 4: In vitro and ex vivo characterization of 6-HMA analogues 
 
Solution phase enzyme inhibition assays and X-ray crystallographic analysis allowed identification 
of promising lead structures from the synthesized library of 6-HMA analogues. The effects of 
selected leads on various aspects of cancer cell biology were characterized using multiple in vitro 
and ex vivo platforms. As is common practice during evaluating novel drug leads, cytotoxicity was 
also evaluated against human established cell lines. 
 
4.1 Effects on cell proliferation and cytotoxicity 
 
The cytotoxic effects of  2-benzofuranyl and 5-pyrimidinyl leads were investigated using the 
Promega CellTitre 96® Aqueous One Solution Cell Proliferation Assay. The assay measures the 
extent to which intracellular dehydrogenase enzymes convert a tetrazolium reagent (MTS) into a 
chromogenic formazan dye that can be quantified using a spectrophotometer. As the assay relies 
on the activity of enzymes upregulated during growth, the technique is unable to differentiate 
between cells that have died or entered senescence in response to drug treatment.300 As such, the 
assay is not strictly a measure of treatment-induced cytotoxicity, but rather is a measure of cell 
viability. Microscopic examination of cell cultures immediately prior to addition of MTS reagent 
provides a way of confirming cytotoxic effects, as indicated either by loss of cells or induction of a 
granular appearance. Despite their shortcomings, MTS and equivalent assays are commonly used 
as surrogate measures of compound cytotoxicity.  
 
Compounds from the 2-benzofuranyl (42) and 5-pyrimidinyl (50) lead classes differed markedly in 
their effects on U-937 human histiocytic lymphoma cell viability (Figure 4.1). Inhibition of U-937 
cell viability by 42 first appeared at concentrations between 1 and 10 M (28% inhibition at 10 
M), with complete inhibition observed at 100 M. In contrast, no inhibition was observed for  the 
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2,4-dimethoxypyrimidine analogue 50 in the range 1 nM-100 M. Microscopic analysis of cultures 
post-treatment revealed a rapid onset for the cytotoxic effects of 42 at 100 M, with cells 
exhibiting phenotypes characteristic of cytotoxic shock (e.g. decreased cell number, granular 
appearance, decreased surface area).301 The cells did not recover over the course of the 
experiment (50 h). 
 
 
Figure 4.1: Effects of 42 and 50 on viability of U-937 Human histiocytic lymphoma cells. Cells were 
harvested 48 h post-passage, plated at a density of 5000 cells/well and incubated at 37 °C, 5% CO2 
for 18 h prior to drug treatment. Vehicle (DMSO) was present in all solutions at 1% (v/v). Cells 
were cultured for 48 h post-drug treatment, incubated for 2 h with MTS reagent and absorbance 
readings obtained at 490 nm. Bars represent the mean ± SEM (n = 4).  
 
To determine whether similar results were observed in adherent cells, compound 42 was tested 
for cytotoxicity against MDA-MB-231 human epithelial breast adenocarcinoma cells. As seen with 
U-937 cells, 42 exhibited a pronounced inhibitory effect at 100 μM (Figure 4.2). HMA was similarly 
cytotoxic at this concentration, while no significant effects were observed for amiloride or the 




Figure 4.2: Effects of 42, HMA, amiloride and cariporide on viability of MDA-MB-231 human breast 
adenocarcinoma cells. Assays were conducted as described in Figure 4.1. Data represent the mean 
± SEM (n = 4). 
 
Microscopic analysis of the cells confirmed the cytotoxicity of 42 and HMA at 100 μM, as indicated 
by the greatly decreased cell numbers and (dead) appearance of cells (Figure 4.3). It appeared that 
the compounds elicited an immediate cytotoxic effect as very low cell numbers were present at 
the time of imaging, indicating that mitotic duplication had not occurred (i.e. the cells had died 




Figure 4.3: Phase-contrast photomicrographs of MDA-MB-231 cells 48 h after treatment with compound 42 or HMA. A pronounced decrease in cell 
number was observed with 42 and HMA at 100 µM relative to vehicle control (1% DMSO v/v). 
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To examine whether the anti-proliferative/cytotoxic effects were consistent within the 2-
benzofuranyl and 5-pyrimidinyl lead classes, other analogues from each class were next 
investigated using MDA-MB-231 cells. 4-Fluoro-2-benzofuranyl analogue 43 was found to be more 
toxic than the unsubstituted analogue 42 in the same cell line, exhibiting almost complete loss of 
viability at 10 M (Figure 4.4). In agreement with the low cytotoxicity of 50 observed in U-937 
cells, pyrimidine-based analogue 48 exhibited only a slight anti-proliferative effect on MDA-MB-
231 cells (30% inhibition) at 100 M.  
 
 
Figure 4.4: Effects of compounds 43 and 48 on viability of MDA-MB-231 human breast 
adenocarcinoma cells. Assays were conducted as described in Figure 4.1. Data represent the mean 
± SEM (n = 4). 
 
To examine whether the cytotoxic effects of the compounds were species-specific, compounds 42 
and 50 were tested in MTS assays using murine macrophage RAW 264.7 cells. The murine myeloid 
cells displayed greater sensitivity to both lead classes relative to human U-937 cells, with complete 




Figure 4.5: Effects of 42 and 50 on viability of RAW 264.7 murine macrophage cells. Assays were 
conducted as described in Figure 4.1. Data represent the mean ± SEM (n = 4). 
 
To complement the data obtained using the MTS assays, analogues 42 and 50 were investigated 
using the Roche Cytotoxicity Detection kit PLUS LDH release assay. Compromised plasma 
membrane integrity and resulting loss of cytoplasmic contents is a well characterized marker of 
cytotoxic cell death.302 The assay functions by detecting activity of lactate dehydrogenase (LDH), 
an enzyme  released from the cytoplasm of necrotic cells in response to drug treatment. Catalytic 
turnover of a chromogenic substrate provides a quantifiable response. To obtain a representative 
maximal signal (control) for cytoplasmic LDH activity, vehicle-treated cells were lysed at the assay 
endpoint using a detergent solution (9% v/v Triton-X100), referred to as lysis control. A matched 
negative control was also included to confirm that LDH is not secreted into the cell culture 
supernatant by healthy cells (vehicle control).  
 
The amount of LDH activity in U-937 cells treated with 42 and 50 (1 nM-100 M) was measured 48 
h after initial compound exposure (Figure 4.6). In line with MTS assay results, only the 2-
benzofuranyl analogue 42 caused a significant release in LDH activity at 100 µM, indicative of cell 
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death. Evidence of slight LDH release at 10 µM was apparent.  No significant LDH release was 
observed with 50 at any concentration. 
 
 
Figure 4.6: Effects of 42 and 50 on LDH release from U-937 cells. Abs490 corresponds to the degree 
of cytotoxic cell death in response to drug treatment. Cells were harvested, cultured and treated 
as described in Figure 4.1. Lysis control cells were subsequently treated for 15 min with 5 µl lysis 
Buffer, incubated for 10 min with reagent mixture and readings obtained at 490 nm. Data 
represent the mean ± SEM (n = 4). 
 
Microscopy immediately prior to LDH assay revealed that 100 µM 42 had caused a substantial loss 
of cells relative to the lower doses or vehicle-treated controls, further confirming that 42 is 




Figure 4.7: Phase contrast photomicrographs of U-937 cells 48 h after treatment with 42 or 50. A 
pronounced decrease in cell number was observed for 42 at 100 µM relative to the vehicle control 
(1% DMSO v/v). 
 
Taken together, these results indicate a marked difference in the cytotoxic effects of the two lead 
series, with the 2-benzofuranyl analogues being clearly more cytotoxic than the pyrimidines. It is 
unclear whether the cytotoxic effects of the benzofuran compounds arose from specific 
interactions with pro-cytotoxic target(s) or whether they were simply a function of their higher 
lipophilicity relative to 5-pyrimidinyl class (benzofurans 42 and 43 ClogD 3.19-3.40; pyrimidines 48, 
49 and 50 ClogD 0.82-1.85), or a combination of these factors.  
 
HMA is known to trigger dose-dependent apoptosis via depletion of endoplasmic Ca2+ stores in 
human umbilical vein endothelial cells (HUVEC).303 In some recent reports, HMA (40 M) was used 
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as a specific inducer of apoptosis.304,305 To examine whether the cytotoxic effects of the 
benzofuran analogues are caused by induction of apoptotic cell death, compound 42 was tested 
using the Promega APO-One Homogenous Caspase 3/7 Assay.  
 
The assay probes the release of pro-apoptotic cysteine aspartic acid proteases (Caspase) 3 and 7 
into the cytoplasm by measuring turnover of a rhodamine-conjugated fluorogenic substrate of 
these enzymes. Cariporide is a potent and selective inhibitor of NHE1 and was included to examine 
whether NHE1 inhibition was also able to induce apoptosis (Cariporide uPA IC50 >> 100 M, see 
Appendix 9.3). Of the compounds 42, HMA and cariporide, only 42 at the highest concentration 
tested (30 M) produced a significant increase in caspase 3/7 activity in HEK-293 cells after 5 h of 
treatment exposure (Figure 4.8). This result supports the cytotoxic effects of 42 being linked to 
induction of apoptosis. 
 
 
Figure 4.8: Caspase 3/7 activation in HEK-293 cells following treatment with 42, HMA and 
cariporide. Cells were plated at 2.0x104 cells/well in black 96-well cell culture plates and incubated 
for 18 h at 37 C, 5% CO2. Cells were treated with compounds or vehicle (1% v/v DMSO) for 5 h, 
shaken for 1 h at 500 rpm using a motorized plate shaker and incubated for 2 h at RT. Caspase 3/7 
fluorogenic substrate in lysis buffer was added and after incubation at RT for 3 h the plates were 
read (ex. 485 nm, em 520 nm). Data represent the mean  SEM (n = 3). 
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4.2 Effects on cell proliferation in real time via xCELLigence assay 
 
To further investigate the cellular effects of the benzofuranyl class, cells were examined in 
response to treatment with 42 using the xCELLigence Real Time Cell Analyzer (Roche Diagnostics 
Australia Pty. Ltd., NSW, Australia). The xCELLigence system measures changes in electrical 
impedance inside a specialized multiwell plate and can be used to monitor various aspects of cell 
behavior, including viability and proliferation rate. As cells proliferate they impede the flow of 
electrons between electrodes fused to the bottom of each well. The impedance change is 
measured and used to calculate a cell index (CI); a dimensionless value that allows relative 
comparison of different compound treatments and conditions on cell behavior (e.g. growth rate).  
 
A highly metastatic variant of the MDA-MB-231 breast adenocarcinoma cell line (MDA-MB-
231HM) was used as it is known to overexpress both uPA and uPAR (M. Ranson, personal 
communication). Cells were plated into proprietary E-plate culture plates and allowed to grow for 
24 h prior to drug addition. Figure 4.9 shows that cells in all treatment groups showed similar 
proliferation rates prior to drug addition at 24 h. Compound 42 at 10 M caused an immediate 
toxic shock to cells with no recovery over time, indicative of cell death. This confirmed the rapid 
onset of cytotoxicity induced by the benzofuranyl analogues, as observed earlier with MTS/LDH 
assays and microscopic analyses.  
 
HMA at 10 M slowed the proliferative rate of MDA-MB-231HM cells, but the cells were able to 
recover and achieve a CI comparable to the vehicle control by the 72 h endpoint. Recovery of HMA 
treated cells suggests that it is not cytotoxic at this dose, corroborating results from the MTS, and 
Caspase 3/7 activation assays and microscopic analysis. Amiloride and cariporide showed minimal 
differences to vehicle control cells. These results highlight intrinsic differences between the 
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cytotoxic effects of HMA, the parent compound amiloride and 6-benzofuran analogue 42. The 





Figure 4.9: xCELLigence real-time analysis of the antiproliferative effects of compounds on MDA-
MB-231HM human breast adenocarcinoma cells over 72 h. Cell index (CI) is a dimensionless 
measure of changes in electrical impedance caused by proliferation of cells. Cells were plated at 
5x103 cells/well. Data points represent the average of two intra-assay replicates. The sharp 
decrease observed at the time of drug addition (24 h) is caused by requilibration of the system 
after mechanical perturbation. 
 
To examine whether the antiproliferative effects of HMA and 42 in MDA-MB-231HM cells were 
uPA-mediated, the xCELLigence assay was repeated using uPA/uPAR-null HEK-293 human 
embryonic kidney cells.59 As seen in MDA-MB-231HM cells, treatment with 10 M 42 caused 
immediate cell death with no recovery over 72 h (Figure 4.10). Likewise, HMA treatment slowed 
proliferation of HEK-293 cells without evidence of cytotoxicity, with CI recovery approaching the 
vehicle control by the end of the assay. Amiloride or cariporide treatment had no effect on 
proliferative rate or final CI. Recapitulation of the MDA-MB-231HM results in uPA/uPAR-null HEK-
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293 cells indicates that the cytotoxic effects of 42 (and modest cytostatic effects of HMA) operate 
via uPA/uPAR-independent mechanisms. 
 
 
Figure 4.10: xCELLigence real-time analysis of the antiproliferative effects of compounds on the 
uPA/uPAR-null HEK-293 human embryonic kidney cells over 72 h. Assays were conducted as 
described in Figure 4.9. The plateau in cell index after ~ 60 h indicates cells reaching confluence. 
 
Dose-dependency of the effects of 42 and HMA was probed by repeating the assay with 
uPA/uPAR-null HEK-293 cells at lower concentrations. Compound 42 at 1 M did not show  the 
dramatic cytotoxic effects observed at 10 M, although CI was reduced by 22% relative to vehicle 
control cells after 70 h (Figure 4.11), suggesting a mild-antiproliferative effect. HMA at 10 M was 
again found to inhibit the rate of cell proliferation, with CI recovering to approximately half that of 
control cells by the assay endpoint. Amiloride treatment at 1 M and 10 M had no effect on CI. 
Compound 42 showed no difference to control cells when present at 100 nM. These findings 
complemented results from the cytotoxicity and apoptosis assays showing that compound 42 has 
no effect at concentrations below 10 M.  
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Figure 4.11: Real-time analysis of the dose-dependent antiproliferative effects compounds. Assays 
were conducted as described in Figure 4.9. 
 
4.3 Effects of 6-HMA analogues in a 3D organotypic cell invasion model 
 
Despite their prevalence, two-dimensional models for studying cancer cell migration and invasion 
do not accurately reflect the dynamic three-dimensional (3D) environment experienced by cancer 
cells in vivo. This shortcoming has fueled much research into the development of 3D cell culture 
models that capture the spatiotemporal milieu of invasive cancers.306 To this end, and to examine 
the extent to which 6-HMA analogues are able to inhibit invasion in an ex vivo setting, a recently 
described collagen I organotypic cell invasion model was employed.307  
 
In this model, a preparation of collagen I isolated from rat tail tendons is seeded with fibroblasts 
and grown in culture. Due to their ECM-component secreting and ordering behaviors, the seeded 
fibroblasts contract the collagen I into a solid, dermal-mimicking plug. Once formed, the 
contracted plugs are overlaid with invasive epithelial cells that form a contiguous monolayer along 
the upper surface. The epithelial cells are then induced to invade into the collagen I matrix by 
transferring the plug to a steel grid and raising the cell culture medium to contact the bottom of 
the matrix, establishing an air-liquid interface. Growth factors and nutrients present in the culture 
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media diffuse into the matrix, providing a chemotactic gradient and trophic incentive that attracts 
epithelial cell invasion downwards into the plug. After an incubation period (3-21 days), cell plugs 
are formalin fixed and paraffin embedded, sectioned and stained, providing a measure of cell 
invasion. This system is an excellent model for examining the effectiveness of uPA inhibitors 
against epithelial cells that rely on the plasminogen activation pathway for invasiveness as 
inhibition of uPA and plasminogen activation should decrease migration of cells into the collagen I 
matrix.  
 
Overexpression of uPAS components is a key determinant of metastatic potential in malignant 
ovarian disease, where uPA levels correlate with FIGO (International Federation of Gynaecology 
and Obstetrics) grade and poor progression-free survival and overall survival.308,309 Differences in 
uPA expression between primary tumour and peritoneal metastasis have been validated as a 
prognostic biomarker for surgical outcome and overall survival.67 These findings suggested 
invasive SKOV-3 ovarian carcinoma cells as being suitable for use in the 3D organotypic model.  
 
SKOV-3 cells seeded at a density of 1.875x105 cells per plug were allowed to invade for 21 days. 
Compound or vehicle containing media was replaced every 72 h, with all compounds present at 2 
M. Cell invasion was quantified by calculating the invasion index (II) for each image, where II = 
number of epithelial cells invaded into collagen plug/number epithelial cells forming a contiguous 
monolayer along top of the plug x 100% (Figures 4.12 & 4.13).  
 
A small but significant decrease in invasion index was observed for the 2-benzofuranyl analogue 42 
relative to the DMSO control group (Figure 4.12, mean II DMSO control = 63.65, 42 = 57.83, p 





Figure 4.12: Inhibition of SKOV-3 ovarian adenocarcinoma cell invasion by compounds. Collagen I 
plugs contracted by human skin-derived fibroblasts were seeded with SKOV-3 cells at a density of 
1.875x105/plug and allowed to invade for 21 days prior to fixing. Stained plug sections were 
imaged and the images quantified for invasion index (II). Compounds were present at a 
concentration of 2 M. Data points represent invasive indices from 10 individual images across 
identically treated plugs. Central lines represent the mean ± SEM. 
 
No significant differences in invasion index were detected for amiloride, HMA, cariporide or the 
2,4-dimethoxy-5-pyrimidinyl compound 50 versus the DMSO control. The lack of effect of both 
amiloride and HMA on SKOV-3 invasion is likely due to too a low a concentration being used given 
the moderate potency of each compound against uPA (amiloride IC50 = 3954 nM, HMA IC50 = 
2206). The finding that both HMA and cariporide did not inhibit cell invasion suggests that NHE1 
does not play a role in invasion in this model. The lack of inhibition of cell invasion by compound 
50 is surprising as this analogue is an ~ 4.3-fold more potent uPA inhibitor than 42 (50 IC50 = 68 
nM, 42 IC50 = 297 nM). Analytical HPLC analysis of the DMSO stock from which compound 50 
treatment was prepared revealed the appearance of 3 peaks in addition to the peak for the pure 
compound, suggesting degradation of 50 had occurred. As such, the concentration of 50 present 
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during the experiment would have been lower than 2 M. Higher doses of 50 (and 42) may be 
needed in future experiments to demonstrate inhibition of uPA-mediated cell invasion in this 
model. 
 
It is possible is that the small decrease in II caused by 42 arose not from inhibition of uPA-
mediated cell invasion but instead from cytotoxic effects of the compound on SKOV-3 and/or TIF 
cells. MTS assays showed that 42 is cytotoxic to both human and murine cells at concentrations > 
7.5 M. While plausible, this explanation is unlikely given that the concentration used (2 M) was 
well below the threshold for cytotoxicity observed in MDA-MB-231 and HEK-293 cells (10 M). 
Experiments measuring the effects of 42 on SKOV-3 and TIF cell viability would be necessary to 
disprove this hypothesis. 
 
Variations in collagen plug density and integrity between experiments and batches of collagen I 
have been identified by colleagues in our laboratory (Nathanial Harris, personal correspondence). 
Degree of contraction, plug width and matrix density is heavily dependent on the functional state 
of fibroblasts, where contraction times can vary significantly between cultures (6-14 days). As 
shown in Figure 4.13, matrices were imperfect and contained small gaps. These variables may 





Figure 4.13: Representative images showing SKOV-3 human ovarian carcinoma cell invasion matrices contracted by human skin-derived fibroblasts. 
Cells were allowed to invade for 21 days prior formalin fixing. Cytokeratin stained plugs were imaged using bright-field microscopy with 10 images 
collected across three plugs for each treatment group. All compounds were present at 2 M, with compound-containing media refreshed every 72 h.
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SKOV-3 cells are known to overexpress large amounts of uPAR.310 However, relative to other 
ovarian cancer cell lines, SKOV-3 cells secrete only moderate amounts of HMW-uPA (full-length, 
active uPA that’s able to bind uPAR).69 In addition, telomerase-immortalized fibroblasts do not 
secrete large amounts of HMW-uPA, making endogenous uPA expression by SKOV-3 cells the sole 
source of the enzyme in this system (Harris et al., manuscript submitted). It is therefore possible 
that uPAR occupancy and uPA-mediated cell invasion was low, decreasing the dynamic range for a 
measurable effect. Addition of exogenous HMW-uPA in future experiments would ensure 
complete occupation of uPAR has been used previously in our laboratory with success (N. Harris, 
personal communication). 
 
SKOV-3 cells are considered to be moderate to highly invasive but they showed only mild 
invasiveness in this model, requiring a long time (21 days) for sufficient invasion.74 Selection of a 
more aggressive cell line that relies on uPA/plasminogen for invasion (e.g. MDA-MB-231 breast 
adenocarcinoma cells, 10 day invasion) may provide a more sensitive platform for measuring the 
anti-invasive effects of 6-HMA analogues and other uPA inhibitors in general.  
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4.4 Effects of 6-HMA analogues in combination with chemotherapy drugs on 
neoplastic cell phenotypes 
 
The acidic tumour microenvironment is increasingly being linked to the responsiveness of 
cancerous cells to a variety of conventional chemotherapy drugs.311,312 Drugs with pKa values near 
the pH range observed in tumour microenvironments will exist as charged or neutral species, 
depending on their acidic/basic groups.313 Maximizing the proportion of drug present in an 
uncharged state is crucial for compounds that act on intracellular targets as the neutral species is 
able to passively diffuse across the plasma membrane.314 
 
NHE1 blockade has been suggested as a possible approach for sensitizing tumour cells to weakly 
basic drugs acting on intracellular targets. The theory is that preventing NHE1-driven acidification 
of the extracellular space will increase the amount of drug present in the membrane-permeable 
neutral form.85 A commonly used, weakly basic anticancer drug is the vinca alkaloid vinblastine 
(pKa ~ 8.8).295 Vinblastine is an antimitotic agent that binds to -tubulin subunits, preventing 
functional microtubule assembly and mitotic spindle formation that leads to cell cycle arrest 
during mitosis, and ultimately apoptosis.87 Clinically, vinblastine is often used in combination with 
cisplatin or mitomycin C for ovarian, lung and brain tumours and Hodgkin’s lymphoma. It is also 
used as a salvage therapy in metastatic breast cancers non-responsive to first-line therapies.315,316 
 
To test this hypothesis, the effects of combinations of 6-HMA analogues 42, 43 and 49 and 
vinblastine on MDA-MB-231 cell growth and viability were explored using MTS assays. NHE1 
activity in cells was stimulated by serum starvation (0.2% FCS).122 The use of low serum media 
increased the cytotoxic effects of benzofuran compounds 42 and 43, with complete cell death  
observed at 5 M for both compounds (c.f. 10 M using 10% FCS media, section 4.3). Vinblastine 
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alone at 5 M decreased cell viability by ~ 25% relative to vehicle treated cells and 1 nM 
vinblastine had no effect (Figure 4.14 A). The cytotoxicity of Vinblastine at 5 nM was increased by 
36% and 30% when combined with 1 M and 0.25 M 42, respectively (p 0.0039 and 0.0002). 
Slightly less potentiation was observed with 1 nM vinblastine and 42 at 1 M or 0.25 M, 
respectively (19% and 29% decreases in cell viability, p 0.0196 and p 0.001). In contrast, no 
potentiation of the effect of 5 nM vinblastine was observed with any combination of 43. However, 
small but significant increases were observed with 1 nM vinblastine and both 1 M and 0.25 M 
43 (18% and 11% decreases in cell viability, p 0.0004 and p 0.0039). The differences between the 
benzofuran and 4-fluorobenzofuran analogues suggest that potentiation of vinblastine cytotoxicity 
is probably not general for the 2-benzofuranyl class.  
 
No significant potentiation was observed for any combination of vinblastine with the pyrimidine 
analogue 49 compared to vinblastine alone. Compared to the benzofuran analogues 42 and 43, 
the highest concentration of 49 (5 M) showed no effects on cell viability, again highlighting the 
differences in the intrinsic cytotoxicity of the 5-pyrimidine versus 2-benzofuranyl lead classes. 
 
Contrary to expectation, potent NHE1 inhibitor cariporide appeared to protect MDA-MB-231 cells 
from the effects of vinblastine, increasing viability by 69% at 5 M cariporide compared to when 
vinblastine was present at 5 nM alone (Figure 4.14). In cells treated with cariporide alone viability 
was decreased in the range 19-35%. 
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Figure 4.14: Effects of vinblastine/6-HMA analogue combinations on MDA-MB-231 cell viability 
using MTS assays. Data represent the mean ± SEM (n = 4). Statistical significance between groups 
was tested using the unpaired parametric t-tests in GraphPad PRISM v6.0. Level of significance 
was denoted as: * p < 0.05, ** p < 0.02, *** p < 0.005. 
 
When co-administered with cariporide, 1 nM vinblastine showed negligible effects at all cariporide 
doses. At 5 nM vinblastine alone cell viability was decreased by ~ 60%. The incomplete killing of 
cells at this high dose of vinblastine suggested the existence of a resistant subpopulation.    
 
A concentration-response experiment conducted to determine the effects of vinblastine on MDA-
MB-231 cell viability gave an IC50 value of 2.33 M and showed the presence of a resistant 




Figure 4.15: The effect of vinblastine treatment on cell viability as determined by analysis of total 
cell area using the Incucyte ZOOM Live-Cell Analysis System. Data represent the mean ± SEM (n = 
4). 
  
MDA-MB-231 cell growth was also monitored in real time using the Essen Biosciences Incucyte 
ZOOM Live-Cell Analysis System, which allowed real time evaluation of the effects of the 
compound combinations on cell confluency (Figure 4.16). An immediate and potent cytotoxic 
response was observed with 5 M 42, both alone and in combination with vinblastine (Figure 4.14 
A & B, 4.16 A). Vinblastine alone showed dose-dependent inhibition of cell growth, with 1 nM and 
5 nM concentrations decreasing normalized confluency by 13% and 33%, respectively, after 52 h. 
The initial slow growth of cells treated with 5 nM vinblastine suggests the presence of a resistant 
population of cells, as an appreciable increase in normalized confluency was not seen until 18 h 
post-treatment. 
 
No cytotoxic effect relative to control was seen for 42 at 1 M.  The combination of 1 M 42 with 
1 nM or 5 nM vinblastine resulted in 20% and 10% decreases, respectively, in normalized 
confluency at 52 h relative to cells treated with vinblastine alone (Figure 4.16A). No cytotoxic 
effect was observed for the pyrimidine-based compound 49 at the highest concentration tested (5 
M, Figure 4.16 B).  
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Figure 4.15: Real time analysis of the effects of vinblastine/6-HMA analogue combinations on 
MDA-MB-231 cell growth. Representative images from each treatment group were acquired every 
2 h under a 10X objective using the Incucyte ZOOM Live-Cell Analysis System. All data are 




No significant effects of 49 in combination with vinblastine were observed, with confluency 
tracking closely relative to cells treated with vinblastine alone. Data from combinations of 
vinblastine with 0.25 M 42 and 49 were omitted due to their similarity to that obtained with the 
compounds present at 1 M. 
 
Phase contrast photomicrographs taken 52 h post-treatment illustrate the effects of 
42/vinblastine combinations on MDA-MB-231 morphology (Figure 4.17). Cytotoxic effects of 42 at 
5 M are evident in panels A-C, where the remaining cells show greatly reduced cell area, rounded 
appearance and high granularity. Lower doses of 42 did not alter morphology relative to vehicle 
treated controls. Cells treated with 1 M or 0.25 M 42 in combination with 5 nM vinblastine 
displayed a smaller, more rounded morphology and decreased cell number relative to cells treated 
with 5 nM vinblastine alone. Cells treated with 1 nM vinblastine in the presence 1 M or 0.25 M 
42 showed a similar appearance to matched combinations at 5 nM vinblastine, albeit with slightly 
increased cell area. Vinblastine alone at 5 nM and 1 nM induced cells towards a tightly packed 
‘cobblestone-like’ appearance compared to control cells, which displayed a more elongated and 
polarized morphology. 
 
In general, the vinblastine/6-HMA analogue combinations did not show notable potentiation 
relative to vinblastine-treated MDA-MB-231 cells. The modest potentiation of 5 nM vinblastine by 
42 may be anomalous as the readout for cells treated with this dose of vinblastine alone appears 
to be high relative to similar treatments in matched experiments (Figure 4.14A rightmost black bar 
c.f. 4.14 B-D).  
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Figure 4.16: Phase contrast photomicrographs of MDA-MB-231 human breast adenocarcinoma cells treated with combinations of 6-HMA analogue 
42 and vinblastine. Representative images from each treatment group were acquired 52 h post-treatment under a 10X objective using the Incucyte 
ZOOM Live-Cell Analysis. Yellow bars represent scale (100 m). 
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Paclitaxel is an atypical antimitotic agent used in the treatment of aggressive cancers, including 
ovarian and breast.317,318 In contrast to microtubule destabilizing drugs like vinblastine, paclitaxel 
promotes formation of -tubulin heterodimers upon binding to -tubulin, causing the 
stabilization of microtubules and consequent cell cycle arrest during late G2 or M phase.94 
Paclitaxel in combination with cisplatin is a standard therapy for patients with triple-negative and 
HER2+ metastatic breast carcinomas who have relapsed following first line chemotherapy.96,319 
NHE1 downregulation by paclitaxel via the PKA/p38 MAPK signaling pathway is thought to be a 
mediator of proapoptotic effects of paclitaxel.99 NHE1 inhibition by the 5-substituted amiloride 
analogue DMA 28 has been shown to increase paclitaxel-induced cell death in MDA-MB-435 
melanoma-like cells.99,320  
 
More recently, low dose HMA (10 nM) was shown to potentiate the cytotoxic and anti-migratory 
effects of paclitaxel in aggressive, hormone receptor triple-negative MDA-MB-231 breast 
adenocarcinoma cells.112 Similar results were reported using the NHE1 specific inhibitor EMD 
87580 (Rimeporide), supporting NHE1 inhibition as the mechanism underlying potentiation. Given 
the relevance to this thesis work, combinations of 6-substituted HMA analogues, HMA and the 
NHE1-specific inhibitor cariporide with paclitaxel were investigated for their effects on MDA-MB-
231 cells. 
 
As found previously, 5 M concentrations of 2-benzofuranyl analogues 42 and 43 caused 
immediate and complete cell death, when administered alone and in combination with 0.5 nM or 
5 nM paclitaxel (Figure 4.18). No cytotoxicity was observed in cells treated with the 5-pyrimidinyl 
analogues 48 or 49 (5 M), HMA (5 M) or cariporide (1 M).  
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Disappointingly, no potentiation of paclitaxel cytotoxicity was observed in combination with HMA, 
6- HMA analogues or cariporide at any of the concentrations tested (Figure 4.18).  
 
 
Figure 4.17: Effects of paclitaxel/6-HMA analogue combinations on MDA-MB-231 cell viability. 
MTS assays were conducted as described in Figure 4.14. 
 
Cell viability assays using real-time analysis of cell growth following compound/combination 
treatments showed that 43 and 49 produced no synergistic effects when used with paclitaxel 
(Figure 4.19). Similar results seen with the 6-HMA analogues 43 and 49, co-administration of 
cariporide did not potentiate paclitaxel induced cytotoxicity. 
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Combinations of HMA with paclitaxel were found to show the greatest effects on cell confluency 
(Figure 4.20). Normalized confluency decreased ~ 20% in cells receiving 5 nM paclitaxel + 5 M or 
1 M HMA relative to cells treated with 5 nM paclitaxel alone. Greater effects on confluency were 
observed for 0.5 nM paclitaxel combinations with 1 M HMA or 5 M HMA, where 23% and 30% 
reductions in confluency were seen, respectively. These effects on confluency did not coincide 
with decreases in cell viability, as shown for HMA in Figure 4.18F. Data from 43, 49 and HMA at 
0.25 M +/- paclitaxel were omitted due to similarity with to data obtained at 1 M. 
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Figure 4.18: Real time analysis of the effects of Paclitaxel/6-HMA analogue combinations on MDA-
MB-231 cell growth. Images were acquired as described in Figure 4.15. 
 
It is challenging to understand why we were not able to reproduce results similar to those 
reported by Amith et al. with HMA and MDA-MB-231 cells.112 Misidentification of the cell line used 
for the assays was ruled out using short tandem repeat analysis of cell DNA (92.8% match to ATCC 




Figure 4.20: Real time analysis of the effects of paclitaxel/HMA or paclitaxel/cariporide 
combinations on MDA-MB-231 cell growth. Images were acquired as described in Figure 4.15. 
 
One difference between experimental protocols, however, was the use of far greater compound 
concentrations in our experiments relative to those reported for HMA (10 nM). Intuitively, it 
would be expected that synergistic effects of HMA or 6-HMA analogues with paclitaxel should be 
larger at higher concentrations. To rule out the possibility that synergy is only observed at low 
concentrations, HMA 42, 48 and 49 were examined at 25 nM in combination with paclitaxel at 0.5 
nM (Figure 4.21). 
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Figure 4.219: Effects of low-dose combinations of HMA and analogues 42, 48 and 49 with 
paclitaxel on cell viability in MDA-MB-231 cells. Assays were conducted as described in Figure 
4.14. 
 
No significant effect was observed for any compound, either alone or in combination with 
paclitaxel, relative to vehicle treated control cells. 
 
4.5 Inhibitory effects of 6-HMA analogues on ENaCs 
 
The diuretic and antikaliuretic properties of amiloride arise through inhibition of epithelial sodium 
channels (ENaCs) in the distal nephron of the kidney.189 Loss of ENaC inhibitory effects upon 
substitution at the amiloride 5-position have been documented with alkyl substitution of the 5-
NH2 group resulting in large decreases in potency.
242 As diuretic and antikaliuretic activities would 
be undesirable in an anticancer drug, a key hope in this project was to establish that substitution 
of HMA at the 6-position would produce compounds that lack activity against ENaCs. Amiloride, 
HMA and a representative subset of 6-HMA analogues were screened for inhibitory activity 
against HEK-293 cells that transiently express the ,  and  subunits of Human ENaC (Figure 4.22). 
The assays used a fluorescent membrane potential dye kit and an automated fluorescence plate 
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reader (FLIPRTETRA, Molecular Devices, Sunnyvale, California, USA). The experiments were 
performed under contract by Charles River Laboratories, Cleveland, Ohio, USA. My role was to 
liaise with the company, advising on compound solubility and other experimental parameters. 
 
 
Figure 4.20: Inhibition of ENaC activity in ENaC-overexpressing recombinant HEK-293 human 
embryonic kidney cells. All cells were stimulated with ENaC agonist S3969. All compounds were 
present at 10 M. Data were normalized to uninhibited (0%) and benzamil treated (ENaC 
antagonist, 100%) controls. Data represent the mean ± SD (n = 4). 
 
Substitution of the 6-position of HMA had no effect on ENaC activity, with HMA and all 6-HMA 
analogues showing similar effects (12-21% inhibition). In comparison, amiloride showed 68% 
inhibition at the same concentration. The results clearly demonstrate that 6-HMA analogues retain 
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the low ENaC potency previously noted for HMA. As such, it is unlikely that 6-HMA analogues 
would display the antikaliuretic and diuretic properties of amiloride in vivo. This is a key finding in 
this work as it implies that if anticancer therapeutics were eventually developed from this class 
they would be unlikely to carry the potentially life-threatening cardiac effects associated with K+ 
retention, as observed with amiloride overdose.
159 
4.6 Summary and conclusions 
 
Cell viability and proliferation assays conducted with a variety of human and murine cell 
lines revealed a large difference in the intrinsic cytotoxicity of compounds from the two lead 
classes of 6-HMA amiloride analogues. In general, members of the 2-benzofuranyl class (42 
and 43) showed greater in vitro cytotoxic effects than the 5-pyrimidine analogues (48, 49 
and 50) with complete cell death observed for compounds 42 and 43 at concentrations as 
low as 5 M. In contrast the 5-pyrimidines showed no significant effects on cell viability up 
to 100 M against the majority of human cell lines. In the case of 42, caspase 3/7 activity 
assays revealed that the cytotoxicity observed with this class was mediated through 
induction of apoptosis.  
 
2-Benzofuranyl analogue 42 showed modest inhibition of SKOV-3 cell invasion in a 3D 
organotypic cell invasion model. Potentiation of the cytotoxic effects of the standard 
chemoptherapy drugs vinblastine and paclitaxel was not observed with analogues from 
either lead class. A selection of 6-substituted analogues, including representatives from both 
lead classes, were found (like HMA) to not inhibit ENaC, providing evidence that the diuretic 
effects of the parent amiloride had been removed.  
 
Taken together, these findings show that compounds from both lead classes do not possess 
potent cytotoxic effects and are unlikely to show diuretic activity in vivo. As such, they are 






CHAPTER 5: Development of a 96-well plate-based assay for 




Na+/H+ exchange activity has been measured using a variety of techniques, including 22Na+-
flux, patch clamping, atomic absorption spectroscopy (AAS) and fluorescence-based 
methods.321-323 The major disadvantages of radiometric, electrophysiological and AAS 
approaches are the requirement for expensive, specialist equipment and expertise and low 
throughput. Confocal microscopic and flow cytometry-based fluorescence methods suffer 
from similar limitations.324,325 Fluorescence plate readers, on the other hand, are designed 
for high sample throughput (up to 1536-well capability in some cases) and are common 
instruments in academic and industrial cell biology laboratories. The development of a new 
plate-based method for medium throughput screening of compounds for NHE1 activity 
would constitute a significant contribution to the field. This chapter describes the first 
reported 96-well plate-based fluorescence assay for the quantitation of NHE1 activity and 
inhibition in the presence of antagonists. 
 
5.2 Fluorescence plate assay and comparison to gold standard 
 
Fluorescence-based methods for measuring NHE1 activity have typically used the ratiometric 
dye (2’,7’-Bis-(2-carboxyethyl)-5-(and-6)-carboxyfluorescein (BCECF). The poly 
acetoxymethyl ester form (BCECF-AM) is able to diffuse across plasma membranes and enter 
the cytosol, where it is cleaved by non-specific esterases to an active, charged form  that 
becomes trapped within cells. The pH sensitivity of the fluorescence properties of the 
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‘trapped’ BCECF allows dynamic measurement of changes in pHi. pHi can be calibrated by 
exposing dye-loaded cells to buffer solutions at set pH values containing the membrane 
permeable H+ ionophore nigericin. Nigericin acts to shuttle protons across the cell 
membrane, causing rapid equilibration of pHi with pHe, and allowing the creation of a 
standard curve. BCECF features pH-sensitive and insensitive (isobestic point) fluorescence 
excitation maxima at 500 nm and 439 nm, respectively, and an emission maximum at 535 
nm (Figure 5.1).  
 
 
Figure 5.1: Excitation spectra of BCECF showing the pH sensitivity across the physiological 
range of its maximum at ~ 500 nm. Excitation at 500 nm increases with increasing pH. pH-
insensitive isobestic point is present at 439 nm (shown at 10x magnification). Adapted from 
Molecular Probes BCECF Technical Manual. 
 
Using dual-excitation with single emission measurements, ratiometric calculations (e.g. pH 
sensitive signal/isobestic signal) are able to be employed to correct for sample variability; 
e.g. degree of dye loading, activity of esterases, photobleaching etc.326  
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Fluorescence plate reader assays utilizing the pH-sensitive ratiometric dye BCECF to measure 
intracellular pH have been reported with a variety of cell types, including S. pneumoniae 
(bacteria), S. cerevisiae (yeast), Trypanosoma (parasitic protist) and primary and established 
mammalian epithelial cells (Obexer et al., 1997).327-330 Of these reports, Obexer et al. 1997 is 
the only example that exploited the high throughput capacity of a multiwell plate reader. 
This report used BCECF-AM to screen a library of anti-trypanosomal compounds and 
determine IC50 values.  
 
In addition to assays using standard fluorescence plate readers, there have been reports 
using a proprietary automated fluorescence plate reader (FLIPR) to measure NHE activity. 
The FLIPR High-throughput Cellular Screening System (Molecular Devices, Sunnyvale, 
California, USA) is a robotically controlled fluorescence plate reader specifically designed for 
screening compound libraries against transmembrane ion channels and GPCR targets. 
Despite the FLIPR system being well suited to the aims of this work, its prohibitive cost 
(+$800K AUD) limits broad uptake (G. Monteith, personal communication). To our 
knowledge, a straightforward assay for quantitating NHE1 inhibitory potency of compounds 
in adherent mammalian cells using commonly available fluorescence plate readers has not 
been described.  
 
Validation of the novel plate-based assay required comparison of the data produced to data 
derived from currently accepted standard methods. To obtain such validation, a 
collaboration was established with Prof. Larry Fliegel at the University of Alberta, Canada, an 
internationally renowned expert in the molecular and cellular biology of NHE1.189,192,331,332 
The Fliegel lab uses a traditional cuvette-based fluormetric method for determination of 
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NHE1 activity in adherent cell monolayers. This method is considered ‘gold standard’ for the 
evaluation of NHE1 inhibitor potency and is used by Prof. Fliegel in a number of active 
collaborations with groups developing NHE1-targeting compounds within academia and 
industry. Figure 5.2 shows a pHi calibration trace as it varies in response to different 


















Figure 5.2: pHi calibration trace for MDA-MB-231 breast adenocarcinoma cells using a 
fluorimeter-based NHE activity assay. Figure adapted from reference 112. See text for 
details. 
 
Cells are initially exposed to Na+-containing buffer, allowing them to equilibrate pHi to a 
resting state value (1). Introduction of NH4Cl to the buffer causes immediate alkalinization of 
pHi (2), as NH3 rapidly enters the cell and establishes a new NH3 ⇄ NH4
+ equilibrium as NH3 
molecules sequester H+ in the cytosol. This transient alkalinization diminishes over time 
extracellular NH4
+ crosses the plasma membrane. This process is orders of magnitude slower 
than NH3 passage due the species positive charge. Switching the buffer quickly to a Na
+-
free/NH4Cl-free solution causes rapid acidification of pHi (3) as NH3 rushes out of the cell 
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down its concentration gradient. The absence of Na+ in the system deprives NHE1 of the Na+ 
gradient necessary to drive NHE1-mediated translocation of intracellular H+, thus preventing 
recovery of pHi. Reintroduction of Na
+ (4) to the buffer switches on NHE1 activity, restoring 
pHi to a new steady state within minutes.
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The fluorometric method involves culturing adherent epithelial cells on cell culture treated 
coverslips in complete media. Once 80% confluence is achieved, cells are serum starved 
(cultured in 0.2% FCS-containing media) for approximately 24 h to stimulate NHE1 activity. 
Cells are then incubated for 20 min with the cell membrane-permeable fluorescent dye 
BCECF-AM. After dye loading, the coverslips are transferred to a custom-made glass cuvette 
designed to position the cell monolayer in the light path of a fluorimeter (PTI Deltascan 
Illumination System, Photon Technology International, New Jersey, USA). The cuvette is 
filled with Na+-containing assay buffer for 3 minutes, allowing the cells to equilibrate pHi 
through the action of NHE1. Cells are then subjected to a transient acid load with a pulse of 
NH4Cl (50 mM) before being transferred to a second cuvette containing Na
+-free media. This 
results in a rapid decrease in pHi as NH3 diffuses out of the cells. pHi remains acidic until Na
+ 
is reintroduced, causing NHE1 function to be restored and returning pHi to resting values. 
Following NHE1-mediated pH recovery, intracellular pH signal is calibrated by sequentially 
equilibrating the cells in nigericin-containing buffers at set pH values. By measuring initial 
recovery of pHi in the presence of different concentrations of inhibitors, dose-response 
curves can be plotted and IC50 values for inhibition of NHE obatined.  
 
A plate reader assay could follow the same general principles with key modifications to 
adapt the assay to a 96-well plate format. All liquid addition steps were performed using a 
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multichannel air-displacement pipette. Liquids were removed by vigourously shaking out the 
plate into a receptacle followed by visual inspection of wells to ensure total removal of 
liquids. A schematic overview of the assay is presented in Figure 5.3. 
 
 
Figure 5.3: Summary of fluorescence plate assay for determining NHE activity/inhibition.  
 
Cells were plated at a density of 2x104 cells/well in black cell culture-treated 96-well plates 
and cultured in RPMI 1640/10%FCS for ~ 42 h to ensure formation of a confluent monolayer. 
On the day of experiments, cells were starved for 3-4 h in low serum (0.2% FCS) media. Cells 
were then loaded with 5 M BCECF-AM in serum-free media and incubated for 30 min. The 
dye solution was then removed and cells washed once with 100 L Na+-containing buffer 
and equilibrated for 3 min with additional Na+-containing buffer (Step 1). The buffer was 
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then replaced with Na+-containing buffer containing 50 mM NH4Cl and equilibrated for 3 min 
(Step 2). NH4Cl-containing buffer was replaced by 100 L Na
+-free buffer, decreasing pHi as 
NH3 diffuses out of the cell (Step 3). Compounds diluted in Na
+- containing buffer in a 
separate 96-well plate were then added allowing measurement of NHE1-driven recovery in 
the presence or absence of inhibitors. (Step 4, n = 3 wells for each compound 
concentration). Intrinsic fluorescence of compounds was corrected for by including 
identically treated dye-free control cells at each compound concentration. Finally, control 
cells were successively equilibrated using nigericin-containing buffers at set pH values (Steps 
5-7), allowing initial rates of recovery (pH/s) to be calculated for each compound 
concentration with normalization against untreated control cells. Throughout Steps 1-7 
readings were obtained using a POLARstar Omega Fluorescence plate reader with the 
settings outlined in Table 5.1  
 
Table 5.1: POLARstar OMEGA settings used for plate-based NHE1 inhibition assays. 
Setting Value 
Measurement type Fluorescence Intensity, top optic 
Read Mode Plate, multichromatic  
No. of cycles 1-3 dependent on step 
Cycle time  107 seconds 
Scan mode Orbital averaging 
Scan diameter/No. flashes 1 mm/ 8 flashes per well 
Filter settings 
1. pH-sensitive couple 
2. Isobestic couple 
Excitation Emission Gain 
1. 485 ± 12 
nm 
520 nm 1450 
2. 440 nm 520 nm 1450 
Assay Temperature  37 C 
  
 
In addition to Na+/H+-exchange, HCO3-driven processes (e.g. Cl
-/HCO3
- exchanger and 
Na+/HCO3
- co-transporters) are also contributors to transmembrane pH homeostasis.130 
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Dependence on HCO3
- or Na+-driven processes for regulating transmembrane pH has been 
shown to vary between established neoplastic cell lines, with some lines displaying a 
preference for one pathway over the other.132 MDA-MB-231 breast adenocarcinoma cell 
were chosen for this work due to their reliance on Na+/H+-exchange driven regulation of 
pHi.
112,333 MDA-MB-231 cells also express NHE1 exclusively over other plasma membrane 
NHE isoforms (L. Fliegel, personal communication). HCO3-driven contributions to pH 
recovery were negated by using HCO3
--free solutions in all experiments. Identical buffer 
compositions were used in all experiments across both NHE1 measurement techniques 
(Table 5.2). 
 
Table 5.2: Composition of buffers used in NHE1 activity assays. The membrane-impermeant 
N-Methyl-D-glucamine was used in place of Na+ to maintain isotonicity in Na+-free buffers. 
Buffer Composition 
Na+-containing buffer 135 mM NaCl, 5 mM KCl, 1.8 mM CaCl2, 1 
mM MgSO4, 5.5 mM glucose, 10 mM HEPES. 
Na+/NH4Cl-containing buffer 135 mM NaCl, 5 mM KCl, 1.8 mM CaCl2, 1 
mM MgSO4, 5.5 mM glucose, 10 mM HEPES, 
50 mM, NH4Cl. 
Na+-free buffer 135 mM N-methyl-D-glucamine, 5 mM KCl, 
1.8 mM CaCl2, 1 mM MgSO4, 5.5 mM 
glucose, 10 mM HEPES. 
pH calibration buffer 5 mM N-methyl-D-glucamine, 135 mM KCl, 
1.8 mM CaCl2, 1 mM MgSO4, 5.5 mM 












5.3 Results  
 
A representative pH calibration curve obtained from the successive equilibration of vehicle 
control cells in nigericin-containing buffer at pH 6-8 is presented in Figure 5.4. By performing 
linear regression analysis on the respective fluorescence ratios (pH sensitive signal/isobestic 
signal) at each pH, an equation relating pHi to the observed fluorescence ratio was derived. 
Using the equation, observed fluorescence ratios were converted to discrete pH values, 
allowing determination of pH/s for each sample. Calibration was performed each time in 
each Individual assay to account for interassay variations. 
 
 
Figure 5.4: Representative pH calibration curve from fluorescence plate reader assay. 
Fluorescence ratios from pH sensitive/isobestic signals were determined for control cells 
equilibrated in nigericin-containing buffers at different pHs. Linear regression analysis was 
performed and the resulting linear equation used to calibrate fluorescence ratios relative to 
pHi. Data represent mean  SEM (n = 6). 
 
Data were obtained from both the plate-based and traditional cuvette assays and dose-
response curves were calculated using GraphPad PRISM 6.0v. Representative dose-response 




Figure 5.5: Representative dose response curves for standard NHE1 inhibitors from A) 
cuvette and B) fluorescence plate reader assays. Data represent: A) mean  SEM (n = 3-4); B) 
mean  SEM (n = 3). MDA-MB-231 cells were used in all assays. Fluorescence measurements 
were obtained using: A) PTI Deltascan Illumination System (Photon Technology 
International, New Jersey, USA) B) POLARstar OMEGA Fluorescence Plate reader (BMG-
Labtech). Data were analyzed using Graphpad PRISM v.6.0 and fitted using log inhibitor vs 
normalized response – variable slope algorithm to calculate IC50 values. Data in A) was 
provided by J.Wilkinson (Fliegel Lab), University of Alberta, Canada. 
 
IC50 values obtained for selected 6-HMA analogues and known NHE1 inhibitors using each 
technique are provided in Table 5.3. Goodness of fit analysis of curves generated from the 
two assay types revealed that the fluorescence plate technique generally yielded more 
sigmoidal dose-response relationships (fluorimeter R2 range: 0.5745-0.8326, mean: 0.7009 n 
= 6; plate R2 range: 0.7553-0.9580, mean: 0.8877, n = 5). Standard errors of the mean for 
each data point were found to be significantly lower in the plate-based assay compared to 
the fluorimeter assay (fluorimeter SEM range: 1.71%-18.46%, Plate SEM range: 0.81%-
11.10%; mean Fluorimeter SEM = 7.866 ± 0.6912, n = 37, mean plate SEM = 4.070 ± 0.4663, 
n = 28, p <0.0001).  
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Table 5.3: Comparision of inhibitory potencies of amiloride, HMA, selected 6-HMA 
analogues and known NHE1 inhibitors (EMD87580 and cariporide) as determined using 
traditional cuvette and plate-based fluorometric assays in MDA-MB-231 breast 
adenocarcinoma cells. N/D = not determined. 
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Concordance between IC50 values and order of NHE1 inhibitory potencies among the 6-HMA 
analogues obtained from the two assays was not evident. HMA and 2-benzofuranyl analogue 
42 were found to be nearly equipotent in the cuvette-based protocol (IC50 = 523 nM vs. 553 
nM), whereas HMA was 3.9-fold more potent (IC50 = 240 nM) then 42 (IC50 = 932 nM) in the 
plate-based method. Poor agreement was observed between assays for 5-pyrimidinyl 
analogue 48, which appreared as the most potent 6-HMA analogue via the cuvette assay 
(IC50 = 397 nM) but showed 5-fold lower activity in the plate assay (IC50 = 2,046 nM). Good 
agreement between both techniques was observed, however, for the p-methoxy-5-
pyrimidinyl analogue 49, the least potent NHE1 inhibitor of the series (IC50cuvette = 21,512 nM 
vs IC50plate = 19,650 nM).  
 
A wider selection of 6-HMA analogues were subsequently screened for NHE1 inhibition at a 




Figure 5.6: Inhibition of NHE1 activity in MDA-MB-231 cells using the plate-based assay. All compounds were present at a single concentration 
(10 M). Data represent the mean  SEM (n = 3-6). Normalized data were pooled across multiple assays. 
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Results from the single concentration assays revealed similar trends to those observed in the 
fluorimetric and plate-based dose-response assays. In agreement with the plate-based 
experiments, HMA was the most active inhibitor. 2-Benzofuranyl analogue 42 showed ~ 2-
fold lower activity than HMA. Fluorination at the 4-position of the benzofuran to give 43 
decreased activity a further 2-fold. Substitution of the furanyl oxygen with S to give 
benzothiophene 41 or NH indole 40 decreased inhibition 2- to 3-fold relative to 42. 2-Furanyl 
and 3-furanyl isomers 46 and 47 showed only slightly decreased activity relative to HMA (~ 2 
to 3-fold). In contrast, pyrazole compound 38 was ~ 10-fold less active than HMA.  
 
As noted in the fluorimetric dose-response experiments, 5-pyrimidinyl analogue 48 showed 
strong activity and was, being equipotent with HMA. p-Methoxy substitution of the 
pyrimidine to give 49 decreased activity considerably (~ 7-fold). Trifluoromethylphenyl 35, 
3,5-dimethoxyphenyl 54, 2,4-dimethoxypyridinyl 51 and 2,5-dimethoxypyridazinyl 55 
derivatives all showed some activity at 10 M. Isoquinolinyl analogue 37 was a poor 
inhibitor, as was p-methoxypyrimidinyl analogue 49. The 6-phenylethynyl analogue 56 
showed the lowest activity, being ~ 15-fold less potent than HMA. 
 
These results provide the first insights into SAR at the 6-position of HMA against NHE1. 
Generally speaking, substitution with 2-benzofuranyl (42 and 43) or 5-pyrimidinyl 
substituents (48) was well tolerated, with potency varying within 2-fold of HMA in the 
cuvette-based assay. Substitution of 48 with a single methoxy group between the two 
pyrimidine nitrogens to give 49 resulted in a remarkable decrease in NHE1 inhibitory 
potency (IC50cuvette = 21,512 nM,  ~ 55-fold loss relative to 48). Compounds 42 and 43 both 
feature bulky benzofuran moieties at the 6-position, which would project beyond the region 
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of space occupied by the p-methoxy group of 43. As such, it is unlikely that the deleterious 
interactions formed by the p-methoxy group are purely steric. This supposition, of course, 




Increased sample throughput enabled by the 96-well plate assay format for NHE1 inhibitor 
screening is a major advantage relative to the labour and time-intensive cuvette assay, 
where maximum throughput for a skilled worker generates IC50 determinations for 2 
compounds per day only (n = 3-4 replicates at each concentration, L. Fliegel personal 
correspondence). In contrast, 7-point dose-response curves (n = 3 at each concentration) 
can be obtained by a single person for 8+ compounds per day using the plate-based 
technique. Throughput could be further increased to 14 compounds in triplicate per plate (~ 
112 per day) at a single concentration (for screening purposes) without alterations to the 
protocol.  
 
NHE1-mediated recovery of pHi begins almost instantaneously upon reintroduction of 
extracellular Na+ following NH4Cl acid challenge. Ideally, rates of pHi-recovery should be 
determined from the linear portion of plots comparing pHi versus time. The manual addition 
of solutions via a standard 8-channel pipette creates a delay in time between each preceding 
row of cells, reaching a total of ~ 45-60 sec between rows A and H. This delay is  accounted 
for by configuring the reader to reach each row in the order A-H in a left to right fashion. 
Nevertheless, NHE1 will have been active for between 45-60 sec before initial readings are 
obtained for any well. A second read is required to calculate the rate of pH recovery, which 
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occurs 107s after the initial read. It is possible that pHi recovery may have started to plateau 
by this point and, as such, rates calculated may not be truly representative of the initial 
(linear) rate period.  
 
This potential shortcoming might be mitigated by conducting experiments on unstimulated 
cells under standard serum concentrations (5-10% FCS), as serum starvation increases NHE1 
activity and hence the rate of pHi recovery. The rate of pHi recovery is likely to be cell line 
dependent and vary with the conditions used. Efforts should thus be made to measure 
baseline rates of NHE activity when optimizing the assay for new cell types. The traditional 
fluorimeter protocol does not suffer from this issue as pHi recovery is measured immediately 
and continuously after reintroduction of Na+, allowing a real-time analysis of recovery 
kinetics.  
 
A confluent cell monolayer was found to be essential for cell adherence throughout the 
assay. Seeding density was optimized to ensure confluence on the day of experimentation (~ 
42 h post seeding). An appropriate shakeout technique was also crucial as residual liquid in 
wells were found to increase variability in the signals. Liquid removal via multichannel 
pipette was trialed but found to be too slow. Pipetting must be performed such that all 
replicates of a particular sample receive solutions at the same time to prevent staggering of 
equilibration/pHi across a treatment group. The time taken to add Na
+-containing 
buffer/drug dilutions to wells must also be kept to an absolute minimum to prevent large 
differences in the start time of pHi recovery.  
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When using the ‘plate multichromatic’ read mode, the plate is first read using the pH-
sensitive filter couple, which is followed by a second read cycle using the isobestic filter 
couple. The time lag between reading a particular well using each filter couple (~ 30-50s 
depending on the exact protocol used) is inconsequential given the static nature of the 
isobestic signal across the relevant pH range. This was verified using the alternative ‘well 
multichromatic’ read mode, in which each individual well is read rapidly using both filter 
couples prior to moving to the next well. While this approach decreases the potential for 
changes in the sample that may accrue over time it was not used because of the large 
increase in time per read cycle relative to the ‘plate multichromatic read mode’. 
 
The limitations due to reliance of this assay on manual handling for the addition and removal 
of buffers were apparent. As such, automation of these steps using liquid handling robotics 
would likely improve the accuracy and reproducibility of NHE1 activity measurements. The 
Illawarra Health and Medical Research Institute (Ranson Lab) has recently acquired a 
Molcular Devices FlexStation 3 Multimode plate reader. The FlexStation 3 is a multimode 
fluorescence/luminescence plate reader with an integrated liquid handling microfluidics 
system capable of automating all liquid addition steps in the assay. Use of the FlexStation 3 
should allow for a large increase in data density as the minimum time needed to read plates 
at both wavelengths is ~ 30s (c.f. 107s for the POLARstar assay). These advantages may 
support the POLARstar system as the preferred platform for performing this assay. Efforts to 
optimize the assay for use with the FlexStation 3 are targeted for the near future. 
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In conclusion, the protocols described in this chapter constitute a novel, straightforward and 























CHAPTER 6: Thesis conclusions and Future Directions 
 
The potassium-sparing diuretic drug amiloride shows robust anticancer activities in animal 
models. We proposed that this anticancer side activity arises from amiloride’s moderate 
inhibition (low M) of two unrelated biological targets; the pro-metastatic serine protease 
uPA and the Na+/H+ exchanger isoform 1 (NHE1), a key driver of oncogenic transformation. 
 
The primary aim of this work was to develop novel (and patentable) uPA/NHE1 dual-
targeting amiloride analogues suitable for advancement towards anticancer drugs. A library 
of 24 6-HMA analogues was successfully synthesized and evaluated, with compounds 
showing sub-M potency against uPA identified. As it was unknown whether substitution at 
the 6-position would affect the high potency of HMA against the pro-carcinogenic ion 
channel NHE1, a secondary aim was to evaluate whether 6-HMA analogues retained activity 
against this target.  
 
Development of novel synthetic methodology allowed the expeditious generation of 
structurally diverse 6-heteroaryl-HMA analogues. Recent efforts in the Kelso laboratory have 
led to the development of a superior acyl guanidinylation method utilizing a 2M solution of 
free guanidine in MeOH with DMF as solvent. Final products were easily obtained in good 
yields as the free base form without the need for further purification, avoiding costly amd 
labourious preparative HPLC. 
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Evaluation of the uPA inhibitory potency of these compounds via enzyme activity assays 
identified 15 analogues with improved potency over the parent HMA, with gains ranging 
from 1.03 to 32-fold. From these, active analogues, two physicochemically diverse lead 
classes; the 2-benzofuranyl and 5-pyrimidinyl analogues (exemplified by compounds 42 and 
49 respectively, Figure 6.1) were further examined in enzyme selectivity and cell assays.  
 
 
Figure 6.1: Properties of lead compounds 42 and 49. 
 
Favourable cytotoxicity profiles for both lead classes were seen across a variety of human 
and murine cell lines. Preliminary organotypic cell invasion assays demonstrated the ability 
of 42 to inhibit epithelial cell invasion in a physiologically relevant context. X-ray co-
crystallographic analysis of uPA:6-HMA analogue complexes enabled the rationalization of 
SAR trends and shed light on the structural requirements for favourable occupancy of the 
S1 subsite by 6-substituents on analogues. 
 
Development of a novel fluorescence-based high throughput assay allowed elucidation of 
SAR around the 6-position of the HMA scaffold. Excitingly, the high potency of HMA against 
NHE1 was maintained in several 6-substituted analogues, with the exception of 49, which 
represents a selective uPA inhibitor (uPA IC50 = 86 nM; NHE1 IC50 = 21 M). This new 
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technique will soon be submitted for publication, providing the NHE1 drug discovery 
community with a rapid and straightforward method for the screening of compounds 
against this important target. 
 
The work has satisfied the aims described in Chapter 1 and provides a wealth of exciting 
avenues for future research. Analogues from both lead classes met activity, selectivity and 
toxicity endpoints necessary for entry into in vivo efficacy models. In addition to the 
discovery of leads with dual uPA/NHE1 potency, identification of p-methoxypyrimidine 
analogue 49, which shows activity only for uPA (not NHE1), provides scope for the 
examination of truly uPA selective pharmacological probes. This separation of uPA/NHE1 
activity for members of the amiloride class is a significant advance given the abundance of 
reports using amiloride and its 5-substituted analogues to study diverse physiological 
phenomena and the potential of these activities, namely inhibition of uPA and NHE1, to 
simultaneously effect the processes studied. We hope to make these improved probes 
available to the broader research community. 
 
It is worthwhile noting that while this work satisfied aims, the medicinal chemistry described 
herein is by no means exhaustive. Further work could involve synthesis of an expanded 
library of 6-HMA analogues using the Suzuki-Miyaura and other transition metal-catalyzed 
cross-coupling chemistries (e.g. Sonogashira chemistry, as well as ‘click’ chemistry), with the 




This project formed part of a larger campaign focused on the development of novel dual-
targeting anticancer and anti-tuberculosis compounds from amiloride. Parallel efforts from 
other group members have resulted in the generation of analogous 6-substituted and 5,6-
disubstituted amiloride analogues that possess similar activity, selectivity and toxicity 
profiles to those described herein. Competitive grant funding from the Australian National 
Health and Medical Research Council and the Health Research Council of New Zealand has 
provided the resources necessary to advance development of promising 6-AML and 6-HMA 
analogues. Recent in vivo ADMET experiments revealed that compounds 42 and 49 possess 
desirable pharmacokinetic parameters (e.g. plasma t1/2 3-7 h, favourable Vds, no indication 
of acute toxicities etc.), with some compounds showing similar profiles to amiloride. 
Pharmacokinetic parameters will be used to inform dose scheduling for in vivo efficacy 
experiments planned over the next 6-18 months.  
 
In vitro studies confirmed that the 6-HMA and 6-AML analogues are not active against ENaC, 
the diuretic and antikaliuretic target of amiloride, suggesting success in our efforts to 
selectively optimize amiloride’s side activity with loss of the original clinically-relevant 
interaction. Studies to confirm the lack of effect of these leads on urinary Na+/K+ levels in 
animals will commence shortly.  
 
In vivo anticancer activity of 42 and 49 will be evaluated using orthotopic xenograft models 
of pancreatic and breast (highly uPA/uPAR overexpressing) metastasis in mice, as well as in a 
spontaneous model of metastatic breast carcinoma. The finding that 6-HMA analogues show 
pronounced species specificity, where inhibitory activity is substantially decreased against 
the murine enzyme, is a concern for these studies as the lower inhibition of MuPA may lead 
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to an underestimation of the anticarcinogenic/antimetatstatic effects. Ultimately, the 
species selectivity issue may be redundant as the robust anticancer effects of high-dose 
amiloride across various murine cancer models has been repeatedly observed despite 
amiloride showing only moderate inhibitory potency against both human and murine uPA 
(e.g. low M, similar to the potency of 6-HMA analogues against MuPA). Future work will 
involve the design of analogues where interspecies specificity has been addressed, namely 6-
HMA analogues that replace the 5-azepane ring with smaller groups. 
 
It is hoped that a demonstration of in vivo efficacy will enable selection of genuine pre-
clinical candidates for further study and entry into first-in-man studies within the next 24 
months. In addition, it is hoped that the broader research community will relish the 
opportunity to screen novel members of a long-studied class of compounds against the 
known and undiscovered targets of amilorides. Further elucidation of the SAR around 6-
substituted amilorides against such targets, may result in the discovery of leads for the 











CHAPTER 7: Experimental 
 
7.1 Synthesis – General 
 
Reagents and solvents were used as obtained from suppliers without further purification, 
unless otherwise stated. Toluene and N,N-dimethylformamide (DMF) were decanted from a 
PureSolv Solvent purification system (InertTechnology Inc., Amesbury, Massachusetts, USA) 
immediately prior to use. iPrOH was distilled from BaO powder and stored over 4 Å 
molecular sieves under Ar. Boronic acids/pinacol esters were obtained from various 
suppliers and used without further purification. All other reagents were obtained from 
Sigma Aldrich (St. Louis, MI, USA).  
 
Compounds were weighed using a Sartorius Extend 220g electronic balance (Sartorius AG, 
Göttingen, Germany) or an OHAUS Adventurer Analytical electronic balance (Cat. #AX224, 
OHAUS Corporation, Parsippany, New Jersey, USA). Solvents were removed in vacuo at RT-
60 C with a Büchi RotavaporR-200 rotary evaporator (Büchi Labortechnik AG, Flawil, 
Switzerland) attached to a Vacuubrand CVC2 vacuum pump (Vacuubrand GmbH, Wertheim, 
Germany). Solvent residues were removed in vacuo using a Javac Vector RD-90 double stage 
high vacuum pump (JAVAC Pty. Ltd., Homebush, NSW, Australia). Fractions collected from 
preparative rp-HPLC purifications were concentrated by lyophilization using a freeze-drying 
system consisting of a Christ Alpha 1-4 LOC-1M (MartinChrist GmBH, Osterode am Harz, 
Germany) condenser attached to an Alcatel Pascal 2015 SD high vacuum pump (Pfeiffer 
Vacuum GmbH, Annecy, France). Analytical thin layer chromatography was performed on 
Merck 0.2 mm silica gel 60 F254 coated aluminium plates (Merck Millipore, Massachusetts, 
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USA). Compounds on silica plates were visualized under UV light ( = 254 nm). Flash column 
chromatography was performed on Merck silica gel 60 (230-400 mesh). All compounds were 
purified to >95% purity for biological evaluation using a Waters PLC/DSC LC150 system 
(Waters Corporation, Milford, Massachusetts, USA) with dual detection at 254 nm and 210 
nm. Purifications were performed using gradient elutions with solvents A (100% H2O, 0.1% 
TFA) and B (100% ACN, 0.1% TFA) on a Waters Sunfire PREP C18 OBD 5 µm (dimensions) 
column at a flow rate of 20 mL.min-1. Purity analysis of fractions collected was performed 
using a Shimadzu CLASS-VP LC10 Analytical HPLC system (Shimadzu Corporation, Kyoto, 
Japan) with detection at 254 nm, gradient elutions of solvents A and B on a Waters VisionHT 
3 µm C18 column (150 mm x 4.6 mm) and at a flow rate of 0.5 mL.min-1. 
 
Melting points were obtained using a Griffin Analogue Melting Point Apparatus (Thermo-
Fisher Scientific, Waltham, Massachusetts, USA). Electrospray ionization mass spectra were 
obtained using a Shimadzu LCMS-2010 (Shimadzu Corporation, Kyoto, Japan). High 
resolution electrospray ionization mass spectra were obtained using a Waters XEVO QToF 
mass spectrometer (Waters Corporation, Milford, Massachusetts, USA) with leucine 
encephalin as the internal standard. 
 
7.2 Compound Characterization  
 
1H and 13C NMR spectra were obtained using Varian Inova 500 MHz or Varian Premium 
Shielded 500 MHz spectrometers at 25 C. Chemical shift values are reported in  (ppm) 
relative to TMS ( 0.00 ppm), internal standards (CDCl3,  = 7.26 ppm) or other residual 
solvent peaks. The following abbreviations are used throughout: Ar = aryl, bs = broad singlet, 
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s = singlet, d = doublet, t = triplet and m = multiplet, SM = starting material, RM = reaction 
mixture and RT = room temperature. All compounds in this work bear several exchangeable 
protons attached to nitrogen atoms. The 1H chemical shifts for these protons were 
temperature and concentration dependent. Compounds marked with * denote structures 
previously described in the literature for which full characterization data was not reported.  
 
Methyl 3-amino-5-(azepan-1-yl)-6-phenylpyrazine-2-carboxylate (33a)* 
Methyl 3-amino-5-(azepan-1-yl)-6-chloropyrazine-2-carboxylate 32 
(101 mg, 3.54x10-4 mol) was combined with K2CO3 (488 mg, 3.53x10
-3 
mol),  phenylboronic acid (65 mg, 5.32x10
-4 mol) and Pd(Ph3)4 (21 mg, 
18.0x10-5 mol) and the reaction vessel purged with Ar. Anhydrous toluene (12 mL), followed 
by MeOH (3 mL) were added via syringe and the mixture heated at reflux for 1 h. TLC 
analysis indicated absence of SM and the presence of a UV active spot (Rf = 0.95, 1:4 
EtOAc:Pet. spirit) after 1 h. The RM was allowed to cool to RT, vacuum filtered through celite 
and washed through with CH3CN (3x20 mL) to remove catalyst. Solvent was removed under   
reduced pressure. The crude product was re-dissolved in EtOAc and adsorbed onto silica gel 
under reduced pressure. The product was isolated via silica gel flash chromatography (5:95 
EtOAc:Hexane) to yield 33a as a light yellow solid (106 mg, 91%). 1H NMR (500 MHz, CDCl3) δ 
7.50 (d, J = 7.5 Hz, 2H,  ArC2” and ArC6”), 7.38 (t, J = 7.5 Hz, 2H, ArC3” and ArC5”), 7.29 (t, J = 
7.5 Hz, 1H, ArC4”), 3.89 (s, 3H, Ester CH3), 3.33 (t, J = 5.75 Hz, 4H, C2’H2 and C7’H2), 1.61 (s, 
4H, C3’H2 and C6’H2), 1.47 (s, 4H, C4’H2 and C5’H2). 
13C NMR (126 MHz, CDCl3) δ 167.67 (Ester 
C=O), 154.99 (ArC5), 153.66 (ArC3), 140.99 (ArC1”), 132.03 (ArC5), 128.63 (ArC3” and ArC5”), 
128.09 (ArC2” and ArC6”), 127.52 (ArC4”), 112.45 (ArC2), 52.13 (Ester CH3), 51.12 (C2” and 
C7”), 28.11 (C3” and C6”), 27.20 (C4” and C5”). LR ESI-MS (M + H)+ 327. 
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Methyl 3-amino-5-(azepan-1-yl)-6-(4-(methylthio)phenyl)pyrazine-2-carboxylate (34a) 
Methyl 3-amino-5-(azepan-1-yl)-6-chloropyrazine-2-carboxylate 32 
(102 mg, 3.60x10-4 moles), (4-(methylthio)phenyl)boronic acid (93 
mg, 5.45x10-4 moles), K2CO3 (508 mg, 3.87x10-3 moles)  and 
Pd(PPh3)4 (9.9 mg, 1.05x10
-5 moles) were added to a round bottom flask. Anhydrous toluene 
(12 mL) followed by MeOH (3 mL) were added via syringe and heated to reflux. After 15 min 
a UV active spot (Rf = 0.5, 1:4 EtOAc:Pet spirit) was detected via TLC, with disappearance of 
SM after 1 h. After 30 min the RM was allowed to cool to RT, stirred for 1 h, filtered through 
celite and washed with EtOAc (4x20 mL). Solvent was removed under reduced pressure. The 
crude material was dissolved in EtOAc and adsorbed to silica and purified by silica gel flash 
column chromatography (gradient elution:2.5:97.5 EtOAc:Pet. Spirit  5:95 EtOAc:Pet. 
Spirit) to give 34a as a yellow solid (104 mg,  77%): MP: 132-134° C; 1H NMR (500 MHz, 
CDCl3) δ 7.42 (d, J = 8.1 Hz, 2H, ArH3” and ArH5”), 7.25 (d, J = 8.1 Hz, 2H, ArH2” and ArH6”), 
6.20 (bs, 2H, Ar3NH2), 3.88 (s, 3H, Ester CH3), 3.36  (t, J = 5.5 Hz, 4H, C2’ H2 and C7’ H2), 2.48 
(s, 3H, thioetherCH3), 1.62 (s, 4H, C3’ H2 and C6’ H2), 1.43 (s, 4H, C4’ H2 and C5’ H2); 
13C 
NMR (126 MHz, CDCl3) δ 167.42 (Ester C=O), 154.77 (ArC5), 153.43 (ArC3), 137.77 (ArC4”), 
137.47 (ArC1”), 131.19 (ArC6), 128.29 (ArC2” and ArC6”), 126.77 (ArC3” and ArC5”), 112.45 
(ArC2), 51.90 (Ester CH3), 51.01 (C2’ and C7’), 27.96 (C3’ and C6’), 27.08 (C4’ and C5’) 16.05 
(thioetherCH3); HRESI-MS m/z (M + H)
+: Calc 373.1698, Obs 373.1688. Anal-HPLC (70:30 A:B/ 






Methyl 3-amino-5-(azepan-1-yl)-6-(4-(trifluoromethyl)phenyl)pyrazine-2-carboxylate (35a) 
Methyl 3-amino-5-(azepan-1-yl)-6-chloropyrazine-2-carboxylate 32 
(100 mg, 3.53x10-4 mol) was combined with K2CO3 (501 mg, 3.62x10
-
3 mol), 4-trifluoromethylphenylboronic acid (100 mg, 5.26x10
-4 mol)  
and Pd(Ph3)4 (21 mg, 18.0x10
-5 mol) and the reaction vessel purged with Ar. Anhydrous 
toluene (12 mL), followed by MeOH (3 mL) were added via syringe and the mixture heated 
to reflux for 10 min. TLC analysis indicated absence of SM and the presence of a UV active 
spot (Rf = 0.90, 1:4 EtOAc:Pet. spirit) after 10 min. The RM was allowed to cool to RT, 
vacuum filtered through celite and washed through with CH3CN (3x20 mL) to remove 
catalyst. Solvent was removed under reduced pressure. The crude product was re-dissolved 
in EtOAc and adsorbed onto silica gel under pressure. The product was isolated via silica gel 
flash column chromatography (5:95 EtOAc:Hexane) to yield 35a as a light brown solid (101 
mg, 72%): mp 154-156˚C; 1H NMR (500 MHz, CDCl3) δ 7.63 (s, 4H, Ar”Hs) 3.89 (s, 3H, Ester 
CH3), 3.34 (s, 4H, C2’H2 and C7’H2) 1.65 (s, 4H, C3’H2 and C6’H2), 1.44 (s, 4H, C4’H2 and C5’H2); 
13C NMR (126 MHz, CDCl3) δ 167.40 (Ester C=O), 154.89 (ArC5), 153.72 (ArC3), 144.58 
(ArC1”), 129.42 (ArC2” and ArC6”), 129.16 (ArC3” and ArC5”), 128.23 (ArC4”), 125.58 (Ar-
CF3), 123.35 (ArC6), 113.11 (ArC2), 52.20 (Ester CH3), 51.26 (C2’ and C7’), 28.04 (C3’ and C6’), 
27.30 (C4’ and C5’); HRESI-MS m/z (M + Na)+: Calc. 417.1526, Obs 417.1514. Anal-HPLC (100 







Methyl 3-amino-5-(azepan-1-yl)-6-(benzo[d][1,3]dioxol-5-yl)pyrazine-2-carboxylate (36a) 
Methyl 3-amino-5-(azepan-1-yl)-6-chloropyrazine-2-carboxylate 32 
(99 mg, 3.49x10-4 mol), benzo[d][1,3]dioxol-5-ylboronic acid (85 mg, 
5.15 x10-4 mol), K2CO3 (486 mg, 3.70 x10
-3 mol)  and Pd(PPh3)4 (20 
mg, 1.70 x10-5 mol) were added to a stoppered two-neck round bottom flask and the flask 
was charged with Ar. The flask was fitted to a reflux condenser followed by addition of 
anhydrous toluene (12 mL) and MeOH (3 mL) via syringe. The flask was heated to reflux for 1 
h. A UV active spot (Rf = 0.75, 1:4 EtOAc:Pet. Spirit) was detected via TLC. After 1 h the RM 
was allowed to cool to RT, filtered through celite and washed through with EtOAc (4x20 mL). 
Solvent was removed under reduced pressure. The crude material was re-dissolved in EtOAc 
and adsorbed to silica prior to purification by silica gel flash column chromatography (2.5 
EtOAc:97.5 Pet spirit – 10:90 EtOAc:Pet. spirit) to give 36a as a yellow solid (66 mg, 51% 
yield); MP: 156-158° C; 1H NMR (500 MHz, CDCl3) δ 7.02 (s, 1H, ArH2”), 6.93 (d, J = 8.0 Hz, 
1H, ArH9”), 6.80 (d, J = 8.0 Hz, 1H, ArH8”), 5.96 (s, 2H, C5”H2), 3.88 (s, 3H, Ester CH3), 3.38 (s, 
4H, C2’H2 and C7’H2) 1.63 (s, 4H, C3’ H2 and C6’ H2), 1.44 (s, 4H, C4’ H2 and C5’ H2); 
13C NMR 
(126 MHz, CDCl3) δ 167.55 (Ester C=O), 154.89 (ArC5), 153.46 (ArC3), 147.86 (ArC3”), 147.05 
(ArC7”), 134.93 (ArC1”), 131.51 (ArC6), 121.69 (ArC9”), 112.20 (ArC2), 108.73 (ArC2”), 
108.34 (ArC8”), 101.12 (C5”), 51.94 (Ester CH3), 50.99 (C2’ and C7’), 28.08 (C3’ and C6’), 
27.10 (C4’ and C5’); HRESI-MS m/z (M + H)+: Calc. Mass 371.1719. Obs 371.1734; Anal-HPLC 






Methyl 3-amino-5-(azepan-1-yl)-6-(isoquinolin-4-yl)pyrazine-2-carboxylate (37a) 
Methyl 3-amino-5-(azepan-1-yl)-6-chloropyrazine-2-carboxylate 32 
(203 mg, 7.12x10-4 mol), 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)isoquinoline (271 mg, 1.06x10-3 mol), K2CO3 (970 mg, 7.01x10-3 mol)  
and Pd(PPh3)4 (40 mg, 3.44x10
-5 mol) were added to a round bottom flask. Anhydrous 
toluene (24 mL) followed by MeOH (6 mL) were added via syringe and heated to reflux. After 
2 h a UV active spot (Rf = 0.25, 1:4 EtOAc:Pet. Spirit) was detected via TLC along with 
disappearance of SM after 2.5 h. After 1 h the RM was allowed to cool to RT, filtered through 
celite and washed through with EtOAc (4x20 mL). Solvent was removed under reduced 
pressure. The crude material was re-dissolved in EtOAc and adsorbed to silica prior to 
purification by silica gel flash column chromatography (5:95 EtOAc:Pet. Spirit  10:90 
EtOAc:Pet. Spirit) to give 37a  as a brown solid (156 mg, 58%); MP 140-142° C; 1H NMR (500 
MHz, CDCl3) δ 9.23 (s, 1H, ArH2”), 8.58 (s, 1H, ArH4”), 8.00 (d, J = 8.0 Hz, 1H ArH6”), 7.81 (d, J 
= 8.0 Hz, 1H. ArH9”), 7.68 (t, J = 7.5 Hz, 1H, ArH7”), 7.62 (t, J = 7.5 Hz, 1H, ArH8”), 3.86 (s, 3H, 
EsterCH3), 3.21 (t, J = 5.5 Hz, 4H, C2’ H2 and C7’ H2), 1.47(s, 4H, C3’ H2 and C6’ H2), 1.38 (s, 
4H, C4’ H2 and C5’ H2); 
13C NMR (126 MHz, CDCl3) δ 167.29 (Ester C=O), 155.77 (ArC5), 
154.02 (ArC3), 152.06 (ArC4”), 143.01 (ArC2”), 134.26 (ArC10”), 131.78 (ArC1”), 130.82 
(ArC6”), 128.42 (ArC6), 127.97 (ArC8”), 127.37 (ArC7”), 126.66 (ArC5”), 124.50 (ArC9”), 
112.90 (ArC2), 52.02 (Ester CH3), 50.38 (C2’ and C7’), 27.87 (C3’ and C6’), 26.83 (C4’ and C5’); 
HRESI-MS m/z (M + Na)+: Calc. 400.1749, Obs. 400.1747. Anal-HPLC (100% A  100% B over 





Methyl 3-amino-5-(azepan-1-yl)-6-(1-methyl-1H-pyrazol-4-yl)pyrazine-2-carboxylate (38a) 
Methyl 3-amino-5-(azepan-1-yl)-6-chloropyrazine-2-carboxylate 32 
(101 mg, 3.53x10-4 mol), (1-methyl-1H-pyrazol-4-yl)boronic acid (110 
mg, 5.26 x10-4 mol ), K2CO3 (526 mg, 3.70 x10
-3 mol)  and Pd(PPh3)4 (21 
mg, 1.76 x10-5 mol)  were added to a round bottom flask. Anhydrous toluene (12 mL) 
followed by MeOH (3 mL) were added via syringe and heated to reflux. A UV active spot (Rf = 
0.5, EtOAc) was detected via TLC along with disappearance of SM. After 1 h the RM was 
allowed to cool to RT, filtered through celite and washed through with EtOAc (4x20 mL). 
Solvent was removed under reduced pressure. The crude material was re-dissolved in 
acetone and adsorbed to silica prior to purification by silica gel flash column 
chromatography (5:95 EtOAc:Pet spirit – 10:90 EtOAc:Pet. spirit) to give 38a as a yellow solid 
(89 mg; 77%); MP: 134-136°; 1H NMR (500 MHz, CDCl3) δ 7.64 (s, 1H, ArH2”), 7.57 (s, 1H, 
ArH6”), 6.17 (bs, 2H, 3NH2), 3.91 (s, 3H, 4”CH3), 3.89 (s, 3H, Ester CH3), 3.47 (t, J = 6 Hz, 4H, 
C2’ H2 and C7’ H2), 1.66 (s, 4H, C3’ H2 and C6’ H2), 1.47 (s, 4H, C4’ H2 and C5’ H2); 
13C NMR 
(126 MHz, CDCl3) δ 167.34 (Ester C=O), 155.54 (ArC5), 153.40 (ArC3), 138.73 (ArC6”), 129.11 
(ArC2”), 125.25 (ArC1”), 122.56 (ArC6), 112.42 (ArC2), 52.08 (Ester CH3), 51.16 (C2’ and C7’), 
39.00 (C4” CH3), 28.00 (C3’ and C6’), 27.17 (C4’ and C5’); HRESI-MS m/z (M + H)
+: Calc 











carboxylate 32 (99 mg, 3.48x10-4 mol), 4-(2-(4-(4,4,5,5-
tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-
yl)ethyl)morpholine (165 mg, 5.36x10-4 mol), K2CO3 (522 mg, 3.78 x10
-3 mol)  and Pd(PPh3)4 
(21 mg, 1.77 x10-5 mol)  were added to a stoppered two-neck round bottom flask and the 
flask was charged with Ar. The flask was fitted to a reflux condenser followed by addition of 
anhydrous toluene (12 mL) and MeOH (3 mL) via syringe. The flask was heated to reflux for 
16 h. A UV active spot (Rf = 0.44, 85:10:5 EtOAc:MeOH:NH3) was detected via TLC, along with 
the disappearance of SM (Rf = 0.95) after 16 h. After 17 h the RM was allowed to cool to RT, 
filtered through celite and washed with CH3CN (4x20 mL). Solvent was removed under 
reduced pressure. The crude material was dissolved in CH3CN and adsorbed to silica prior to 
purification by silica gel flash column chromatography (EtOAc  6% MeOH:EtOAc) to give 
39a as a yellow solid (119 mg, 80%): MP: 132-134° C; 1H NMR (500 MHz, CDCl3) δ 7.70 (s, 1H, 
ArH5”), 7.61 (s, 1H, ArH2”), 6.24 (bs, 2H, ArNH23), 4.25 (s, 2H, C7H2), 3.89 (s, 3H, Ester CH3), 
3.69 (s, 4H, C11H2 and C13H2), 3.46 (s, 4H, C2’H2 and C7’H2), 2.84 (s, 2H, C8H2) 2.50 (s, 4H, 
C10H2 and C14H2), 1.65 (s, 4H, C3’ H2 and C6’ H2), 1.47 (s, 4H, C4’ H2 and C5’ H2); 
13C NMR 
(126 MHz, CDCl3) δ 167.20 (Ester C=O), 155.50 (ArC5), 153.33 (ArC3), 138.62 (ArC5”), 128.67 
(ArC2”), 125.13 (ArC1”), 122.10 (ArC6), 112.41 (ArC2), 66.94 (C11CH2 and C13CH2), 58.19 
(C8CH2), 53.68 (C10CH2 and C14CH2), 51.91 (Ester CH3), 51.05 (C2’ and C7’), 49.55 (C7CH2), 
27.94 (C3’ and C6’), 27.02 (C4’ and C5’); HRESI-MS m/z (M + H)+: Calc. 430.2567, Obs. 
430.2553. Anal-HPLC (70:30 A:B 100% B over 30 min, tr = 21.6 min). 
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Methyl 3-amino-5-(azepan-1-yl)-6-(1H-indol-2-yl)pyrazine-2-carboxylate (40a) 
Methyl 3-amino-5-(azepan-1-yl)-6-chloropyrazine-2-carboxylate 32 
(201 mg, 7.06x10-4 moles), (1H-indol-2-yl)boronic acid (278 mg, 
1.73x10-3 moles), K2CO3 and Pd(PPh3)4 (41 mg, 3.52x10-5 moles)  
were added to a round bottom flask. Anhydrous toluene (24 mL) followed by MeOH (6 mL) 
were added via syringe and heated to reflux. After 30 min a UV active spot (Rf = 0.85, 2:3 
EtOAc:Pet. Spirit) was detected via TLC along with disappearance of SM after 1 h. After 1 h 
the RM was allowed to cool to RT, filtered through celite and washed with EtOAc (4x20 mL). 
Solvent was removed under reduced pressure. The crude material was re-dissolved in EtOAc 
and adsorbed to silica prior to purification by silica gel flash column chromatography (10:90 
EtOAc:Pet. Spirit  20:80 EtOAc:Pet. Spirit) to give 40a  of a orange solid (88 mg, 34%); MP 
152-154° C; 1H NMR (500 MHz, CDCl3) δ 9.14 (s, 1H, ArNH2”), 7.57 (d, 1H, J = 7.7 Hz, ArH7”), 
7.37 (d, 1H, J = 7.7 Hz, ArH4”), 7.16 (t, 1H, J = 7.0 Hz, ArH5”), 7.08 (t, 1H, J = 7.0 Hz, ArH6”), 
6.52 (s, 1H, ArH9”), 3.93 (s, 3H, Ester CH3), 3.58 (t, J = 5.75 Hz, 4H, C2’ H2 and C7’ H2), 1.70 (s, 
4H, C3’ H2 and C6’ H2), 1.50 (s, 4H, C4’ H2 and C5’ H2); 
13C NMR (126 MHz, CDCl3) δ 167.18 
(Ester C=O), 155.09 (ArC5), 153.15 (ArC3), 135.96 (ArC3”), 135.68 (ArC1”), 128.95 (ArC8”), 
124.51 (ArC6), 122.36 (ArC5”), 120.67 (ArC7”), 119.92 (ArC6”), 112.71 (ArC2), 111.06 
(ArC4”), 101.95 (ArC9”), 52.05 (Ester CH3), 51.65 (C2’ and C7’), 28.12 (C3’ and C6’), 27.53 (C4’ 
and C5’); HRESI-MS m/z (M + H)+: Calc. 388.1730, Obs. 388.1731; Anal-HPLC (100%A  100% 






Methyl 3-amino-5-(azepan-1-yl)-6-(benzo[b]thiophen-2-yl)pyrazine-2-carboxylate (41a) 
Methyl 3-amino-5-(azepan-1-yl)-6-chloropyrazine-2-carboxylate 32 
(203 mg, 7.12x10-4 mol), benzo[b]thiophen-2-ylboronic acid (193 
mg, 1.08x10-3 mol), K2CO3 (1.02 g, 7.39x10-3 mol) and Pd(PPh3)4 (41 
mg, 3.57x10-5 mol) were added to a round bottom flask. Anhydrous toluene (24 mL) 
followed by MeOH (6 mL) were added via syringe and heated to reflux. After 10 min a UV 
active spot (Rf = 0.85, 2:3 EtOAc:Pet. Spirit) was detected via TLC along with disappearance 
of SM after 30 min. After 30 min the RM was allowed to cool to RT, filtered through celite 
and washed with EtOAc (4x20 mL). Solvent was removed under reduced pressure. The crude 
material was re-dissolved in EtOAc and adsorbed to silica prior to purification by silica gel 
flash column chromatography (2.5:97.5 EtOAc:Pet. Spirit  10:90 EtOAc:Pet. Spirit) to give 
41a  of a bright yellow solid (245 mg, 90% yield); MP 146-148 °C; 1H NMR (500 MHz, CDCl3) δ 
7.80 (d, J = 7.5 Hz, 1H, ArH4”), 7.71 (d, J = 7.5 Hz, 1H, ArH7”), 7.22 (m, 2H, ArH5” and ArH6”), 
7.21 (t, J = 7.0 Hz , 1H, ArH9”), 3.91 (s, 3H, Ester CH3), 3.51 (t, J = 5.75 Hz, 4H, C2’ H2 and C7’ 
H2), 1.69 (s, 4H, C3’ H2 and C6’ H2), 1.48 (s, 4H, C4’ H2 and C5’ H2); 
13C NMR (CDCl3): δ 167.10 
(Ester C=O), 155.01 (ArC5), 153.40 (ArC3), 143.09 (ArC8”), 140.02 (ArC5”), 139.90 (ArC6”), 
125.22 (ArC8”), 124.23 (ArC5”), 123.63 (ArC6”), 123.46 (ArC6), 122.15 (ArC7”), 122.83 
(ArC4”), 112.98 (ArC2”), 52.18 (Ester CH3), 51.10 (C2’ and C7’), 27.98 (C3’ and C6’), 27.23 (C4’ 
and C5’). HRESI-MS m/z (M + Na)+: Calc. 405.1394. Obs. 405.1361; Anal-HPLC (100% A 






Methyl 3-amino-5-(azepan-1-yl)-6-(benzofuran-2-yl)pyrazine-2-carboxylate (42a) 
Methyl 3-amino-5-(azepan-1-yl)-6-chloropyrazine-2-carboxylate 32 
(250 mg, 8.78x10-4 mol), benzofuran-2-ylboronic acid (490 mg, 3.02 
x10-3 mol), K2CO3 (485 mg, 3.70 x10
-3 mol) and Pd(PPh3)4 (51 mg, 
4.39 x10-5 mol) were added to a round bottom flask. Anydrous 
toluene (12 mL) followed by MeOH (3 mL) were added via syringe and heated to reflux. A UV 
active spot (Rf = 0.45, 1:4 EtOAc:Pet. spirit) was detected via TLC after 1 h. Methyl ester SM 
was not detectable by TLC after 21 h. After 24 h the RM was allowed to cool to RT and 
filtered through celite, washed through with EtOAc (4x20 mL). Solvent was removed under 
reduced pressure. The crude material was re-dissolved in EtOAc and adsorbed to silica prior 
to purification by silica gel flash column chromatography (1 EtOAc:99 Pet spirit – 15:85 
EtOAc:Pet. spirit) to give 42a as a bright yellow solid (116 mg, 36%); MP: 118-120 °C; 1H NMR 
(500 MHz, CDCl3) δ 7.57 (d, J = 7.5 Hz, 1H, ArH4”) 7.47 (d, J = 7.5 Hz, 1H, ArH7”), 7.25 (m, 2H, 
ArH5”and ArH6”) 6.92 (s, 1H, ArH9”), 3.90 (s, 3H, Ester CH3), 3.46 (t, J = 5.8 Hz, 4H, C2’ H2 
and C7’ H2)  1.68 (s, 4H, C3’ H2 and C6’ H2), 1.48 (s, 4H, C4’ H2 and C5’ H2); 
13C NMR (126 
MHz, CDCl3) δ 167.13 (Ester C=O), 154.79 (ArC5), 154.64 (ArC3”), 154.47 (ArC1”), 154.11 
(ArC3), 129.16 (ArC8”), 124.30 (ArC5”), 123.07 (ArC6”) 121.38 (ArC6), 121.18 (ArC7”), 112.84 
(ArC2), 111.46 (ArC4”), 105.07 (ArC9”), 52.24 (Ester CH3), 50.16 (C2’ and C7’), 28.11 (C3’ and 
C6’), 27.24 (C4’ and C5’); HRESI-MS m/z (M + H)+: Calc. 367.1831, Obs. 367.1770; Anal-HPLC 






Methyl 3-amino-5-(azepan-1-yl)-6-(4-fluorobenzofuran-2-yl)pyrazine-2-carboxylate (43a) 
Methyl 3-amino-5-(azepan-1-yl)-6-chloropyrazine-2-carboxylate 32 
(101 mg, 3.55x10-4 mol), (4-fluorobenzofuran-2-yl)boronic acid (95 
mg, 5.31x10-4 mol), K2CO3 (485.0 mg, 3.51x10-3 mol)  and Pd(PPh3)4 
(22 mg, 1.89x10-5 mol) were added to a round bottom flask. Anhydrous toluene (12 mL) 
followed by MeOH (3 mL) were added via syringe and heated to reflux. After 1 h a UV active 
spot (Rf = 0.25, 20:80 EtOAc:Pet. Spirit) was detected via TLC along with disappearance of SM 
after 2 h. After 2 h the RM was allowed to cool to RT and filtered through celite, washed 
through with EtOAc (4x20 mL). Solvent was removed under reduced pressure. The crude 
material was re-dissolved in EtOAc and adsorbed to silica prior to purification by silica gel 
flash column chromatography (10:90 EtOAc:Pet. Spirit  20:80 EtOAc:Pet. Spirit) to give 43a  
as a yellow solid (80 mg, 58%); MP: 108-110° C; 1H NMR (500 MHz, CDCl3) δ 7.27 (d, 1H, 
ArH5”), 7.20 (m, 1H, ArH7”), 6.99 (s, 1H, H3”), 6.93 (t, 1H, J = 8.5 Hz, ArH6’), 3.91 (s, 3H, 
EsterCH3), 3.46 (s, 4H, C2’ H2 and C7’ H2), 1.69 (s, 4H, C3’ H2 and C6’ H2), 1.49 (s, 4H, C3’ H2 
and C6’ H2); 
13C NMR (126 MHz, CDCl3) δ 167.0 (Ester C=O), 156.9 (ArC5), 156.2 (ArC3), 154.7 
(ArC8”), 154.0 (ArC4”), 138.3 (ArC1”), 124.6 (ArC6”), 120.5 (ArC6), 118.0 (ArC2), 115.9 
(ArC3”), 110.4 (ArC5”), 108.6 (ArC7”), 107.6 (ArC2”), 52.2 (Ester CH3), 50.0 (C2’ and C7’), 28.0 
(C3’ and C6’), 27.1 (C4’ and C5’); HRESI-MS m/z (M + Na)+: Calc. 407.1495, Obs. 407.1504 






Methyl 3-amino-5-(azepan-1-yl)-6-(thiophen-2-yl)pyrazine-2-carboxamide (44a) 
Methyl 3-amino-5-(azepan-1-yl)-6-chloropyrazine-2-carboxylate 32 
(100 mg, 3.52 x10-4 mol) was combined with K2CO3 (512 mg, 3.70x10
-3 
mol), thiophene-2-ylboronic acid (70 mg, 5.49x10
-4 mol) and  Pd(Ph3)4 
(20 mg, 17.5x10-5 mol) and the reaction vessel purged with Ar. Anhydrous toluene (12 mL), 
followed by MeOH (3 mL) were added via syringe and the mixture heated towards reflux for 
3 h. TLC analysis indicated absence of SM and the presence of a UV active spot (Rf = 0.80, 1:4 
EtOAc:Pet. spirit) after 3 h. The RM was allowed to cool to RT. The RM was vaccuum filtered 
through celite and washed through with CH3CN (3x20 mL) to remove catalyst. Solvent was 
removed under reduced pressure. The crude product was re-solubilized in MeOH and 
adsorbed onto silica gel under reduced pressure. The product was isolated via silica gel flash 
column chromatography (gradient elution, 5:95 to 10:90 EtOAc:Hexane) to yield 44a as a 
light yellow solid (99 mg, 85%): MP: 118-120 °C; 1H NMR (500 MHz, CDCl3) δ 7.27 (d, J = 5 Hz, 
1H, ArH3”), 7.03 (d, J = 3 Hz, 1H, ArH5”) 6.98 (m, 1H, ArH4”) 3.89 (s, 3H, Ester CH3), 3.43 (t, J 
= 5.7 Hz, 4H, C2’H2 and C7’H2), 1.67 (s, 4H, C3’H2 and C6’H2), 1.47 (s, 4H, C4’H2 and C5’H2); 
13C 
NMR (126 MHz, CDCl3) δ 167.28 (Ester C=O), 155.24 (ArC5), 153.52 (ArC3), 142.83 (ArC1”), 
126.89 (ArC3”), 125.96 (ArC4”), 125.78 (ArC5”), 125.54 (ArC6), 112.70 (ArC2), 52.13 (Ester 
CH3), 51.11 (C2’ and C7’), 28.15 (C3’ and C6’), 27.26 (C4’ and C5’); HRESI-MS m/z (M + Na)
+: 









Methyl 3-amino-5-(azepan-1-yl)-6-chloropyrazine-2-carboxylate 32 
(100 mg, 3.55x10-4 mol) was combined with K2CO3 (492 mg, 3.56x10
-3 
mol), thiophen-3-ylboronic acid (75 mg, 5.84x10
-4 mol)  and Pd(Ph3)4 (20 mg, 1.73x10
-5 mol) 
and the reaction vessel purged with Ar. Anhydrous toluene (12 mL), followed by  MeOH (3 
mL) were added via syringe and the mixture heated to reflux for 2 h. TLC analysis indicated 
absence of SM and the presence of a UV active spot (Rf = 0.75, 1:4 EtOAc:Pet. Spirit) after 2 
h. The RM was allowed to cool to RT, vacuum filtered through celite and washed through 
with CH3CN (3x20 mL) to remove catalyst. Solvent was removed under reduced pressure. 
The crude product was re-solubilized in MeOH and adsorbed onto silica gel under reduced 
pressure. The product was isolated via silica gel flash column chromatography (gradient 
elution, 5:95 to 10:90 EtOAc:Hexane) to yield 45a as an off white solid (100 mg, 85%). MP: 
118-120°C: 1H NMR (500 MHz, CDCl3) δ 7.38 (s, 1H, ArH2”), 7.29 (m, 1H ArH4”), 7.25 (d, J = 5 
Hz, 1H, ArH5”), 3.88 (s, 3H, Ester CH3), 3.38 (t, J = 5.8 Hz, 4H, C2’H2 and C7’H2), 1.63 (s, 4H, 
C3’ H2 and C6’ H2), 1.44 (s, 4H, C4’ H2 and C5’ H2); 
13C NMR (126 MHz, CDCl3) δ 167.35 (Ester 
C=O), 155.30 (ArC5), 153.53 (ArC3), 141.34 (ArC1”), 128.06 (ArC5”), 127.86 (ArC6), 125.39 
(ArC4”), 122.83 (ArC2”), 112.16 (ArC2), 51.97 (Ester CH3), 50.90 (C2’ and C7’), 28.01 (C3’ and 
C6’), 27.05 (C4’ and C5’); HRESI-MS m/z (M + H)+: Calc. 355.1205, Obs. 355.1197; Anal-HPLC 






Methyl 3-amino-5-(azepan-1-yl)-6-(furan-2-yl)pyrazine-2-carboxylate (46a) 
Methyl 3-amino-5-(azepan-1-yl)-6-chloropyrazine-2-carboxylate 32 
(102 mg, 3.59x10-4 mol)  was combined with K2CO3 (519 mg, 3.76x10
-3 
mol), furan-2-ylboronic acid (59 mg, 5.26x10
-4 mol)  and Pd(Ph3)4 (20 
mg, 1.75x10-5 mol)  and the reaction vessel purged with Ar. Anhydrous toluene (12 mL), 
followed by  MeOH (3 mL) were added via syringe and the mixture heated to reflux for 1.5 h. 
TLC analysis indicated absence of SM and the presence of a UV active spot (Rf = 0.90, 1:4 
EtOAc:Pet. spirit) after 2 h. The RM was allowed to cool to RT, vacuum filtered through celite 
and washed through with CH3CN (3x20 mL) to remove catalyst. Solvent was removed under 
reduced pressure. The crude product was solubilized in MeOH and adsorbed onto silica gel 
under reduced pressure. The product was isolated via silica gel flash column 
chromatography (gradient elution, 5:95 to 15:85 EtOAc:Hexane) to yield 46a as an off white 
solid (111 mg, 98%): MP: 114-116 °C; 1H NMR (500 MHz, CDCl3) δ 7.41 (s, 1H, ArH3”), 6.54 (d, 
J = 2.75 Hz, 1H, ArH5”), 6.45 (s, 1H, ArH4”), 3.89 (s, 3H, Ester CH3), 3.37 (t, J = 5.8 Hz ,4H, 
C2’H2 and C7’H2), 1.66 (s, 4H, C3’H2 and C6’H2), 1.47 (s, 4H, C4’H2 and C5’H2); 
13C NMR (126 
MHz, CDCl3) δ 167.16 (Ester C=O), 154.76 (ArC5), 154.00 (ArC3), 152.24 (ArC1”), 141.49 
(ArC3”), 122.04 (ArC6), 112.15 (ArC2), 111.68m (ArC4”), 108.73 (ArC5”), 52.11 (Ester CH3), 
50.06 (C2’ and C7’), 28.11 (C3’ and C6’), 27.03 (C4’ and C5’); HRESI-MS m/z (M + Na)+: Calc. 







Methyl 3-amino-5-(azepan-1-yl)-6-(furan-3-yl)pyrazine-2-carboxylate (47a) 
Methyl 3-amino-5-(azepan-1-yl)-6-chloropyrazine-2-carboxylate 32 
(107 mg, 3.89x10-4 mol), furan-3-yl boronic acid (81 mg, 4.16 x10-4 
mol), K2CO3 (483 mg, 3.68 x10
-3 mol) and Pd(PPh3)4 (20 mg, 1.69 x10
-5 
mol) were added to a round bottom flask. Anhydrous toluene (12 mL) followed by MeOH (3 
mL) were added via syringe and heated to reflux. A UV active spot (Rf = 0.55, 1:4 EtOAc: Pet 
spirit) was detected via TLC along with disappearance of SM. After 1 h the RM was allowed 
to cool to RT, filtered through celite and washed through with EtOAc (3x20 mL). Solvent was 
removed under reduced pressure. The crude material was re-dissolved in EtOAc and 
adsorbed to silica prior to purification by silica gel flash column chromatography (5:95 
EtOAc:Pet spirit – 10:90 EtOAc:Pet. spirit) to give 47a of a yellow solid (114 mg , 93%); MP: 
122-124° C; 1H NMR (500 MHz, CDCl3) δ 7.64 (s, 1H, ArH2”), 7.41 (s, 1H, ArH4”), 6.61 (s, 1H, 
ArH5”), 6.20 (Ar3NH2), 3.89 (s, 3H, Ester CH3), 3.48 (t, J = 5 Hz, 4H, C2’ H2 and C7’ H2), 1.66 (s, 
4H, C3’ H2 and C6’ H2), 1.47 (s, 4H, C4’ H2 and C5’ H2); 
13C NMR (126 MHz, CDCl3) δ 167.30 
(Ester C=O), 155.56 (ArC5), 153.60 (ArC3), 142.62 (ArC4”), 140.63 (ArC2”), 125.82 (ArC1”), 
124.77 (ArC6), 112.55 (ArC2), 111.15 (ArC5”), 51.97 (Ester CH3), 50.99 (C2’ and C7’), 28.02 
(C3’ and C6’), 27.10 (C4’ and C5’); HRES-MS m/z (M + H)+: Calc. 316.1614, Obs. 316.1604; 
Anal-HPLC (70:30 A:B B over 30 min, tr = 30.9 min). 
 
Methyl 3-amino-5-(azepan-1-yl)-6-(pyrimidin-5-yl)pyrazine-2-carboxylate (48a) 
Methyl 3-amino-5-(azepan-1-yl)-6-chloropyrazine-2-carboxylate 32 
(100 mg, 3.50x10-4 mol), pyrimidin-5-ylboronic acid (69 mg, 5.58x10-4 
mol), K2CO3 (508 mg, 3.67x10-3 mol) and Pd(PPh3)4 (25 mg, 2.12x10-5 
mol) were added to a round bottom flask. Anhydrous toluene (12 mL) followed by MeOH (3 
200 
mL) were added via syringe and heated to reflux. After 15 min a UV active spot (Rf = 0.25, 2:3 
EtOAc:Pet. Spirit) was detected via TLC along with disappearance of SM after 40 min. After 
45 min the RM was allowed to cool to RT, filtered through celite and washed through with 
EtOAc (3x20 mL). Solvent was removed under reduced pressure. The crude material was re-
dissolved in EtOAc and adsorbed to silica prior to purification by silica gel flash  column 
chromatography (10:90 EtOAc:Pet. Spirit  40:60 EtOAc:Pet. Spirit) to give 48a  as an off 
white solid (95 mg, 83%); MP 178-180° C; 1H NMR (500 MHz, CDCl3) δ 9.13 (s, 1H, ArH4”), 
8.89 (s, 2H, ArH2” and ArH6”), 3.91 (s, 3H, EsterCH3), 3.35 (t, J = 5.0 Hz, 4H, C2’ H2 and C7’ 
H2), 1.68 (s, 4H, C3’ H2 and C6’ H2), 1.48 (s, 4H, C4’ H2 and C5’ H2); 
13C NMR (126 MHz, CDCl3) 
δ 167.06 (Ester C=O), 157.05 (ArC4”), 155.63 (ArC2” and ArC6”), 155.22 (ArC5), 153.82 
(ArC3), 134.85 (ArC1”), 124.47 (ArC6), 114.38 (ArC2), 52.25 (EsterCH3), 51.45 (C2” and C7”), 
27.95 (C3” and C6”), 27.35 (C4” and C5”). HRESI-MS m/z (M + Na)+: Calc. 351.1545, Obs. 
351.1535; Anal-HPLC (70:30 A:B B over 30 min, tr = 23.4 min). 
 
Methyl 3-amino-5-(azepan-1-yl)-6-(2-methoxypyrimidin-5-yl)pyrazine-2-carboxylate (49a) 
Methyl 3-amino-5-(azepan-1-yl)-6-chloropyrazine-2-carboxylate 32 
(100 mg, 3.50x10-4 mol), 2-methoxypyrimidin-5-ylboronic acid (79 
mg, 5.13 x10-4 mol), K2CO3 (479 mg, 3.60 x10
-3 mol) and Pd(PPh3)4 
(20 mg, 1.74 x10-5 mol) were added to a round bottom flask. Anhydrous toluene (12 mL) 
followed by MeOH (3 mL) were added via syringe and heated to reflux. After 20 min a UV 
active spot (Rf = 0.13, 1:4 EtOAc: Pet spirit) was detected via TLC along with disappearance of 
SM. After 20 min the RM was allowed to cool to RT, filtered through celite and washed 
through with EtOAc (3x20 mL). Solvent was removed under reduced pressure. The crude 
material was re-dissolved in EtOAc and adsorbed to silica prior to purification by silica gel 
201 
flash  column chromatography (10:90 EtOAc:Pet. Spirit  20:80 EtOAc:Pet. Spirit) to give 
49a as a light yellow solid (111 mg, 88%); MP: 141-143° C; 1H NMR (500 MHz, CDCl3) δ 8.66 
(s, 2H, ArH2”and ArH6”), 4.05 (s, 3H, p-methoxyCH3), 3.90 (s, 3H, Ester CH3), 3.38 (t, J = 6 Hz, 
4H, C2’ H2 and C7’ H2), 1.67 (s, 4H, C3’ H2 and C6’ H2), 1.48 (s, 4H, C4’ H2 and C5’ H2); 
13C 
NMR (126 MHz, CDCl3) δ 167.03 (Ester C=O), 164.54 (ArC4”), 158.09 (ArC2” and ArC6”), 
155.14 (ArC5), 153.67 (ArC3), 128.66 (ArC6), 125.05 (ArC1”), 113.75 (ArC2), 55.06 (p-
methoxyCH3), 52.03 (Ester CH3), 51.21 (C2’ and C7’), 27.85 (C3’ and C6’), 27.16 (C4’ and C5’); 
HRESI-MS m/z (M + H)+: Calc. 359.1832, Obs. 359.1848; Anal-HPLC (70:30 A:B 100% B over 




Methyl 3-amino-5-(azepan-1-yl)-6-chloropyrazine-2-carboxylate 32 
(101 mg, 3.53x10-4 mol), 2,4-dimethoxypyrimidin-5-ylboronic acid 
(100 mg 5.13x10-4 mol), K2CO3 (479 mg, 3.65x10-3 mol)  and Pd(PPh3)4 (12 mg, 1.02x10-5 mol)  
were added to a round bottom flask. Anhydrous toluene (12 mL) followed by MeOH (3 mL) 
were added via syringe and heated to reflux. After 30 min a UV active spot (Rf = 0.8, EtOAc) 
was detected via TLC along with disappearance of SM. After 30 min the RM was allowed to 
cool to RT, filtered through celite and washed through with EtOAc (3x20 mL). Solvent was 
removed under reduced pressure. The crude material was re-dissolved in EtOAc and 
adsorbed to silica prior to purification by silica gel flash column chromatography (10:90 
EtOAc:Pet. Spirit  20:80 EtOAc:Pet. Spirit) to give 50a  of a light yellow solid (124 mg, 91%): 
MP: 150-152° C; 1H NMR (500 MHz, CDCl3) δ 8.36 (s, 1H, ArH6”), 4.03 (s, 3H, p-methoxyCH3), 
3.94 (s, 3H, o-methoxyCH3), 3.87 (s, 3H, Ester CH3), 3.39 (s, 4H, C2’ H2 and C7’ H2), 1.60 (s, 
202 
4H, C3’ H2 and C6’ H2), 1.46 (s, 4H, C4’ H2 and C5’ H2); 
13C NMR (126 MHz, CDCl3) δ 168.30 
(ArC2”), 167.18 (Ester C=O), 164.76 (ArC4”), 158.09 (ArC6”), 155.34 (ArC5), 154.05 (ArC3), 
123.75 (ArC6), 117.06 (ArC1”), 112.64 (ArC2), 54.96 (p-methoxyCH3), 54.10 (m-methoxyCH3), 
51.95 (Ester CH3), 50.06 (C2’ and C7’), 27.98 (C3’ and C6’), 26.95 (C4’ and C5’); HRESI-MS m/z 
(M + H)+: Calc. 389.1937, Obs. 389.1929; Anal-HPLC (70:30 A:B B over 30 min, tr = 27.1 
min). 
 
Methyl 3-amino-5-(azepan-1-yl)-6-(2,6-dimethoxypyridin-3-yl)pyrazine-2-carboxylate (51a) 
Methyl 3-amino-5-(azepan-1-yl)-6-chloropyrazine-2-carboxylate 32 
(200 mg, 7.03x10-4 moles), 2,6-dimethoxypyridin-3-ylboronic acid 
(200 mg, 1.09x10-3 moles), K2CO3 (1.04 g, 7.53x10
-3 moles)  and 
Pd(PPh3)4 (35 mg, 3.30x10
-5 moles)  were added to a 10 mL glass sample vial charged with Ar. 
To the flask was added anhydrous toluene (4 ml) followed by MeOH (1 mL) and the mixture 
stirred at RT for 18 h. After 18 h a UV active spot (Rf = 0.3 40:60 EtOAc: Pet spirit) was 
detected via TLC along with SM (Rf = 0.5, 1:4 EtOAc:Pet. Spirit). After 18 h the RM was 
filtered through celite and washed through with EtOAc (3x20 mL). Solvent removed under 
reduced pressure. The crude material was dissolved in EtOAc and adsorbed to silica prior to 
purification by silica gel flash column chromatography (10:90 EtOAc:Pet. Spirit  20:80 
EtOAc:Pet. Spirit) to give 51a as a yellow solid (115 mg, 42%); MP: 134-136° C; 1H NMR (500 
MHz, CDCl3) δ 7.66 (d, J = 8.0 Hz, 1H, ArH5”), 6.38 (d, J = 8.0 Hz, 1H, ArH4”), 3.92 (s, 3H, p-
methoxyCH3), 3.87 (s, 3H, Ester CH3), 3.86 (s, 3H, m-methoxyCH3), 3.45 (bs, 2H, C2’ and C7’), 
3.31 (bs, 2H, C2’ and C7’), 1.57 (s, 4H, C3’ H2 and C6’ H2), 1.44 (s, 4H, C4’ H2 and C5’ H2); 
13C 
NMR (126 MHz, CDCl3) δ 167.52 (Ester C=O), 162.79 (ArC6”), 159.68 (ArC2”), 155.29 (ArC5), 
153.92 (ArC3), 141.52 (ArC4”), 127.61 (ArC6), 116.24 (ArC3”), 112.21 (ArC2), 101.33 (ArC5”), 
203 
53.72 (p-methoxyCH3), 53.48 (o-methoxyCH3), 51.90 (Ester CH3), 50.14 (C2’ and C7’), 28.12 
(C3’ and C6’), 27.07 (C4’ and C5’); HRESI-MS m/z (M + H)+: Calc. 388.1985, Obs. 388.1983; 




Methyl 3-amino-5-(azepan-1-yl)-6-chloropyrazine-2-carboxylate 32 
(100 mg, 3.52x10-4 mol), 2-fluoropyridin-3-ylboronic acid (75 mg, 
5.29x10-4 mol), K2CO3 (519 mg, 3.75x10
-3 mol) and Pd(PPh3)4 (21 mg, 1.77x10
-5 mol) were 
added to a stoppered two-neck round bottom flask and the flask was charged with Ar. The 
flask was fitted to a reflux condenser followed by addition of anhydrous toluene (12 mL) and 
MeOH (3 mL) via syringe. The flask was heated to reflux for 45 min. A UV active spot (Rf = 
0.55, 2:3 EtOAc:Pet. spirit) was detected via TLC after 3 min. TLC at 45 min revealed the 
disappearance of methyl ester SM (Rf = 0.8, 2:3 EtOAc:Pet. spirit). The RM was allowed to 
cool to RT, filtered through celite and washed through with  CH3CN (3x20 mL). Solvent 
removed under reduced pressure. The crude product was re-solubilized in MeOH and 
adsorbed onto silica gel under reduced pressure. The product was isolated via silica gel flash 
column chromatography (gradient elution, 5:95 to 15:85 EtOAc:Hexane) to give 52a as a 
light brown solid (92 mg, 76%): MP: 156-158°C; 1H NMR (500 MHz, CDCl3) δ 8.17 (d, J = 4.3 
Hz, 1H, ArH6”) 8.06 (m, 1H, ArH5”), 7.29 (t, J = 5.5 Hz, 1H, ArH4”), 3.89 (s, 3H, Ester CH3), 
3.36 (s, J = 5.7 Hz, 4H, C2’H2 and C7’H2), 1.63 (s, 4H, C3’H2 and C6’H2), 1.46 (s, 4H, C4’H2 and 
C5’H2). 
13C NMR (126 MHz, CDCl3) δ 167.21 (Ester C=O), 161.32 (ArC2”), 155.23 (ArC5), 
154.10 (ArC3), 146.80 (ArC6”), 141.07 (ArC4”), 124.54 (ArC5”), 123.84 (ArC6), 122.15 
(ArC3”), 113.34 (ArC2), 52.27 (Ester CH3), 50.34 (C2’ and C7’), 28.13 (C3’ and C6’), 27.29 (C4’ 
204 
and C5’); HRESI-MS m/z (M + Na)+: Calc. 368.1499, Obs. 368.1489. Anal-HPLC (100% A 
100% B 30 min, tr = 26.3 min). 
 
Methyl 3-amino-5-(azepan-1-yl)-6-(2,4-dimethoxyphenyl)pyrazine-2-carboxylate (53a) 
Methyl 3-amino-5-(azepan-1-yl)-6-chloropyrazine-2-carboxylate 32 
(201 mg, 7.07x10-4 mol), 2,4-dimethoxyphenylboronic acid (128 mg, 
7.02x10-4 mol), K2CO3 (1.02 g, 7.41x10-3 mol)  and Pd(PPh3)4 (40 mg, 
3.48x10-5 mol) were added to a round bottom flask. Anhydrous toluene (24 mL) followed by 
MeOH (6 mL) were added via syringe and heated to reflux. After 1 h a UV active spot (Rf = 
0.4, 1:4 EtOAc:Pet. Spirit) was detected via TLC along with disappearance of SM after 2 h. 
After 2.75 h the RM was allowed to cool to RT, filtered through celite and washed through 
with EtOAc (3x20 mL). Solvent was removed under reduced pressure. The crude material 
was re-dissolved in EtOAc and adsorbed to silica prior to purification by silica gel flash 
column chromatography (10:90 EtOAc:Pet. Spirit  20:80 EtOAc:Pet. Spirit) to give 53a  as a 
light yellow solid (143 mg, 53%): MP: 106-108 °C; 1H NMR (500 MHz, CDCl3): 1H NMR (500 
MHz, CDCl3) δ 7.33 (d, J = 8.3 Hz, 1H, ArH6”), 6.54 (dd, J = 8.3 Hz, J = 2.1 Hz 1H, ArH5”), 6.42 
(d, J = 2.1 Hz, 1H, ArH3”) 3.85 (s, 3H, p-methoxyCH3), 3.82 (s, 3H, o-methoxyCH3), 3.70 (s, 3H, 
Ester CH3), 3.44 (s, 2H, C2’ H2 and C7’ H2), 3.26 (s, 2H, C2’ H2 and C7’ H2), 1.58 (s, 2H, C3’ H2 
and C6’ H2), 1.53 (s, 2H, C3’ H2 and C6’ H2), 1.46 (s, 2H, C4’ H2 and C5’ H2), 1.39 (s, 2H, C4’ H2 
and C5’ H2).
 13C NMR (126 MHz, CDCl3) δ 165.95 (Ester C=O), 160.93 (ArC4”), 158.21 (ArC2”), 
155.42 (ArC5), 153.99 (ArC3), 131.10 (ArC6”), 129.22 (ArC1”), 123.71 (ArC6), 111.77 (ArC2), 
105.07 (ArC5”), 98.67 (ArC3”), 55.74 (d, J = 2.1 Hz, p-methoxyCH3), 55.66 (d, J = 2.1 Hz, m-
methoxyCH3), 51.99 (EsterCH3), 50.62 (C2’ and C7’), 27.81 (C3’ and C6’), 26.93 (C4’ and C5’). 
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HRESI-MS m/z (M + Na)+: Calc. 409.1852, Obs. 409.1866; Anal-HPLC (100%A 100% B over 
30 min, tr = 28.6 min). 
 
Methyl 3-amino-5-(azepan-1-yl)-6-(3,5-dimethoxyphenyl)pyrazine-2-carboxylate (54a) 
Methyl 3-amino-5-(azepan-1-yl)-6-chloropyrazine-2-carboxylate 32 
(200 mg, 7.02x10-4 mol), 3,5-dimethoxyphenylboronic acid (128 mg, 
7.02x10-4 mol), K2CO3 (1.02 g, 7.41x10-3 mol)  and Pd(PPh3)4 (40 mg, 
3.48x10-5 mol)  were added to a round bottom flask. Anhydrous toluene (24 mL) followed by 
MeOH (6 mL) were added via syringe and heated to reflux. After 1 h a UV active spot (Rf = 
0.4, 1:4 EtOAc:Pet. Spirit) was detected via TLC along with disappearance of SM after 3 h. 
After 3 h min the RM was allowed to cool to RT, filtered through celite and washed through 
with EtOAc (3x20 mL). Solvent was removed under reduced pressure. The crude material 
was re-dissolved in EtOAc and adsorbed to silica prior to purification by silica gel flash  
column chromatography (2.5:97.5 EtOAc:Pet. Spirit  10:90 EtOAc:Pet. Spirit) to give 54a  of 
a light yellow solid (166 mg, 61%); MP: 96-98° C; 1H NMR (500 MHz, CDCl3) δ 6.64 (s, 2H, 
ArH2” and ArH6”), 6.40 (s, 1H, ArH4”), 3.88 (s, 3H, Ester CH3), 3.81 (s, 6H, m-methoxyCH3), 
3.38 (t, J = 6.0 Hz, 4H, C4’ H2 and C5’ H2), 1.64 (s, 4H, C3’ H2 and C6’ H2), 1.44 (s, 4H, C4’ H2 
and C5’ H2); 
13C NMR (126 MHz, CDCl3) δ 167.50 (Ester C=O), 160.98 (ArC3” and ArC5”), 
154.73 (ArC5), 153.67 (ArC3), 142.75 (ArC1”), 131.59 (ArC6), 111.97 (ArC2), 106.32 (ArC2” 
and ArC6”), 99.95 (ArC4”), 55.61 (m-methoxyCH3), 51.98 (EsterCH3), 50.89 (C2’ and C7’), 
28.09 (C3’ and C6’), 27.14 (C4’ and C5’). HRESI-MS m/z (M + Na)+: Calc. 409.1852, Obs. 





Methyl 3-amino-5-(azepan-1-yl)-6-chloropyrazine-2-carboxylate 32 
(102 mg, 3.59x10-4 mol), 3,6-dimethoxypyridazin-4-ylboronic acid 
(97 mg, 5.26x10-4 mol), K2CO3 (485 mg, 3.51x10-3 mol)  and 
Pd(PPh3)4 (22 mg, 1.89x10
-5 mol)  were added to a round bottom flask. Anhydrous toluene 
(24 mL) followed by MeOH (6 mL) were added via syringe and heated to reflux. After 1 h a 
UV active spot (Rf = 0.5, 2:3 EtOAc:Pet. Spirit) was detected via TLC along with disappearance 
of SM after 2 h. After 2 h the RM was allowed to cool to RT, filtered through celite and 
washed through with EtOAc (3x20 mL). Solvent was removed under reduced pressure. The 
crude material was re-dissolved in EtOAc and adsorbed to silica prior to purification by silica 
gel flash column chromatography (10:90 EtOAc:Pet. Spirit  20:80 EtOAc:Pet. Spirit) to give 
55a  as a yellow solid (94 mg, 68%): MP: 152-154° C; 1H NMR (500 MHz, CDCl3) δ 7.17 (s, 1H, 
ArH2”), 4.08 (s, 3H, o-methoxyCH3), 4.00 (s, 3H, m-methoxyCH3), 3.88 (s, 3H, EsterCH3), 3.43 
(s, 2H, C2’ H2 and C7’ H2), 3.29 (s, 2H, C2’ H2 and C7’ H2), 1.63 (s, 4H, C3’ H2 and C6’ H2), 1.44 
(s, 4H, C3’ H2 and C6’ H2); 
13C NMR (126 MHz, CDCl3) δ 166.97 (Ester C=O), 162.75 (ArC3”), 
159.61 (ArC6”), 154.70 (ArC5), 154.14 (ArC3), 135.05 (ArC1”), 122.88 (ArC6), 119.39 (ArC2”), 
113.08 (ArC2), 54.82 (o-methoxyCH3), 54.62 (m-methoxyCH3), 52.07 (Ester C=O), 49.74  (C2” 
and C7”), 27.98 (C3” and C6”), 27.20 (C4” and C5”); HRESI-MS m/z (M + Na)+: Calc. 411.1757, 





Methyl 3-amino-5-(azepan-1-yl)-6-(phenylethynyl)pyrazine-2-carboxylate (56a) 
Methyl 3-amino-5(azepan-1-yl)-6-pyrazine-2-carboxylate 32 (101 
mg, 3.53x10-4 mol), Pd(PPh3)Cl2 (12 mg, 1.65x10
-5 mol) and CuI (9.9 
mg, 5.2 x10-5 mol)  were added dry to a 10 mL round bottom flask 
and dissolved in anhydrous THF (3.5 ml). To this solution Et3N (147 
µL, 1.05 x10-3 mol) and phenylacetylene (58 µL, 5.27 x10-4 mol) were added via pipette. The 
solution was sparged with N2 and heated to reflux with vigorous stirring. After 24 h the 
reaction was allowed to cool to RT. The crude RM was filtered through celite and washed 
through with EtOAc (3x20 mL). Solvent was removed under reduced pressure. The product 
was isolated via silica gel flash column chromatography (gradient elution 1-7.5% 
EtoAc:petroleum spirit) to yield 56a as a brown solid (73 mg, 59%): MP: 126-128 °C; 1H NMR 
(500 MHz, CDCl3) δ 7.50 (m, 2H, ArH2” and ArH6”), 7.32 (m, 3H, ArH3”, ArH4” and ArH5”), 
4.00 (t, J = 5.5 Hz, 4H, C2’H2 and C7’H2), 3.91 (s, 3H, Ester CH3), 1.87 (s, 4H, C3’H2 and C6’ H2), 
1.58 (s, 4H, C4’H2 and C5’ H2); 
13C NMR (126 MHz, CDCl3) δ 166.65 (Ester C=O), 155.26 
(ArC5), 153.79 (ArC3), 131.45 (ArC4”), 128.41 (ArC3” and ArC5”), 128.34 (ArC2” and ArC6”), 
123.43 (ArC1”), 113.71 (ArC2), 113.47 (ArC6), 90.44 (C7), 89.04 (C8), 52.15 (Ester CH3), 50.44 
(C2’ and C7’), 28.60 (C3’ and C6’), 26.84 (C4’ and C5’); HRESI-MS m/z (M + H)+: Calc. 








General Method for acyl guanidinylation: 
 
General Method 
Free guanidine was generated via neutralization of guanidine.HCl with Na+ iPrO- in iPrOH to 
create a 2-fold molar excess relative to the 6-substituted pyrazinoyl methyl ester.  A stock 
solution of iPrO- was prepared by adding Na(s) (typically 30-70 mg) in anhydrous 
iPrOH under 
N2 and heated at 70 °C for 30 min. From this stock solution an amount of 
iPrO- was removed 
via syringe and made up to 10 mL in anhydrous iPrOH. To this solution was added a 
stoichiometric amount of guanidine hydrochloride and the mixture stirred at 70 °C for 30 
min. This solution was gravity filtered onto the neat 6-substituted pyrazinoyl methyl ester. 
Once filtration was complete, the mixture was heated to reflux and allowed to react for 
between 1-6 h. The reactions were monitored by MS and TLC and terminated by removal of 
solvent under reduced pressure. Final products were isolated by rp-HPLC. All compounds 
were isolated as TFA salts and exchanged to their respective HCl salts by stirring with 












The compound was prepared using the General Method (2.5 h 
reaction time) with methyl 3-amino-5-(azepan-1-yl)-6-
phenylpyrazine-2-carboxylate 33a (70 mg, 2.14x10-4 mol). The 
residue was taken up in solvent A:B (2 mL) and purified by preparative HPLC (70:30 
A:B100% B over 30 min). Collected fractions containing purified product were pooled 
concentrated via freeze drying to yield 33 as a bright yellow solid (TFA salt, 7.3 mg, 7%) after 
HPLC); MP: 126-130 °C; 1H NMR (500 MHz, CD3OD) δ 8.98 (s, 1H, Amide NH), 8.26 (bs, 2H 
Guanidine NH2), 7.59 (bs, 2H Guanidine NH2) 7.45 (d, J = 7.5 Hz, 2H, ArH2” and ArH6”), 7.40 
(d, J = 7.5 Hz, 2H, ArH3” and ArH5”), 7.33 (d, J = 7.5 Hz, 1H, ArH4”), 3.38 (t, J = 5.0 Hz 4H, 
C2’H2 and C7’H2), 1.63 (s, 4H, C3’H2 and C6’H2), 1.45 (s, 4H, C3’H2 and C6’H2). 
13C-APT δ 
167.93 (Amide C=O), 160.25 (Guanidine C), 155.77 (ArC5), 155.04 (ArC3), 145.55 (ArC1”), 
130.13 (ArC6), 130.01 (ArC2” and ArC6”), 129.88 (ArC3” and ArC5”), 125.23 (ArC6), 124.78 
(Ar-CF3), 112.89 (ArC2), 51.61 (C2’ and C7’), 28.63 (C3’ and C6’), 27.58 (C4’ and C5’). LRESI-




The compound was prepared using the General Method (3 h 
reaction time) with methyl 3-amino-5-(azepan-1-yl)-6-(4-
(methylthio)phenyl)pyrazine-2-carboxylate 34a (81 mg, 2.16x10-
4 mol). The residue was taken up in A:B (2 mL) and purified by preparative HPLC (70:30 
A:B100% B over 30 min). Collected fractions containing purified product were pooled 
concentrated via freeze drying to yield 34 as a yellow solid (TFA salt, 5.5 mg, 5% after HPLC) 
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MP 152-154°C; 1H NMR (500 MHz, CDCl3) δ 10.31 (s, 1H, Amide NH), 9.44 (s, 2H, Guanidine 
NH2), 8.47 (s, 2H, Guanidine NH2), 7.44 (d, J = 8.1 Hz, 2H, ArH3” and ArH5”), 7.28 (d, J = 8.1 
Hz, 2H, ArH2” and ArH6”), 3.40 (t, J = 5.5 Hz, 4H, C2’H2 and C7’H2), 1.60 (s, 4H, C3’H2 and C6’ 
H2), 1.46 (s, 4H, C4’H2 and C5’ H2).
 13C NMR (126 MHz, CDCl3) δ 166.04 (Amide C=O), 156.63 
(Guanidine C), 155.71 (ArC5), 153.56 (ArC3), 138.99 (ArC4”), 136.40 (ArC1”), 131.19 (ArC6), 
128.14 (ArC2” and ArC6”), 126.61(ArC3” and ArC5”), 110.96 (ArC2), 51.47 (C2’ and C7’), 
27.89 (C3’ and C6’), 27.11 (C4’ and C5’), 15.45. (thioetherCH3). HRESI-MS m/z (M + H)
+ 400, 
Anal. for C19H26N7OS: Calc. 400.1920, Obs. 400.1935. Anal-HPLC (70:30 A:B100% B over 30 




The compound was prepared using the General Method (2.5 h 
reaction time) with methyl 3-amino-5-(azepan-1-yl)-6-(4-
(trifluoromethyl)phenyl)pyrazine-2-carboxylate 35a (101 mg, 
2.56x10-4 mol). The residue was taken up in solvent A:B (2 mL) and purified by preparative 
HPLC (70:30 A:B100% B over 30 min). Collected fractions containing purified product were 
pooled concentrated via freeze drying to yield 35 as a bright yellow solid (TFA salt, 16 mg, 
12% after HPLC); MP: 126-130 °C; 1H NMR (500 MHz, CD3OD) :7.68 (d, J = 8.0 Hz, 2H, ArH3” 
and ArH5”), 7.65 (d, J = 8.0 Hz, 2H, ArH2” and ArH6”), 3.38 (t, J = 5.0 Hz 4H, C2’H2 and C7’H2), 
1.65 (s, 4H, C3’H2 and C6’H2), 1.46 (s, 4H, C3’H2 and C6’H2). 
13C NMR (126 MHz, CDCl3) δ 
167.93 (Amide C=O), 160.25 (Guanidine C), 155.77 (ArC5), 155.04 (ArC3), 145.55 (ArC1”), 
130.13 (ArC6), 130.01 (ArC2” and ArC6”), 129.88 (ArC3” and ArC5”), 125.23 (ArC6), 124.78 
(Ar-CF3), 112.89 (ArC2), 51.61 (C2’ and C7’), 28.63 (C3’ and C6’), 27.58 (C4’ and C5’). HRESI-
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MS m/z (M + H)+: Calc. 422.1911, Obs. 422.1912; Anal-HPLC (70:30 A:B 100% B over 30 




The compound was prepared using the General Method (3 h 
reaction time) using methyl 3-amino-5-(azepan-1-yl)-6-
(benzo[d][1,3]dioxol-5-yl)pyrazine-2-carboxylate 36a (54 mg, 
1.46x10-4 mol). The residue was taken up in solvent A:B (2 mL) and purified by preparative 
HPLC (70:30 A:B100% B over 30 min). Collected fractions containing purified product were 
pooled concentrated via freeze drying to yield 36 as a yellow solid (HCl salt, 5.7 mg, 9% after 
IEX) MP 154-156°C; 1H NMR (500 MHz, DMSO-d6) δ 10.39 (s, 1H, Amide NH), 8.71 (s, 2H, 
Guanidine NH2), 8.27 (s, 2H, Guanidine NH2), 7.31 (s, 1H, ArC2”) 6.97 (d, J = 8.0 Hz, 1H, 
ArH9”), 6.93 (d, J = 8.0 Hz, 1H, ArH8”), 6.08 (s, 2H, C5”H2), 3.40 (t, J= 5.75 Hz, 4H, C2’ H2 and 
C7’ H2), 1.60 (s, 2H, C3’ H2 and C6’ H2), 1.39 (s, 2H,C4’ H2 and C5’ H2). 
13C NMR (126 MHz, 
DMSO-d6) δ 166.23 (Amide C=O), 155.15 (Guanidine C), 154.75 (ArC5), 153.61 (ArC3), 147.26 
(ArC3”), 146.71 (ArC7”), 133.39 (ArC1”), 130.28 (ArC6), 121.43 (ArC9”), 112.73 (ArC2), 
108.47 (ArC2”), 107.96 (ArC8”), 101.15 (C5”), 50.44 (C2’ and C7’), 27.21 (C3’ and C6’), 26.07 
(C4’ and C5’). HRESI-MS m/z (M + H)+  398: Calc. 398.1941, Obs. 398.1929. Anal-HPLC (70:30 







The compound was prepared using the General Method (2.5 h 
reaction time) with methyl 3-amino-5-(azepan-1-yl)-6-(isoquinolin-
4-yl)pyrazine-2-carboxylate 37a (156 mg, 4.13x10-4 mol). The 
residue was taken up in anhydrous DMSO (2 mL) and purified by 
preparative HPLC (70:30 A:B100% B over 30 min). Collected fractions containing purified 
product were pooled concentrated via freeze drying to yield 37 as an orange solid (TFA salt, 
31 mg, 15% after HPLC) MP 158-160°C; 1H NMR (500 MHz, CD3OD) δ 10.47 (s, exchange with 
solvent, Amide NH), 9.57 (bs, 1H, ArH2”), 9.19 (s, exchange with solvent, Guanidine NH2), 
9.09 (s, exchange with solvent, Guanidine NH2), 8.69 (bs, 1H, Ar4H”), exchange with solvent, 
Guanidine NH2), 8.40 (d, J = 8.2 Hz, 1H ArH6”), 8.01 (t, J = 7.5 Hz, 1H ArH7”), 7.91 (t, J = 7.5 
Hz, 1H ArH8”), 7.81 (d, J = 8.2 Hz, 1H ArH9”), 3.37 (s, 2H, C2’ H2 and C7’ H2), 3.23 (s, 2H, C2’ 
H2 and C7’ H2), 1.53 (s, 4H, C3’ H2 and C6’ H2), 1.44 (s, 4H, C4’ H2 and C5’ H2). 
13C NMR (126 
MHz, CD3OD) δ 167.51 (Amide C=O), 157.74 (Guanidine C), 156.87 (ArC5), 156.36 (ArC3), 
149.67 (ArC4”), 137.60 (ArC1”), 136.92 (ArC2”), 136.87 (ArC10”), 136.82 (ArC6”), 131.61 
(ArC8”), 131.42 (ArC7”), 129.044 (ArC6), 125.72 (ArC9”), 124.73 (ArC5”), 112.97 (ArC2), 
51.58 (C2’ and C7’), 28.94 (C3’ and C6’), 27.75 (C4’ and C5’). HRESI-MS m/z (M + H)+: Calc. 










The compound was prepared using the General Method (2 h 
reaction time) with methyl 3-amino-5-(azepan-1-yl)-6-(1-methyl-
1H-pyrazol-4-yl)pyrazine-2-carboxylate 38a (69 mg, 2.07x10-4 
mol). The residue was taken up in solvent A:B (2 mL) plus 3 drops CH3CN and purified by 
preparative HPLC (70:30 A:B100% B over 30 min). Collected fractions containing purified 
product were pooled concentrated via freeze drying to yield 38 as a yellow solid (HCl salt, 31 
mg, 38% after IEX) MP 150-152°C; 1H NMR (500 MHz, CDCl3) δ 10.49 (s, 1H, Amide NH), 8.83 
(s, 2H, Guanidine NH2), 8.52 (s, 2H, Guanidine NH2), 8.00 (s, 1H, ArH2”), 7.57 (s, 1H, ArH6”), 
5.49 (bs, 2H, Ar3NH2), 3.93 (s, 3H, ArN3”CH3), 3.50 (t, J = 5.75 Hz, 4H, C2’H2 and C7’H2), 1.69 
(s, 4H, C3’H2 and C6’ H2), 1.49 (s, 4H, C4’H2 and C5’ H2). 
13C NMR (126 MHz, CDCl3) δ 166.57 
(Amide C=O), 156.35 (Guanidine C), 156.07 (ArC5), 153.40 (ArC3), 137.39 (ArC6”), 130.73 
(ArC2”), 125.04 (ArC1”), 121.70 (ArC6), 111.08 (ArC2), 51.54 (C2’ and C7’), 38.67 (ArN3”CH3), 
27.85 (C3’ and C6’), 27.27 (C4’ and C5’). HRESI-MS m/z (M + H)+: Calc. 358.2104, Obs. 




The compound was prepared using the General Method 
(3 h reaction time) with methyl 3-amino-5-(azepan-1-
yl)-6-(1-(2-morpholinoethyl)-1H-pyrazol-4-yl)pyrazine-2-
carboxylate 39a (99 mg, 2.29x10-4 mol). The residue was taken up in solvent A:B (2 mL) and 
purified by preparative HPLC (70:30 A:B100% B over 30 min). Collected fractions 
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containing purified product were pooled concentrated via freeze drying to yield 39 as an 
orange solid (TFA salt, 38 mg, 30% after HPLC) MP 136-138°C; 1H NMR (500 MHz, CDCl3) δ 
10.48 (s, 1H, Amide NH), 8.86 (s, 2H, Guanidine NH2), 8.65 (s, 2H, Guanidine NH2), 7.89 (s, 
1H, ArH5”), 7.56 (s, 1H, ArH2”), 4.67 (s, 2H, C7H2), 3.93 (s, 4H, C11H2 and C13H2), 3.69 (s, 2H, 
C8H2), 3.47 (s, 4H, C10H2 and C14H2), 3.42 (bs, 2H, C2’ and C7’), 3.05 (bs, 2H, C2’ and C7’) 
1.67 (s, 4H, C3’ H2 and C6’ H2), 1.49 (s, 4H, C4’ H2 and C5’ H2). 
13C NMR (126 MHz, CDCl3) δ 
166.63 (Amide C=O), 156.35 (Guanidine C), 156.06 (ArC5), 153.63 (ArC3), 139.96 (ArC5”), 
130.58 (ArC2”), 124.10 (ArC1”), 122.90 (ArC6), 111.31 (ArC2), 63.78 (C11CH2 and C13CH2), 
57.19 (C8CH2), 53.29 (C10CH2 and C14CH2), 51.40 (C2’ and C7’), 46.38 (C7CH2), 27.89 (C3’ 
and C6’), 27.17 (C4’ and C5’). HRESI-MS m/z (M + H)+: Calc. 457.2788, Obs. 457.2796. Anal-
HPLC (70:30 A:B100% B over 30 min, tr =19.0 min). 
 
3-amino-5-(azepan-1-yl)-N-carbamimidoyl-6-(1H-indol-2-yl)pyrazine-2-carboxamide (40) 
The compound was prepared using the General Method (3 h 
reaction time) with methyl 3-amino-5-(azepan-1-yl)-6-(1H-indol-
2-yl)pyrazine-2-carboxylate 40a (76 mg, 2.09x10-4 mol). The 
residue was taken up in solvent A:B (4 mL) and purified by 
preparative HPLC (70:30 A:B100% B over 30 min, 2 separate 2 mL injections). Collected 
fractions containing purified product were pooled concentrated via freeze drying to yield 40 
as an orange solid (TFA salt, 29 mg, 31% yield after HPLC) MP 152-154°C; 1H NMR (500 MHz, 
CDCl3) δ 11.09 (s, 1H, ArNH2”), 10.82 (s, 1H, Amide NH), 8.82 (s, 2H, Guanidine NH2), 7.92 (s, 
2H, Guanidine NH2), 7.55 (d, 1H, J = 7.7 Hz, ArH7”) 7.41 (d, 1H, J = 7.7 Hz, ArH7”), 7.12 (t, 1H, 
J = 7 Hz, ArH5”), 7.03 (t, 1H, J = 7 Hz, ArH6”), 6.44 (s, 1H, ArH9”), 3.64 (t, J = 5.0 Hz, 4H, C2’ H2 
and C7’ H2), 1.73 (s, 4H, C3’ H2 and C6’ H2), 1.50(s, 4H, C4’ H2 and C5’ H2). 
13C NMR (126 MHz, 
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CDCl3) δ 166.66 (Amide C=O), 156.22 (Guanidine C), 155.69 (ArC5), 152.98 (ArC3), 136.62 
(ArC3”), 134.89 (ArC1”), 128.32 (ArC8”), 125.72 (ArC6), 122.71 (ArC5”), 120.49 (ArC7”), 
119.81 (ArC6”), 111.74 (ArC2), 110.83 (ArC4”), 102.31 (ArC9”), 52.13 (C2’ and C7’), 27.88 (C3’ 
and C6’), 27.55 (C4’ and C5’); HRESI-MS m/z (M + H)+: Calc. 393.2151, Obs. 393.2159. Anal-




The compound was prepared using the General Method (3 h 
reaction time) with methyl 3-amino-5-(azepan-1-yl)-6-
(benzo[b]thiophen-2-yl)pyrazine-2-carboxylate 41a (225 mg, 
5.88x10-4 mol). The residue was taken up in solvent A:B (2 mL, 
partially soluble) and purified by preparative HPLC (70:30 A:B100% B over 30 min). 
Collected fractions containing purified product were pooled concentrated via freeze drying 
to yield 41 as a yellow solid (HCl salt, 10 mg, 4% after IEX) MP: 220-224°C (dec); 1H NMR (500 
MHz, CD3OD) δ, 7.78 (d, J = 7.5 Hz, 1H, ArH4”), 7.71 (d, J = 7.5 Hz, 1H, ArH7”), 7.31-7.26 (m, 
2H, ArH5” & 6”), 7.24 (s, 1H, ArH9”), 3.48 (t, J = 6.0 Hz, 4H, C2’ H2 and C7’ H2), 1.66 (s, 4H, C3’ 
H2 and C6’ H2), 1.47 (s, 4H, C4’ H2 and C5’ H2). 
13C NMR (126 MHz, CD3OD) δ 168.23 (Amide 
C=O), 164.88 (ArC9”), 160.75 (Guanidine C), 156.54 (ArC5), 155.41 (ArC3), 144.08 (ArC1”), 
141.34 (ArC8”), 141.16 (ArC3”), 125.75 (ArC5”), 125.51 (ArC6”), 124.66 (ArC6), 123.45 
(ArC7”), 123.07 (ArC4”), 113.47 (ArC2), 52.01 (C2’ and C7’), 29.22 (C3’ and C6’), 28.07 (C4’ 
and C5’). HRESI-MS m/z (M + H)+: Calc. 410.1763, Obs. 410.1780. Anal-HPLC (70:30 




The compound was prepared using the General Method (6 h 
reaction time) with methyl 3-amino-5-(azepan-1-yl)-6-
(benzofuran-2-yl)pyrazine-2-carboxylate 42a (116 mg, 3.17x10-4 
mol). The residue was taken up in anhydrous DMSO (2 mL) and 
purified by preparative HPLC (70:30 A:B100% B over 30 min). Collected fractions 
containing purified product were pooled concentrated via freeze drying to yield 42 as a 
yellow solid (TFA salt, 52 mg, 34% yield after HPLC) MP: 126-132°C; 1H NMR (CD3OD) δ 7.64 
(d, J = 7.5 Hz, 1H, ArH4”), 7.50 (d, J = 8.0 Hz, 1H, ArH7”), 7.31 (t, J = 8.0 Hz, 1H, ArH6”), 7.26 
(t, J = 7.5 Hz, 1H, ArH5”), 7.05 (s, 1H, ArH7”), 3.51 (t, J = 6.0 Hz, C2’ H2 and C7’ H2), 1.71 (s, 
4H, C3’ H2 and C6’ H2), 1.54 (s, 4H, C4’ H2 and C5’ H2). 
13C NMR (CD3OD) δ 167.44 (Amide 
C=O), 164.32 (Guanidine C), 154.61 (ArC5), 154.47 (ArC3”), 154.37 (ArC1”), 154.09 (ArC3), 
129.67 (ArC8”), 124.98 (ArC5”), 123.66 (ArC6”), 121.64 (ArC6), 121.08 (ArC7”), 112.44 
(ArC2), 111.52 (ArC4”), 105.63 (ArC9”), 50.31 (C2’ and C7’), 28.62 (C3’ and C6’), 27.39(C4’ 
and C5’).  HRESI-MS m/z (M + H)+: Calc. 394.1991, Obs. 394.1975. Anal-HPLC (70:30 




The compound was prepared using the General Method (3 h 
reaction time) using moles methyl 3-amino-5-(azepan-1-yl)-6-(4-
fluorobenzofuran-2-yl)pyrazine-2-carboxylate 43a (54 mg, 
1.39x10-4). The residue was taken up in anhydrous DMSO (2 mL) 
and purified by preparative HPLC (100% A100% B over 30 min). Collected fractions 
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containing purified product were pooled concentrated via freeze drying to yield 43 as an 
orange solid (TFA salt, 15 mg, 26% yield after HPLC), MP 132-136 °C. 1H NMR (500 MHz, 
CD3OD) δ 10.47 (s, exchange with solvent, Amide NH), 8.98 (s, exchange with solvent, 
Guanidine NH2), 8.33 (s, exchange with solvent, Guanidine NH2), 7.36 (t, J = 8.7Hz, 1H, 
ArH7”), 7.32 (q, J = 5.5Hz, 1H, ArH6”), 7.22 (s, 1H, ArH2”), 7.02 (t, J = 8.7Hz, 1H, ArH5”), 3.44 
(t, J = 5.8 Hz, 4H, C2’ H2 and C7’ H2) 1.72 (s, 4H, C3’ H2 and C6’ H2), 1.51 (s, 4H, C4’ H2 and C5’ 
H2). 
13C NMR (126 MHz, CD3OD) δ 167.32 (Amide C=O), 158.20 (ArC8”), 157.38 (Guanidine 
C), 156.89 (ArC5), 156.23 (ArC4”), 156.18 (ArC1”), 155.73 (ArC3), 126.57 (ArC6”), 121.13 
(ArC3”), 118.90 (ArC6), 112.16 (ArC2), 109.75 (ArC5”), 108.65 (ArC7”), 102.44 (ArC2”), 51.08 
(C2” and C7”), 29.02 (C3” and C6”), 27.88 (C4” and C5”). HRESI-MS m/z (M + H)+: Calc. 
412.1897, Obs. 412.1909. Anal-HPLC (100% A100% B over 30 min, tr =25.6 min). 
 
3-amino-5-(azepan-1-yl)-N-carbamimidoyl-6-(thiophen-2-yl)pyrazine-2-carboxamide (44) 
The compound was prepared using the General Method (3 h 
reaction time) with methyl 3-amino-5-(azepan-1-yl)-6-(thiophen-2-
yl)pyrazine-2-carboxylate 44a (99 mg, 2.98x10-4 mol). The residue 
was taken up in 70:30 solvent A:B (2 mL) and purified by preparative HPLC (70:30 A:B100% 
B over 30 min). Collected fractions containing purified product were pooled concentrated via 
freeze drying to yield 44 as a bright yellow solid (TFA salt, 1.9 mg, 2% yield after HPLC); MP 
1H NMR (500 MHz, CDCl3) δ 10.10 (s, 1H, Amide NH), 10.04 (bs, 2H Guanidine NH2), 8.08 (bs, 
2H Guanidine NH2), 7.26 (d, J = 5 Hz, 1H, ArH3”), 7.03 (d, J = 3 Hz, 1H, ArH5”), 3.47 (t, J = 5.75 
Hz, 4H, C2’H2 and C7’H2), 1.68 (m, 4H, C3’H2 and C6’H2), 1.49 (m, 4H, C4’H2 and C5’H2). 
13C 
NMR (126 MHz, CDCl3) δ 166.97 (Amide C=O), 156.30 (Guanidine C), 156.05 (ArC5), 153.39 
(ArC3), 139.86 (ArC1”), 128.44 (ArC5”), 128.18 (ArC6), 125.24 (ArC4”), 124.54 (ArC2”), 
218 
111.07 (ArC2), 51.04 (C2’ and C7’), 27.82 (C3’ and C6’), 27.12 (C4’ and C5’). HRESI-MS m/z (M 




The compound was prepared using the General Method (2 
reaction time) using (103 mg, 3.09x10-4 mol) moles methyl 3-
amino-5-(azepan-1-yl)-6-(thiophen-3-yl)pyrazine-2-carboxylate 
45a. The residue was taken up in 50:50 solvent A:B (2 mL) and purified by preparative HPLC 
(100% A100% B over 30 min). Collected fractions containing purified product were pooled 
concentrated via freeze drying to yield 45 as a bright yellow solid (TFA salt, 24 mg, 17% yield 
after HPLC); MP: 138-140°C; 1H NMR (500 MHz, CDCl3) δ 10.44 (s, 1H, Amide NH), 8.71 (bs, 
4H, 2x Guanidine NH2), 7.48 (s, 1H, ArH2”), 7.29 (m, 1H ArH4” and ArH5”), 3.43 (t, J = 5 Hz, 
4H, C2’H2 and C7’H2), 1.65 (s, 4H, C3’ H2 and C6’ H2), 1.46 (s, 4H, C4’ H2 and C5’ H2);
 13C NMR 
(126 MHz, CDCl3) δ 166.66 (Amide C=O), 156.24 (Guanidine C), 156.02 (ArC5), 153.58 (ArC3), 
140.12 (ArC1”), 128.40 (ArC5”), 127.79 (ArC6), 125.88 (ArC4”), 123.57 (ArC2”), 110.74 
(ArC2), 51.27 (C2’ and C7’), 27.92 (C3’ and C6’), 27.14 (C4’ and C5’). HRESI-MS m/z (M + H)+: 
Calc. 360.1607, Obs. 360.1611. Anal-HPLC (100% A100% B over 30 min, tr = 25.0). 
 
3-amino-5-(azepan-1-yl)-N-carbamimidoyl-6-(furan-2-yl)pyrazine-2-carboxamide (46) 
The compound was prepared using General Method (2 h reaction 
time) using methyl 3-amino-5-(azepan-1-yl)-6-(furan-2-yl)pyrazine-
2-carboxylate 46a (111 mg, 3.52x10-4 mol). The residue was taken up in 
solvent A:B (2 mL) and purified by preparative HPLC (70:30 A:B100% B over 30 min). 
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Collected fractions containing purified product were pooled concentrated via freeze drying 
to yield 46 as a bright yellow solid (TFA salt, 25 mg, 16% yield after HPLC); MP: 146-150 °C. 
1H NMR (500 MHz, CD3OD), 7.50 (s, 1H, ArH3”), 6.55 (d, J = 3.0 Hz, 1H, ArH5”), 6.50 (s, 1H, 
ArH4”), 3.37 (t, J = 6.0 Hz, 4H, C2’H2 and C7’H2), 1.64 (s, 4H, C3’H2 and C6’H2), 1.47 (s, 4H, 
C4’H2 and C5’H2). 
13C NMR (126 MHz, CD3OD) δ 168.1 (Amide C=O), 160.7 (Guanidine C) 
156.3 (ArC5), 153.4 (ArC3), 142.8 (ArC1”), 141.49 (ArC3”), 122.4 (ArC6), 112.6 (ArC2), 112.4 
(ArC4”), 109.9 (ArC5”), 50.9 (C2’ and C7’), 29.2 (C3’ and C6’), 27.8 (C4’ and C5’).  HRESI-MS 
m/z (M + H)+ 344: Calc. 344.1835, Obs. 344.1830. Anal-HPLC (70:30 A:B100% B over 30 
min, tr = 24.3 min). 
 
3-amino-5-(azepan-1-yl)-N-carbamimidoyl-6-(furan-3-yl)pyrazine-2-carboxamide (47) 
The compound was prepared using the General Method (2 h 
reaction time) with moles methyl 3-amino-5-(azepan-1-yl)-6-
(furan-3-yl)pyrazine-2-carboxylate 47a (90 mg, 2.85x10-4). The 
residue was taken up in solvent A:B (2 mL) and purified by preparative HPLC (70:30 
A:B100% B over 30 min). Collected fractions containing purified product were pooled 
concentrated via freeze drying to yield 47 as a bright yellow solid (HCl salt, 41 mg, 35% yield 
after HPLC); MP 146-148°C; 1H NMR (500 MHz, CDCl3) δ 10.42 (s, 1H, Amide NH), 8.54  (s, 4H, 
2X Guanidine NH2), 7.63 (s, 1H, ArH2”), 7.42 (s, 1H, ArH4”), 6.63 (s, 1H, ArH5”), 5.35 (bs, 2H, 
Ar3NH2), 3.52 (t,  J = 5.75 Hz, 4H, C2’H2 and C7’H2),  1.68 (s, 4H, C3’H2 and C6’H2) , 1.49 (s, 4H, 
C4’H2 and C5’H2). 13C NMR (126 MHz, CDCl3) δ 166.44 (Amide C=O), 156.29 (Guanidine C), 
155.84 (ArC5), 153.61 (ArC3), 143.19 (ArC4”), 141.10 (ArC2”), 125.32 (ArC1”), 124.87 (ArC6), 
110.82 (ArC2), 110.72 (ArC5”), 51.37 (C2’ and C7’), 27.86 (C3’ and C6’), 27.14 (C4’ and C5’). 
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HRESI-MS m/z (M + H)+: Calc. 344.1835, Obs. 344.1837. Anal-HPLC (70:30 A:B100% B over 
30 min, tr =24.9 min). 
 
3-amino-5-(azepan-1-yl)-N-carbamimidoyl-6-(pyrimidin-5-yl)pyrazine-2-carboxamide (48) 
The compound was prepared using the General Method (3 h 
reaction time) using methyl 3-amino-5-(azepan-1-yl)-6-(pyrimidin-
5-yl)pyrazine-2-carboxylate 48a (86 mg, 2.63x10-4 mol). The 
residue was taken up in anhydrous DMSO (2 mL) and purified by preparative HPLC (70:30 
A:B100% B over 30 min). Collected fractions containing purified product were pooled 
concentrated via freeze drying to yield 48 as an orange solid (TFA salt, 81 mg, 26% yield after 
HPLC); MP: 186-190 °C;1H NMR (500 MHz, CD3OD) δ 10.47 (Amide NH), 9.14 (s, 1H, ArH4”), 
8.98 (s, 2H, ArH2” and ArH6”), 8.83 (s, 2H, Guanidine NH2), 8.33 (s, 2H, Guanidine NH2), 3.44 
(t, J = 5.75 Hz, 4H, C2’ H2 and C7’ H2) 1.72 (s, 4H, C3’ H2 and C6’ H2), 1.51 (s, 4H, C4’ H2 and 
C5’ H2). 
13C NMR (126 MHz, CD3OD) δ 167.44 (Amide C=O), 157.71 (Guanidine C), 157.33 
(ArC4”), 156.91 (ArC5), 156.87 (ArC2” and ArC6”), 155.84 (ArC3), 135.87 (ArC1”), 125.37 
(ArC6), 113.35 (ArC2), 52.43 (C2” and C7”), 28.85 (C3” and C6”), 28.10 (C4” and C5”). HRESI-
MS m/z (M + H)+: Calc. 356.1947, Obs. 356.1944. Anal-HPLC (70:30 A:B100% B over 30 




The compound was prepared using the General Method (3 h 
reaction time) with methyl 3-amino-5-(azepan-1-yl)-6-(2-
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methoxypyrimidin-5-yl)pyrazine-2-carboxylate 49a (111 mg, 3.09x10-4 mol). The residue was 
taken up in solvent A:B (2 mL) and purified by preparative HPLC (70:30 A:B100% B over 30 
min). Collected fractions containing purified product were pooled concentrated via freeze 
drying to yield 49 as a yellow solid (HCl salt, 64 mg, 49% yield after IEX) MP 148-150°C; 1H 
NMR (500 MHz, CDCl3) δ 10.76 (Guanidine NH), 9.27 (s, 2H, Guanidine NH2), 8.51 (s, 2H, 
ArH2” and ArH6”), 8.48 (s, 2H, Guanidine NH2), 4.08 (s, 3H, p-methoxyCH3), 3.35 (t, J = 5.75 
Hz, 4H, C2’H2 and C7’H2), 1.66 (s, 4H, C3’H2 and C6’ H2), 1.46 (s, 4H, C4’H2 and C5’ H2)
 13C 
NMR (126 MHz, CDCl3) δ 166.62 (Amide C=O), 163.99 (ArC4”), 161.93 (Guanidine C), 157.84 
(ArC2” and ArC6”), 156.07 (ArC5), 153.87 (ArC3), 127.83 (ArC6), 124.71 (ArC1”), 112.51 
(ArC2), 55.59 (p-methoxyCH3), 51.59 (C2’ and C7’), 27.76 (C3’ and C6’), 27.13 (C4’ and 
C5’).HRESI-MS m/z (M + H)+: Calc. 386.2076, Obs. 386.2080. Anal-HPLC (70:30 A:B100% B 




The compound was prepared using  the General Method (3 h 
reaction time) with methyl 3-amino-5-(azepan-1-yl)-6-(2,4-
dimethoxypyrimidin-5-yl)pyrazine-2-carboxylate 50a (104 mg, 
2.67x10-4 mol). The residue was taken up in solvent A:B (2 mL) and purified by preparative 
HPLC (70:30 A:B100% B over 30 min). Collected fractions containing purified product were 
pooled concentrated via freeze drying to yield 50 as a yellow solid (HCl salt, 65 mg, 54% yield 
after IEX) MP 184-186°C; 1H NMR (500 MHz, CD3OD) δ 10.46 (s, exchange with solvent, 
Amide NH), 8.79 (s, exchange with solvent, Guanidine NH2), 8.45 (s, 1H, ArC6”), 8.22 (s, 
exchange with solvent, Guanidine NH2), 4.06 (s, 3H, p-methoxyCH3), 4.00 (s, 3H, o-
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methoxyCH3), 3.60 (bs, 2H, C2’ H2 and C7’ H2), 3.41 (s, 2H, C2’ H2 and C7’ H2), 1.64 (s, 2H, C3’ 
H2 and C6’ H2), 1.51 (s, 2H, C4’ H2 and C5’ H2) 
13C NMR (126 MHz, CDCl3) δ 168.25 (Amide 
C=O), 166.45 (ArC4”), 164.14 (ArC2”), 156.81 (ArC6”), 155.89 (ArC5), 153.92 (ArC3), 123.28 
(ArC6), 111.40 (ArC2), 108.06 (ArC1”), 55.36 (p-methoxyCH3), 54.56 (o-methoxyCH3), 50.22 
(C2’ and C7’), 27.84 (C3’ and C6’), 26.93 (C4’ and C5’) HRESI-MS m/z (M + H)+: Calc. 416.2159, 




The compound was prepared using the General Method (3 h 
reaction time) with methyl 3-amino-5-(azepan-1-yl)-6-(2,6-
dimethoxypyridin-3-yl)pyrazine-2-carboxylate 51a (98 mg, 
2.53x10-4 mol). The residue was taken up in solvent A:B (2 mL) and purified by preparative 
HPLC (70:30 A:B100% B over 30 min). Collected fractions containing purified product were 
pooled and concentrated via freeze drying to yield 51 as a yellow solid (HCl salt, 15 mg, 13% 
yield after IEX); MP: 152-154° C; 1H NMR (500 MHz, CDCl3) δ 10.28 (s, 1H, Guanidine NH), 
8.77 (s, 2H, Guanidine NH2), 8.14 (s, 2H, Guanidine NH2), 7.61 (d, J = 8.0 Hz, 1H, ArH5”), 6.39 
(d, J = 8.0 Hz, 1H, ArH4”), 3.94 (s, 3H, p-methoxyCH3), 3.87 (s, 3H, o-methoxyCH3), 3.52 (s, 
2H, C2’ CH2 and C7’ CH2), 3.35 (s, 2H, C2’ CH2 and C7’ CH2), 1.60 (s, 4H, C3’ CH2 and C6’ CH2), 
1.51 (s, 2H, C4’ CH2 and C5’ CH2), 1.44 (s, 2H, C4’ CH2 and C5’ CH2). 
13C NMR (126 MHz, 
CDCl3) δ 166.00 (Amide C=O), 163.16 (ArC6”), 160.10 (Guanidine C), 159.19 (ArC2”), 155.44 
(ArC5), 153.54 (ArC3), 141.10 (ArC4”), 127.98 (ArC6), 114.64 (ArC3”), 110.19 (ArC2), 101.28 
(ArC5”), 53.82 (o-methoxyCH3), 53.54 (p-methoxyCH3), 50.39 (C2’ and C7’), 27.65 (C3’ and 
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C6’), 26.81 (C4’ and C5’). HRESI-MS (M + H): Calc 415.2206, Obs. 415.2191. Anal-HPLC (70:30 




The compound was prepared using  the General Method (2.5 h 
reaction time) with methyl 3-amino-5-(azepan-1-yl)-6-(2-
fluoropyridin-3-yl)pyrazine-2-carboxylate 52a (100 mg, 2.90x10-4 
mol). The residue was taken up in 70:30 solvent A:B (2 mL) and purified by preparative HPLC 
(70:30 A:B100% B over 30 min). Collected fractions containing purified product were 
pooled concentrated via freeze drying to yield 52 as a bright yellow solid (TFA salt, 18 mg, 
13% yield after HPLC); MP: 1H NMR (500 MHz, CDCl3) δ 10.42 (s, 1H, Amide NH), 8.59 (bs, 4H, 
2x Guanidine NH2), 8.17 (m, 2H, ArH4” and ArH6”) 7.29 (t, J = 5.4 Hz, 1H, ArH5”) 5.13 (bs, 2H, 
Ar3NH2), 3.38 (s, 4H, C2’H2 and C7’H2), 1.64 (s, 4H, C3’H2 and C6’H2), 1.47 (s, 4H, C4’H2 and 
C5’H2). 
13C NMR (126 MHz, CDCl3) δ 166.45 (Amide C=O), 160.67 (ArC2”), 155.98 (ArC5), 
155.90 (Guanidine C), 154.01 (ArC3), 146.91 (ArC6”), 141.41 (ArC4”), 124.19 (ArC5”), 123.41 
(ArC6), 122.45 (ArC3”), 111.79 (ArC2), 50.40 (C2’ and C7’), 27.86 (C3’ and C6’), 27.16 (C4’ and 
C5’). HRESI-MS m/z (M + H)+ 355: Calc. 373.1901, Obs. 373.1916. Anal-HPLC (70:30 








The compound was prepared using the General Method (3 h 
reaction time) with methyl 3-amino-5-(azepan-1-yl)-6-(2,4-
dimethoxyphenyl)pyrazine-2-carboxylate 53a (123 mg, 3.17x10-4 
mol). The residue was taken up in solvent A:B (2 mL) and purified by preparative HPLC (70:30 
A:B100% B over 30 min). Collected fractions containing purified product were pooled 
concentrated via freeze drying to yield 53 as a yellow solid (HCl salt, 12 mg, 8.1% yield after 
IEX) MP 156-158°C; 1H NMR (500 MHz, CDCl3) δ 10.19 (s, 1H, Amide NH), 9.10 (bs, 2H, 
Guanidine NH2), 7.79 (bs, 2H, Guanidine NH2), 7.23 (d, J = 8.3 Hz, 1H, ArH2”), 6.58 (dd, J = 8.3 
Hz, J = 2.1 Hz 1H, ArH3”), 6.48 (d, J = 2.1 Hz, 1H, ArH5”) 3.86 (s, 3H, p-methoxyCH3), 3.74 (s, 
3H, o-methoxyCH3), 3.51 (s, 2H, C2’ H2 and C7’ H2), 3.36 (s, 2H, C2’ H2 and C7’ H2), 1.59 (s, 
4H, C3’ H2 and C6’ H2), 1.50 (s, 2H, C4’ H2 and C5’ H2), 1.45 (s, 2H, C4’ H2 and C5’ H2)
 13C NMR 
(126 MHz, CDCl3)
 13C NMR (126 MHz, CDCl3) δ 165.95 (Amide C=O), 161.54 (ArC4”), 157.83 
(ArC2”), 155.71 (Guanidine C), 155.40 (ArC5), 153.75 (ArC3), 130.62 (ArC6”), 129.59 (ArC1”), 
122.11 (ArC6), 109.78 (ArC2), 104.99 (ArC5”), 98.72 (ArC3”), 55.67 (p-methoxyCH3), 55.64 
(m-methoxyCH3), 50.62 (C2’ and C7’), 27.81 (C3’ and C6’), 26.93 (C4’ and C5’). HRESI-MS m/z 









The compound was prepared using the General Method (3 h 
reaction time) with methyl 3-amino-5-(azepan-1-yl)-6-(3,5-
dimethoxyphenyl)pyrazine-2-carboxylate 54a (147 mg, 3.81x10-
4 mol). The residue was taken up in solvent A:B (2 mL) and purified by preparative HPLC 
(70:30 A:B100% B over 30 min). Collected fractions containing purified product were 
pooled concentrated via freeze drying to yield 54 as a yellow solid (HCl salt, 44 mg, 26% yield 
after IEX) MP 138-140°C; 1H NMR (500 MHz, CDCl3) δ 10.75 (s, 1H, Amide NH), 8.81 (bs, 2H, 
Guanidine NH2), 8.60 (bs, 2H, Guanidine NH2), 6.73 (d, J = 2.2 Hz, 2H, ArH2” and ArH6”), 6.58 
(t, J = 2.2 Hz, 1H, ArH4”), 3.84 (s, 6H, m-methoxyCH3), 3.38 (s, 2H, C2’ H2 and C7’ H2), 1.64 (s, 
4H, C3’ H2 and C6’ H2), 1.45 (s, 2H, C4’ H2 and C5’ H2).
 13C NMR (126 MHz, CDCl3)
 13C NMR 
(126 MHz, CDCl3) δ 167.04 (Amide C=O), 160.96 (ArC3” and 5”), 156.35 (Guanidine C), 155.60 
(ArC5), 153.77 (ArC3), 141.64 (ArC1”), 132.92 (ArC6), 110.93 (ArC2), 106.46 (ArC2” and C6”), 
100.28 (ArC4”), 55.92 (m-methoxyCH3), 50.99 (C2’ and C7’), 27.95 (C3’ and C6’), 27.12 (C4’ 
and C5’). HRESI-MS m/z (M + H)+: Calc. 414.2254, Obs. 414.2244. Anal-HPLC (70:30 




The compound was prepared using the General Method (3 h 
reaction time) with methyl 3-amino-5-(azepan-1-yl)-6-(3,6-
dimethoxypyridazin-4-yl)pyrazine-2-carboxylate 55a (94 mg, 
2.43x10-4 mol). The residue was taken up in anhydrous DMSO (2 mL) and purified by 
preparative HPLC (100% A100% solvent B over 30 min). Collected fractions containing 
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purified product were pooled concentrated via freeze drying to yield 55 as a bright yellow 
solid (TFA salt, 21 mg, 17% yield after HPLC); MP 202-204°C; 1H NMR (500 MHz, CD3OD) δ 
10.38 (s, exchange with solvent, Amide NH), 8.77 (s, exchange with solvent, Guanidine NH2), 
8.21 (s, exchange with solvent, Guanidine NH2), 7.35 (s, 1H, ArH2”), 4.06 (s, 3H, o-
methoxyCH3), 3.99 (s, 3H, m-methoxyCH3), 3.35 (s, 4H, C2’ H2 and C7’ H2) 1.66 (s, 4H, C3’ H2 
and C6’ H2) , 1.55 (s, 2H, C4’ H2 and C5’ H2), 1.45 (s, 2H, C4’ H2 and C5’ H2). 
13C NMR (126 
MHz, CD3OD) δ 167.31 (Amide C=O), 164.10 (ArC3”), 160.89 (ArC6”), 156.90 (Guanidine C), 
156.75 (ArC5), 156.10 (ArC3), 136.33 (ArC1”), 123.95 (ArC6), 121.38 (ArC2”), 112.19 (ArC2), 
55.44 (o-methoxyCH3), 55.26 (m-methoxyCH3), 50.98 (C2” and C7”), 28.89 (C3” and C6”), 
27.92 (C4” and C5”). HRESI-MS m/z (M + H)+: Calc. 416.2159, Obs. 416.2150. Anal-HPLC 
(100% A100% solvent B over 30 min, tr =19.0 min). 
 
3-amino-5-(azepan-1-yl)-N-carbamimidoyl-6-(phenylethynyl)pyrazine-2-carboxamide (56) 
The compound was prepared using the General Method (1 h 
reaction time) with methyl 3-amino-5-(azepan-1-yl)-6-
(phenylethynyl)pyrazine-2-carboxylate 56a (54 mg, 1.42x10-4 
mol). The residue was taken up in solvent A:B (2 mL) and 
purified by preparative HPLC (70:30 A:B100% B over 30 min). Collected fractions 
containing purified product were pooled concentrated via freeze drying to yield 56 as a 
brown solid (TFA salt, 9.1 mg, 14% yield after HPLC) MP -°C; 1H NMR (500 MHz, CD3OD) δ 
7.51 (m, 2H, ArH2” and ArH6”), 7.39 (m, 3H, ArH3”, ArH4” and ArH5”), 4.07 (t, J = 5.75 Hz, 
4H, C2’H2 and C7’H2), 1.88 (s, 4H, C3’H2 and C6’ H2), 1.60 (s, 4H, C4’H2 and C5’ H2).
 13C NMR 
(126 MHz, CD3OD) δ 166.82 (Amide C=O), 156.97 (Guanidine C) 156.88 (ArC5), 155.57 (ArC3), 
132.20 (ArC4”), 129.96 (ArC3” and ArC5”), 129.76 (ArC2” and ArC6”), 123.92 (ArC1”), 114.13 
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(ArC2), 112.93 (ArC6), 91.45 (C7), 89.29 (C8), 51.66 (C2’ and C7’), 29.55 (C3’ and C6’), 27.62 
(C4’ and C5’); HRESI-MS m/z (M + H)+: Calc. 378.2037, Obs. 378.2042. Anal-HPLC (70:30 
A:B100% B over 30 min, tr =28.6 min). 
 
7.3 Biology Experimental 
 
Cell culture conditions 
 
Human skin-derived telomerase-immortalized fibroblasts (TIFs) were sourced from Dr. Paul 
Timpson and the Kinghorne Cancer Centre, Sydney, NSW, Australia. All other cells used were 
subcultured from ATCC certified cell lines. SKOV-3 human ovarian adenocarcinoma, MDA-
MB-231 human breast adenocarcinoma, HEK-293 human embryonic kidney and RAW 264.7 
murine Abelson murine leukemia virus induced macrophage and U-937 human histiocytic 
lymphoma cells cell lines were cultured at 37° C, 95% humidity and 5% (v/v) CO2 in a 
ThermoScientific Heracell 150i CO2 incubator (ThermoScientific). ATCC cell lines were 
maintained in RPMI 1640 media supplemented with 5% (v/v) heat-inactivated FBS unless 
otherwise stated (Sigma-Aldrich, St. Louis, MI, USA). TIFs were maintained in Dulbecco’s 
modified Eagle’s medium (DMEM) supplemented with 10% heat-inactivated FBS. Adherent 
cells were passaged via the addition of trypsin/0.05% EDTA solution (GIBCO), followed by 
centrifugation and resuspension in fresh media using a 5 mL Luerlock syringe fitted with an 
18-gauge drawing-up needle (Terumo, Tokyo, Japan). U-937 cells were detached from cell 
culture flasks via mechanical agitation in the absence of trypsin/EDTA detachment solution 
prior to harvest. Haemocytometery with Trypan Blue staining was used to determine the 
concentration of live suspended cells and to ensure a single cell suspension had been 
achieved. Cells were passaged weekly and media changed every 2-3 days. Testing for the 
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presence of mycoplasma was routinely performed using a MycoAlert™ Mycoplasma Test Kit 
(Lonza Group, Basel, Switzerland). No mycoplasma contaminations were detected. All 
experiments were conducted on cells with a passage number lower than 20. 
 
Statistical analysis  
Significance testing was performed using the unpaired parametric t-test function in 
GraphPad PRISM v6.0 (GraphPad Software, San Diego, California, USA). Level of significance 
was denoted as follows: * = p < 0.05, ** = p < 0.02, *** = p < 0.005. Correlation analysis was 
performed using the linear regression function in GraphPad PRISM v6.0. 
 
CellTitre 96® Aqueous One Solution Cell Proliferation Assay (MTS) assay 
Sub-confluent cells (~ 70-80% confluent) were harvested and counted and dissociated into a 
single cell suspension as described above. Cells were seeded at a density of 5000 cells/well 
(final volume 90 L) into a Greiner CELLSTAR® 96-well plate (Greiner Bio-One GmBH, 
Kremsmünster, Austria) via multichannel pipette and incubated for 18h prior to the addition 
of compounds. Compounds were serially diluted from 20-50 mM DMSO stocks in RPMI 1640 
media containing 5% v/v heat inactivated FBS in a separate 96-well plate under sterile 
conditions to give 10x stocks (10 nM-1 mM) on the day of compound addition. 10 L of the 
10x compound/media stocks or matched vehicle/media solutions (for vehicle controls) were 
then transferred via multichannel pipette into the assay plate containing 90 L cell 
suspension via multichannel pipette to give the treated assay plate at the final 1X drug 
concentrations (1 nM-100  M, n = 4 wells at each concentration). Relevant drug blanks or 
vehicle media blanks were included at each concentration to correct for the intrinsic colour 
of the compounds and of the Phenol Red containing media. 200 L media was added to 
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wells A1-12 and H1-12 to decrease evaporation and were not used in the assay itself. 
Compound-treated plates were incubated for 48h prior to development. After 48h 
treatment time, plates were removed from the incubator and 20 L CellTitre 96® Aqueous 
One Solution Cell Proliferation Assay (Cat # G3581, Promega Corporation, Fitchburg, 
Wisconsin, USA) was added to each well. Plates were incubated for a further 2h prior to 
reading at 490 nm using a SpectraMax Plus 384-well plate reader (Molecular Devices LLC, 
Sunnyvale, California, USA). Blank subtracted data was analyzed and graphed using 
GraphPad PRISM v6.0 (GraphPad Software, San Diego, California, USA). 
 
Cytotoxicity Detection Kit(PLUS) (LDH) Assay 
 
Assay and compound dilution plates were prepared as described in Section 7.3 After 48h 
treatment time assay plates were removed from the incubator and 5 L of Lysis solution 
(Bottle 3) of the Roche Cytotoxicity Detection Kit(PLUS) (LDH) (Roche Diagnostics Australia Pty. 
Ltd., NSW, Australia), was added to cell lysis controls. The plate was gently mixed by hand in 
a circular motion atop a bench (similar to the manner one might wax a car) for 30 s and 
incubated for a further 15 min. During this period 2.5 L Catalyst solution (Bottle 1) was 
added to 112.5 L Dye solution (Bottle 2) to form Reaction mixture for each well to be 
assayed. The plate was removed from the incubator and 100 L Reaction mixture added to 
each well. The plate was then wrapped in aluminium foil and incubated for 30 min. After 30 
min 50 L Stop solution was added to each well and read at 490 nm using a SpectraMax Plus 
384-well plate reader (Molecular Devices LLC, Sunnyvale, California, USA). Blank subtracted 




Apo-ONE® Homogeneous Caspase-3/7 Assay 
  
HEK-293 cells were harvested as described in Section x.xx and seeded into a black Greiner 
CELLSTAR® 96-well plate (Cat # 655079, Greiner Bio-One GmBH, Kremsmünster, Austria) at a 
density of 5000 cells/well in a volume of 40 L RPMI 1640 media with incubation for 18h. On 
day of treatment 5x compound stocks in 5%DMSO/media were prepared in a separate 96-
well plate under sterile conditions. 10 L of each 5x compound stock was added to 40 L of 
cell suspension on assay plate to give 1X compound dilutions in 1% v/v DMSO (1-30 M) and 
the plate incubated for 5 h (time sufficient to trigger detectable induction of apoptosis 
according to manufacturer’s instructions). Using the Apo-ONE® Homogeneous Caspase-3/7 
Assay Kit (Cat # G7790, Promega Corporation, Fitchburg, Wisconsin, USA) 30 L of Z-DEVD-
R110 Caspase substrate was diluted into 2970 L Assay buffer and 50 L of the mixture 
added to each assay well and the plate shaken using a plate shaker at 300 rpm for 2 h 
followed by reading using a POLARstar OMEGA Fluorescence Plate reader (BMG-Labtech 
GmBH, Ortenberg, Germany) ex. 480 nm, em 520 nm. Blank subtracted data was analyzed 
and graphed using GraphPad PRISM v6.0 (GraphPad Software, San Diego, California, USA). 
 
Solution-phase uPA inhibition assay 
Urokinase from human kidney cells (Cat # U4010, Sigma-Aldrich, St. Louis, MI, USA) was 
diluted to 900 nM, aliquoted and stored at -80 C until thawed for use in a series of 
experiments (typically 4-5 plates assayed on the same day). Thawed enzyme stocks were 
maintained at -20 C between each respective assay using a Nalgene Labtop Cooler Jr (Cat# 
5115-0012, Thermo-Fisher Scientific, Waltham, Massachusetts, USA). A 5 mM stock solution 
of Urokinase fluorescent substrate III (Z-Gly-Gly-Arg-AMC, Calbiochem Cat # 672159, Merck 
Millipore, Massachusetts, USA) was prepared in dH2O/10% DMSO and aliquoted with 
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storage at -20 C. Assay buffer (20 mM HEPES (pH 7.4), 100 mM NaCl, 0.5 mM EDTA, 0.01% 
v/v Tween-20) was prepared and used within 7 days of preparation with storage at 4 C.  
On the day of experimentation compound stocks (20-50 mM in anhydrous DMSO) were 
serially diluted in assay buffer in a clear Greiner CELLSTAR® 96-well plate on ice (Greiner Bio-
One GmBH, Kremsmünster, Austria) to give each dilution at 2X the final assayed 
concentration. In a separate black Greiner CELLSTAR® 96-well plate (Greiner Bio-One GmBH, 
Kremsmünster, Austria) residual volumes of assay buffer were added via multichannel 
pipette to compound fluorescence blanks and inhibited enzyme control wells as appropriate. 
Next 90 L of dilute fluor (250 M final) was added to all wells, followed by 100 L of 2x 
compound dilution to appropriate wells. Immediately prior to assay 900 nM uPA stock was 
diluted to 15 nM and 10 L of this dilution was added to all relevant wells, initiating 
reaction. Reaction progress was monitored using a POLARStar OMEGA fluorescence plate 
reader (Fluorescence intensity mode, top-optic, ex. 355 nM em. 450 nM, 20 flashes per well, 
double orbital shaking for 3s prior to every read, cycle time 60 s, 45-60 cycles, incubation at 
37 C, BMG-Labtech, Ortenberg, Germany). Blank subtracted data was analyzed and graphed 
using GraphPad PRISM v6.0 (GraphPad Software, San Diego, California, USA). 
 
Chromogenic Trypsin-like serine protease activity experiments 
For experiments using uPA (Cat # U4010, Sigma-Aldrich, St. Louis, MI, USA), trypsin, tPA, 
thrombin and plasmin (all from Marker Gene Technologies Inc., Eugene, OR, USA) 
concentrated stocks were prepared in dH2O and stored at -80 C until thawed for use. 
Thawed enzyme stocks were maintained at -20 C between each respective assay using a 
Nalgene Labtop Cooler Jr (Cat# 5115-0012, Thermo-Fisher Scientific, Waltham, 
Massachusetts, USA). A 312.5 M stock solution of S-2288 chromogenic substrate 2288 (D-
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Ile-L-Pro-l-Arg-p-nitoraniline, Chromogenix, Massachusettes, USA) was prepared in dH2O and 
aliquoted with storage at -20 C. Assay buffer (10 mM HEPES, 150 mM NaCl, 0.01% v/v 
Tween-20, pH 7.4) was prepared and used within 7 days of preparation with storage at 4 C. 
On the day of experimentation compound stocks (20-50 mM in anhydrous DMSO) were 
serially diluted in assay buffer in a clear Greiner CELLSTAR® 96-well plate on ice (Greiner Bio-
One GmBH, Kremsmünster, Austria) to give each dilution at 10X the final assayed 
concentration. In a separate Greiner CELLSTAR® 96-well plate (Greiner Bio-One GmBH, 
Kremsmünster, Austria) residual volumes of assay buffer were added via multichannel 
pipette to compound fluorescence blanks and inhibited enzyme control wells as appropriate. 
Next 80 L of dilute fluor (250 M final) was added to all wells, followed by 10 L of 10x 
compound dilution to appropriate wells. Immediately prior to assay concentrated enzyme 
stocks were diluted to 100 nM and 10 L of this dilution was added to all relevant wells, 
initiating reaction. DMSO was present at a final concentration of 1% v/v. Change in 
absorbance overtime at 405 nm was measured at 37°C using a Molecular Devices 
SpectraMax Plus 384-well plate reader (Molecular Devices LLC, Sunnyvale, California, USA). 
IC50 values were determined by plotting percentage of residual activity (V0) versus log drug 
concentration and fitted to a sigmoidal dose response curve using GraphPad Prism v.6.0 
(GraphPad Software, La Jolla, CA, USA). 
 
For experiments using Human Plasma Kallikrein, Factor Xa, Factor XIa, Activated Protein C or 
uPA H99Y the chromogenic substrates S-2366 (pyroGlu-Pro-Arg-pNA) Human Plasma 
Kallikrein, Factor XIa and Activated Protein C), S-2288 (H-D-Ile-Pro-Arg-pNA, Factor Xia) or S-
2444 (pyroGlu-Gly-Arg-pNA, uPA H99Y) were used (all substrates sourced from 
Chromogenix, Massachusettes, USA). All enzymes were sourced from Marker Gene 
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Technologies, Inc., Eugene, OR, USA. Enzymes were used at the following final 
concentrations: Human Plasma Kallikrein 23.5 nM, Factor Xa 10 nM, Activated Protein C 10 
nM, Factor Xia 2 nM and uPA H99Y 2 nM. Concentrated enzyme stocks were prepared in 
dH2O and stored at -80 C until thawed for use. Experiments were conducted as described 
above for experiments using other trypsin-like serine proteases. DMSO was present at a final 
concentration of 1% v/v. Change in absorbance overtime at 405 nm was measured at 37°C 
using a BioTek Synergy 4 384-well plate reader (BioTek Instruments Inc., Winooski, Vermont, 
USA). IC50 values were determined by plotting percentage of residual activity (V0) versus log 
drug concentration and fitted to a sigmoidal dose response curve using GraphPad Prism 
v.6.0 (GraphPad Software, La Jolla, CA, USA). 
 
Determination of inhibitory constant values (Ki) 
Urokinase substrate III (Fluorogenic) (Cat #672159 - Merck Millipore, Merck KgaA, 
Darmstadt, Germany) was serially diluted in HEPES assay buffer (20 mM HEPES, 100 mM 
NaCl, 0.5 mM EDTA, 0.01% (v/v) Tween-20, pH 7.6) to give final concentrations between 2.0 
M and 250 M. 200x inhibitor stocks in DMSO were diluted 1 in 100 into HEPES assay 
buffer to yield a 2x working stock in 1% DMSO.  The diluted substrate was added to a 
Greiner CELLSTAR black 96-well microtitre plate (Cat. # M9936, Greiner Bio-One GmbH, 
Kremsmünster, Austria), followed by addition of 2x working stock drug dilutions or 
equivalent volumes of assay buffer for controls such that all wells contained 200 L solution, 
0.5% DMSO v/v.  The assay plate was allowed cool on a bed of ice and Urokinase from 
human kidney cells (Cat # U4010, Sigma-Aldrich, St. Louis, MI, USA) from a 900 nM stock was 
diluted in cold assay buffer to give a concentration of 15 nM.  10 L of 15 nM enzyme stock 
was added to appropriate wells (final enzyme concentration = 0.75 nM) and the plate 
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immediately read at ex. 355 nm, em. 460 nm using a BMG Labtech POLARStar Omega 
Fluorescence Plate Reader (BMG Labtech, Ortenberg, Germany), cycle time 60 s, 45-60 
cycles, 3s orbital shaking before each read).  Blank subtracted data from the linear portion of 
the kinetic curve was used to determine initial velocity and data plotted using GraphPad 
PRISM v6.0 (GraphPad Software, La Jolla, California, USA).  Data was fitted using the 
‘competitive inhibition’ function to determine Ki for each inhibitor. 
 
xCELLigence Cell Index Assay 
Sub-confluent cells (~ 70-80% confluent) were harvested and counted and dissociated into a 
single cell suspension as described above. Cells were seeded at a density of 5000 cells/well  
(final volume 180 L, RPMI 1640 + 10% FCS) into a ACEA Biosciences E-16 plate (Roche 
Diagnostics Australia Pty. Ltd., NSW, Australia) and incubated for 18 h prior to 
experimentation. On the day of experimentation the xCELLigence RTCA DP was allowed to 
equilibrate at 37° C, 95% humidity and 5% (v/v) CO2 in a ThermoScientific Heracell 150i CO2 
incubator (ThermoScientific). Using the ‘plate scan’ program within the xCELLigence 
software package, the impendence of the cells was monitored for 24 h. The next day 10x 
drug dilutions were prepared in a Greiner CELLSTAR® 96-well plate (Greiner Bio-One GmBH, 
Kremsmünster, Austria). After 24 h the cell plate was removed from the xCelligence system 
and 10x drug dilutions added to give the desried final concentrations in a total volume of 
200  L (1% DMSO v/v final). Impedence was measured for 48 h following addition of drugs. 
Data was analyzed in the RTCA 2.0 v3.4 software package and graphed using GraphPad 





Incucyte ZOOM Live-Cell Analysis System (Essen Bio Science, Inc., Ann Arbor, MI, USA) was 
maintained in at 37° C, 95% humidity and 5% (v/v) CO2 in a ThermoScientific Heracell 150i 
CO2 incubator (ThermoScientific) throughout the course of all experiments. Sub-confluent 
cells (~ 70-80% confluent) were harvested and counted and dissociated into a single cell 
suspension as described above. Cells were seeded at a density of 5000 cells/well (final 
volume 90 L) into a Greiner CELLSTAR® 96-well plate (Greiner Bio-One GmBH, 
Kremsmünster, Austria) via multichannel pipette and incubated for 18h prior to the addition 
of compounds. On the day of drug addition compound dilutions were prepared and added to 
plates as described above for MTS assays. Images were acquired every 2 h for ~ 52 h 
following the addition of comounds using a 10x objective. Cell confluency for each image 
was calculated using the cell confluence processing definition inside the IncuCyte ZOOM 
software package v.2016A. Cell confluence masks were optimized using representative 
images to exclude cell debris and accurately measure cell area. Data from all images was 
normalized to an initial image taken of the same well immediately prior to drug addition. 
Data was exported from IncuCyte ZOOM and graphed using using GraphPad Prism v.6.0 
(GraphPad Software, La Jolla, CA, USA). All treatments were conducted in triplicate with a 
single image taken from each well at each time point.  
 
Organotypic cell invasion assay 
Tendons from excess deceased laboratory rats were surgically removed after washing in 70% 
v/v ethanol/water solution. Isolated tendons were frozen at -80C and mashed using a glass 
rod prior to dissolution of collagen I in 1500 mL 0.5 M Acetic acid at 4C for 48 h with 
magnetic stirring. Extracted collagen was filtered through wet household paper towel to 
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remove any remaining sheath. The extract was centrifuged at 10,000 rpm at 4C for 1 h and 
the pellet discarded. Sufficient NaCl was added to the supernatant to form a 10% w/v NaCl 
solution in a 2 L conical flask with excess NaCl added until the solution exhibited a persisting 
white colour and no longer separated upon standing. The solution was centrifuged at 10,00 
rpm at 4C for 30 min and supernatant discarded. The precipitate was dissolved in 0.25 M 
acetic acid at a 1:1 ratio for 24 h at 4C with magnetic stirring. The resulting collagen 
solution was dialyzed against 6-8 changes of 5 L 0. 17.4 mM acetic acid with changes 
occurring twice daily. Dialyzed collagen was centrifuged at 20,000 rpm at 4C for 1.5 h. 
Isolated collagen I was adjusted to a concentration of 2.0 mg/mL for use. Purity of extracted 
collagen I was verified by SDS-PAGE. Human skin-derived telomerase-immortalized 
fibroblasts were maintained in culture for 4-14 days post-confluency without changing of 
media prior to harvesting to ensure quiescence. On day of collagen I seeding a collagen I 
matrix solution was prepared by adding 3 mL 10x MEM solution to 25 mL collagen I solution 
along with 3 mL 0.22 M NaOH and subsequent dropwise addition of NaOH until a pH of ~ 7.4 
was achieved as determined by colour change of internal Phenol Red indicator. Harvested 
Fibroblasts were resuspended in 3 mL FBS and seeded at a density of 1.0x106 cells/12 
matrices into the neutralized collagen I matrix solution and 2.5 mL aliquoted into separate 
sterile 35 mm sterile cell culture dishes, followed by. After ~ 30 min ~ 2 mL fibroblast growth 
medium (DMEM/10% FBS/1xPenstrep) was added to and nascent collagen I/fibroblast 
matrices were manually detached from the sides of each dish using a sterile pipette tip with 
rotation of each dish. Matrices were allowed to contract for 8-12 days until they had 
reached a diameter of ~ 20 mm. Following contraction matrices were transferred using 
tweezers to a sterile 24-well cell culture plate. Harvested SKOV-3 ovarian adenocarcinoma 
cells were seeded with a volume of 100 L of cell suspension at a density of 1x106 cells/mL. 
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Seeded plugs were transferred to sterile steel mesh grids in 60 mm cell culture dishes (3 
plugs per grid, 1 grid/treatment group per 60 mm dish) and ~ 10 mL media added such that 
an air liquid interface was established with the bottom of the plug (as growth media diffuses 
from the bottom of the plug towards the top a chemotactic gradient is established, inducing 
epithelial cells seeded atop to invade downwards through the collagen matrix towards the 
bulk growth media). On day of initial drug treatment, culture media was removed from each 
dish and ~ 10 mL of the appropriate drug treatment/vehicle control was added to establish 
an air-liquid interface as described above. After 21 days invasion time plugs were fixed in 4% 
neutral buffered formalin for 24-48h. Fixed samples were processed using a Peloris Dual 
Retort tissue processor (Leica, Germany). Histological staining was conducted on 4 m 
sections deparfinized in xylene and rehydrated via graded washing in ethanol (70% v/v 
ethanol/water-100% ethanol). Cytokeratin staining was performed using an Autostainer XL 
(Leica, Germany). Ten images per treatment group were acquired using a DM4000 bright 
field microscope (Leica, Germany) and analyzed for epithelial cell invasive index where 
invasive index is defined as: (# epithelial cells invaded into collagen plug/ # epithelial cells 
forming contiguous monolayer along top of the plug) x100. Scores for each image were 
collated and statistical analysis performed using Microsoft Excel for Mac 2011 v.14.1.0. 








Whole cell fluorescent membrane potential dye assay for the determination of ENaC 
inhibition 
 
HEK-293 Cells were cultured in Dulbecco’s Modified Eagle Medium/Nutrient Mixture F-12 
(D-MEM/F-12) supplemented with 10% fetal bovine serum, 100 U/mL penicillin G sodium, 
100 g/mL streptomycin sulfate and appropriate selection antibiotics. Semiconfluent cells 
were transfected with cDNA for ENaC ,  and  subunits (genes SCNN1A, SCNN1B and 
SCNN1G) prior to experimentation. Cells were plated at a density of 20,000 cells/well in a 
384-well black wall, flat clear bottom microtiter plates (Type: BD Biocoat Poly-D-Lysine 
Multiwell Cell Culture Plate) and incubated at 37 ºC overnight. Following manufacturer 
instructions, cells were loaded with 20 µl of membrane potential dye solution for 30 min at 
37 C from the FLIPR Membrane Potential Red Dye Fluorescence Assay Kit (Molecular 
Devices, Sunnyvale, California, USA). This assay allows the fluorometric detection of changes 
in membrane potential following modulation of transmembrane ion channel/exchanger 
activity, namely antagonism of stimulated ENaC activity in this case. Drug, vehicle and 
control solutions were prepared from frozen stocks in DMSO on the day of experimentation 
through dilution into HEPES-buffered physiological salt solution (NaCl 137 mM, KCl 4 mM, 
CaCl2 1.8 mM, MgCl2 1 mM, HEPES 10 mM, Glucose 10 mM, DMSO 0.3% v/v, pH 7.4) in a 
384-well microtiter plate ready for addition to the assay plate by the FLIPRTETRA instrument. 
All amiloride analogues were tested at 8 concentrations (n = 4 wells at each concentration). 
Positive control cells were stimulated with 1 µM S-3969 (ENaC agonist, n = 4 wells). Negative 
control cells were first stimulated with 1 µM S-3969 and then treated with 30 µM benzamil 
(potent ENaC antagonist, n = 4 wells). Following dye loading cells were preincubated with 5 
µl drug, vehicle or control solutions for 5 min. Next 5 µl of S-3939 solution (final [S-3969] = 1 
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µM) was added to stimulate ENaC activity. All data was normalized to agonist-treated 
positive and antagonist-treated negative controls such that agonist-treated signal equaled 
100% activity and antagonist-treated signal equaled 0% activity. Normalized data was used 
to determine IC50 values for each amiloride analogue using the log[inhibitor]-normalized 
response variable slope algorithm in GraphPad PRISM v6.0 (GraphPad Software, La Jolla, 
California, USA). This experiment was performed under contract by Charles River 
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Chapter 9: Appendix 
 
Appendix  9.1: Data collection and refinement statistics of Human uPA in complex with 5-(N,N-hexamethylene)amiloride (HMA) and novel 6- 
HMA analogues. Statistics for the highest resolution shell are shown in parentheses. 
          
Data set HMA 38 42 47 46 48 43 49 50 
































34.8  - 
1.7 (1.76 
- 1.70) 
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(1.97 - 
1.90) 








23.92  - 
1.73 (1.79 
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60.35  - 
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   Bonds (Å) 0.101 0.013 0.022 0.010 0.017 0.018 0.027 0.015 0.017 
   Angles () 3.17 1.51 1.77 1.43 1.87 1.45 1.58 1.62 1.72 
          
Average B factors  
(Å2) 
         
   Protein 29.50 33.70 28.10 27.40 26.50 37.70 37.90 66.40 25.10 
   Ligands 29.60 37.20 31.10 28.20 28.70 38.60 36.20 83.60 30.10 
   Solvent  36.20 38.30 39.90 37.20 35.00  39.40 38.40 43.60 37.10 
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Appendix  9.2: Data collection and refinement statistics of Human uPA H99Y in complex with 
5-(N,N-hexamethylene)amiloride (HMA) and novel 6-HMA analogues. Statistics for the 
highest resolution shell are shown in parentheses. 
X-ray data and model 
statistics 
   
Data set HMA 42 50 
Space group R 3 R 3 R 3 









Resolution range (Å) 30.33  - 2.25 
(2.33- 2.25) 
60.42  - 2.90 
(3.00- 2.90) 
60.31  - 2.4 
(2.49 – 
2.40) 
Total reflections 10984 (1071) 4717 (479) 8939 (860) 
Multiplicity 3.8 (3.8) 5.4 (2.5)  
Unique reflections 24667 (2487)   
    
Completeness (%)    






    

















RMS deviations from ideality    
   Bonds (Å) 0.021 0.034 0.017 
   Angles () 1.58 1.64 1.72 
    
Average B factors  (Å2)    
   Protein 50.90 31.80 33.00 
   Ligands 68.00 42.40 33.50 





Appendix 9.3: Concentration-response curves from solution-phase uPA inhibition assays 
with HMA and the NHE1 inhibitor Cariporide. Cariporide did not inhibit uPA activity at 
concentrations up to 100 M. Data points represent the mean ± SEM (n = 3). 
 
 
 
